Professional Documents
Culture Documents
Scientific Program
A NEW comprehensive antiaging system of potent, multi-action products developed to address photoaging at all skin layers.
The most powerful ingredients working synergistically to address the multiple mechanisms of skin aging. Reverse the appearance of deep lines and wrinkles, sagging skin and discoloration. Physician dispensed.
new
LEARNER BILL OF RIGHTS AAD recognizes that you are a life-long learner who has chosen to engage in continuing medical education to identify or fill a gap in knowledge or skill; and to attain or enhance a desired competency. As part of AADs duty to you as a learner, you have the right to expect that your continuing medical education experience with AAD includes the following. Content that: Promotes improvements or quality in healthcare Is current, valid, reliable, accurate and evidence-based Addresses the stated objectives or purpose Is driven and based on independent survey and analysis of learner needs, not commercial interests Has been reviewed for bias and scientific rigor Offers balanced presentations that are free of commercial bias Is vetted through a process that resolves any conflicts of interest of planners and faculty Is evaluated for its effectiveness in meeting the identified educational need A learning environment that: Is based on adult learning principles that support the use of various modalities Supports learners abilities to meet their individual needs Respects and attends to any special needs of the learners Respects the diversity of groups of learners Is free of promotional, commercial and/or sales activities Disclosure of: Relevant financial relationships that planners, teachers and authors have with commercial interests related to the content of the activity Commercial support (funding or in-kind resources) of this activity
American Academy of Dermatology 930 East Woodfield Road, Schaumburg, Illinois 60173 Phone: 847.330.0230, Fax: 847.330.1090, Website: www.aad.org 2011 American Academy of Dermatology, Schaumburg, Illinois No part of this publication may be reproduced without the prior written permission of the American Academy of Dermatology.
COMMERCIAL BIAS A personal judgment in favor of a specific proprietary business interest of a commercial interest.
Source: www.accme.org
www.AAD.ORG
Presidents Message
DERMATOLOGy: THE NEw COLOSSUS
It was more than a century ago when the iconic Statue of Liberty was engraved with Emma Lazaruss sonnet The New Colossus. Most are familiar with its immortal line, Give me your tired, your poor, your huddled masses, but the sonnet also includes these words: From her beacon-hand glows world-wide welcome. The grand statue has become synonymous with New York, but its the words on the statue that express the true sentiment: all are welcome. I think the American Academy of Dermatologys Summer Academy Meeting 2011 aspires to similar ideals. In modern terms, the huddled masses have endured, grown, diversified, and prospered; and may loosely describe everyone from the dermatologists who diagnose and treat patients to the patients themselves. And although the Statue of Liberty will invariably be a symbol of New York City, I think its good to remember the world-wide welcome Lady Liberty was offering. New York City is a hub; a gathering place, as it will be for the Summer Academy Meeting 2011. The actual components of the meeting, however, come from across the United States and abroad; a world-wide group of specialists, lecturers, presenters, and attendees. The Summer Academy Meeting 2011 serves as a port of entry to the newest advances in dermatology, including many new courses, often unveiled for the first time, and some one-of-a-kind sessions and events that only happen at the summer meeting. As you look through the program book, youll find the summation of a century of dermatology advances made relevant for todays practitioner, and tools youll need to move forward into the next century. I want to welcome the world to engage in Summer Academy Meeting 2011, to appreciate the diversity of our specialty, and marvel at the colossus of modern medicine dermatology has become. Sincerely,
Chairs Message
There are several reasons that the American Academy of Dermatology offers two scientific meetings each year. A major reason is the high demand for quality dermatology education. In addition to the core curriculum, the AADs Summer Academy Meetings offer many new sessions, and some that are not available at the Annual Meeting. Another reason the Academy presents two scientific meetings a year is that it addresses the rapid advances in dermatology over a relatively short period of time. For todays dermatologist to keep up with the changes in science, health care, practice management, treatments, as well as to anticipate future changes in the specialty, the Summer Academy Meeting 2011 provides the ideal venue to do so. In addition to all the Summer Academy Meeting 2011 offers, Im particularly excited about the plenary session this summer. We have an array of well recognized experts who will provide the latest advances in dermatology science and research. Timothy M. Johnson, M.D., is presenting the Everett C. Fox, M.D., Memorial Lectureship, and will address the controversy of sentinel node biopsies in dermatology. This summers guest speaker at the Sunday Plenary Session is emblematic of the sort of change and shift we are all undergoing as the world moves a little faster each year. Author and lecturer Don Tapscott is an internationally renowned authority on the strategic impact of information technology on innovation, marketing and talent, facets that are applicable to dermatologists facing a new era of technology. Erik J. Stratman, M.D., has been passionately involved in dermatology education over the years. His talk on Overhauling CME and Dermatology Education: Laps, Gaps, Maps, and Traps, will not only assess the current education system but offer a glimpse at its future. Attendees will be taken on an epidemiologic journey of contact dermatitis, through an informative presentation by David Eric Cohen, M.D., who will also talk about the relevence of patch testing. Sam T. Hwang, M.D., Ph.D., will provide An Update in CTCL: A Tale of Two Kinds of T-Cells to explain the clinical manifestations of Szary syndrome and mycosis fungoides. Another hot dermatology topic is comparative effectiveness research, which makes use of existing therapeutic options to determine which therapy provides the greatest benefits for patients. David J. Margolis, M.D., will talk about the basics of comparative effectiveness in dermatology and how it will impact the provisions of health care. The plenary also includes a presentation by Roy G. Geronemus, M.D., who will provide the latest development in nonablative and ablative fractional resurfacing. As reflected by the Plenary session topics, we have planned the Summer Academy Meeting 2011 with the need of our Academy members in mind. I do hope that you will find the program informative and educational. In addition, New York City is a great city to visit in the summer. The meeting venue is within walking distance to theatres, museum, Central Park, and many tourist sites. I encourage you to start reviewing the program book today, and plan to attend the sessions that will inform and affect your practice in the future. Sincerely,
Recommend AmLactin
Everyday hydration 12% lactic acid provides powerful therapy leaving skin noticeably soft and smooth
Targets severely dry skin features ULTRAPLEX, an extra-strength blend of three alpha-hydroxy compounds, clinically proven to improve smoothness and hydration
TM
1-800-654-2299 www.upsher-smith.com 2010 Upsher-Smith Laboratories, Inc., Maple Grove, MN 55369 103985.02
table of contents
General Information Accreditation ........................................................................... 18 Attendance Verification ..................................................... 25, 28 Badge Information Mailing of ........................................................................... 25 Identification ....................................................................... 26 Certificate of Attendance......................................................... 26 Chairs Message ......................................................................... 4 Charitable Contribution ......................................................... 26 Committee Meetings............................................................. 103 Continuing Medical Education Information Mission ................................................................................. 1 Definition of ......................................................................... 1 Commercial Bias ................................................................... 1 Learner Bill of rights ............................................................. 1 Statement of Need .............................................................. 12 Target Audience .................................................................. 12 Global Learning Objectives ................................................. 12 Disclosure Information .................................................. 12-13 Disclaimer ........................................................................... 13 CME Credit Information ........................................................ 14 Evaluation and CME Verification ........................................... 29 Exhibits AAD Resource Center .............................................. 28, 33-34 Electronic Posters ..................................................... 29, 83-85 Technical ................................................................ 28, 87-100 Alphabetical Directory .............................................. 87-97 Product Category Directory.................................... 98-100 Independence in CME ........................................................ 30 Disclosure ........................................................................... 30 Content Validation.............................................................. 31 Outcomes Measurement ..................................................... 31 Age Limits........................................................................... 31 Camera/Video Recording .................................................... 31 Cell Phones ......................................................................... 31 Smoking .............................................................................. 31 Alcoholic Beverages ............................................................. 31 Official Language ................................................................ 32 Scientific Sessions ................................................................ 32 Hotel and Travel Information Hotel Accommodations and Reservations ........................... 26 Payment Information .......................................................... 26 Hotel Cancellation .............................................................. 27 Air Travel ............................................................................ 27 Car Rental ........................................................................... 27 Indices Subject ....................................................................... 104-107 Faculty ....................................................................... 108-110 Advertising ........................................................................ 112 Letters of Invitation ................................................................ 26 Meeting Handouts .................................................................. 30 Meeting Location .................................................................... 21 On-Site Services and Exhibits Academy Offices/Exhibits ................................................... 28 Registration ......................................................................... 28 Attendance Verification ....................................................... 28 Speaker Ready Room .......................................................... 28 Exhibits .............................................................28-29, 83-100 Business Center ................................................................... 29 Cyber Center ...................................................................... 29 Press Information ................................................................ 30 Tours ................................................................................... 30 Child Care Services ............................................................. 30 Personal Program Schedule ..................................................... 19 Presidents Message .................................................................... 2 Program Overview ............................................................. 17-18 Registration Information Member Instruction ....................................................... 21-22 Non-member Instructions .............................................. 21-22 Spouse/Guest Instructions .............................................. 21-22 Confirmations and Changes ................................................ 22 Registration Categories, Access and Fees ............................. 23 Session Categories, Access and Fees ..................................... 24 Cancellations ....................................................................... 25 Payment Information .......................................................... 26 Scientific Assembly Committee ................................................. 1 Scientific Sessions Thursday, August 4......................................................... 37-51 Friday, August 5 ............................................................. 52-62 Saturday, August 6 ......................................................... 63-74 Sunday, August 7 ........................................................... 75-78 Whats New This Year ............................................................. 24
table of contents
SEPARATE ENCLOSURE
REGISTRATION AND HOUSING BROCHURE
Registration and Housing Form / Office Staff / Registered Nurses Registration Form / Hotel Reservation Information
SOLODYN is indicated to treat only inammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older. SOLODYN did not demonstrate any effect on noninammatory lesions. Safety of SOLODYN has not been established beyond 12 weeks of use. This formulation of minocycline has not been evaluated in the treatment of infections. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, SOLODYN should be used only as indicated.
Minocycline, like other tetracyclines, can cause fetal harm when administered to a pregnant woman. Tetracycline drugs should not be used during tooth development (last half of pregnancy and up to 8 years of age) as they may cause permanent discoloration of teeth. Pseudomembranous colitis has been reported with nearly all antibacterial agents and may range from mild to life-threatening; therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents. Central nervous system side effects, including light-headedness, dizziness, and vertigo, have been reported with minocycline therapy.
In rare cases, photosensitivity has been reported. Should not be used during pregnancy nor by individuals of either gender who are attempting to conceive a child; concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective. This drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines. Safety beyond 12 weeks of use has not been established.
Reference: 1. IMS Health. National Prescription Audit (NPA). Data through December 2010. Data on le, Medicis Pharmaceutical Corporation.
BRIEF SUMMARY (see package insert for full prescribing information) SOLODYN (minocycline HCl, USP) Extended Release Tablets Rx Only KEEP OUT OF REACH OF CHILDREN INDICATIONS AND USAGE Indication SOLODYN is indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older. Limitations of Use SOLODYN did not demonstrate any effect on non-inflammatory acne lesions. Safety of SOLODYN has not been established beyond 12 weeks of use. This formulation of minocycline has not been evaluated in the treatment of infections.
treated early in pregnancy (see Use in Specific Populations). Pseudomembranous Colitis Pseudomembranous colitis has been reported with nearly all antibacterial agents and may range from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents. Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by Clostridium difficile is a primary cause of antibiotic-associated colitis.
visual disturbances prior to initiation of treatment with tetracyclines and should be routinely checked for papilledema while on treatment. Concomitant use of isotretinoin and minocycline should be avoided because isotretinoin, a systemic retinoid, is also known to cause pseudotumor cerebri. Autoimmune Syndromes Tetracyclines have been associated with the development of autoimmune syndromes. The long-term use of minocycline in the treatment of acne has been associated with drug-induced lupus-like syndrome, autoimmune hepatitis and vasculitis. Sporadic cases of serum sickness have presented shortly after minocycline use. Symptoms may be manifested by fever, rash, arthralgia, and malaise. In symptomatic patients, liver function tests, ANA, CBC, and other appropriate tests should be performed to evaluate the patients. Use of all tetracycline-class drugs should be discontinued immediately.
Laboratory Monitoring Periodic laboratory evaluations of organ systems, including hematopoietic, renal and hepatic studies should be performed. Appropriate tests for autoimmune syndromes should be performed as indicated. ADVERSE REACTIONS Clinical Trial Experience Because clinical trials are conducted under prescribed conditions, adverse reaction rates observed in the clinical trial may not reflect the rates observed in practice. The following table summarizes selected adverse reactions reported in clinical trials at a rate of 1% for SOLODYN.
After the diagnosis of pseudomembranous colitis has been established, therapeutic measures should be initiated. Mild cases ofpseudomembranous colitis usually respond to discontinuation of To reduce the development of drugthe drug alone. In moderate to severe resistant bacteria as well as to maintain the cases, consideration should be given to effectiveness of other antibacterial drugs, management with fluids and electrolytes, SOLODYN should be used only as indicated protein supplementation, and treatment (see Warnings and Precautions). with an antibacterial drug clinically effective against Clostridium difficile colitis. CONTRAINDICATIONS This drug is contraindicated in persons whohave shown hypersensitivity to any of the tetracyclines. WARNINGS AND PRECAUTIONS Teratogenic Effects A. MINOCYCLINE, LIKE OTHER TETRACYCLINE-CLASS ANTIBIOTICS, CAN CAUSE FETAL HARM WHEN ADMINISTERED TO A PREGNANT WOMAN. IF ANY TETRACYCLINE IS USED DURING PREGNANCY OR IF THE PATIENT BECOMES PREGNANT WHILE TAKING THESE DRUGS, THE PATIENT SHOULD BEAPPRISED OF THE POTENTIAL HAZARD TO THE FETUS. SOLODYN should not be used during pregnancy or by individuals of either gender who are attempting to conceive achild (see Nonclinical Toxicology & Use in Specific Populations).
Hepatotoxicity Post-marketing cases of serious liver injury, including irreversible drug-induced hepatitis and fulminant hepatic failure (sometimes fatal) have been reported with minocycline use in the treatment of acne. Metabolic Effects The anti-anabolic action of the tetracyclines may cause an increase in BUN. While this is not a problem in those with normal renal function, in patients with significantly impaired function, higher serum levels of tetracycline-class antibiotics may lead to azotemia, hyperphosphatemia, and acidosis. If renal impairment exists, even usual oral or parenteral doses may lead toexcessive systemic accumulations of thedrug and possible liver toxicity. Under such conditions, lower than usual total doses are indicated, and if therapy is prolonged, serum level determinations of the drug maybe advisable.
Selected Treatment-Emergent Adverse Reactions in at least 1% of Clinical Trial Subjects Adverse Reactions SOLODYN PLACEBO (1 mg/kg) N=364 N=674 (%) (%) At least one treatment- 379 (56) 197 (54) emergent event Photosensitivity Headache 152 (23) 83 (23) Photosensitivity manifested by an Fatigue 62 (9) 24 (7) exaggerated sunburn reaction has been Dizziness 59 (9) 17 (5) observed in some individuals taking Pruritus 31 (5) 16 (4) tetracyclines. This has been reported Malaise 26 (4) 9 (3) rarelywith minocycline. Patients should minimize or avoid exposure to natural or Mood alteration 17 (3) 9 (3) artificial sunlight (tanning beds or UVA/B Somnolence 13 (2) 3 (1) treatment) while using minocycline. If Urticaria 10 (2) 1 (0) patients need to be outdoors while using Tinnitus 10 (2) 5 (1) minocycline, they should wear loose-fitting Arthralgia 9 (1) 2 (0) clothes that protect skin from sun exposure Vertigo 8 (1) 3 (1) and discuss other sun protection measures Dry mouth 7 (1) 5 (1) with their physician. Myalgia 7 (1) 4 (1) Postmarketing Experience Serious Skin/Hypersensitivity Reaction Adverse reactions that have been reported Post-marketing cases of anaphylaxis with minocycline hydrochloride use in a and serious skin reactions such as variety of indications include: Stevens-Johnson syndrome and erythema Skin and hypersensitivity reactions: multiforme have been reported with fixed drug eruptions, balanitis, erythema minocycline use in treatment of acne. multiforme, Stevens-Johnson syndrome, anaphylactoid purpura, photosensitivity, pigmentation of skin and mucous membranes, hypersensitivity reactions, angioneurotic edema, anaphylaxis.
Tissue Hyperpigmentation Tetracycline-class antibiotics are known to cause hyperpigmentation. Tetracycline therapy may induce hyperpigmentation in many organs, including nails, bone, skin, eyes, thyroid, visceral tissue, oral cavity (teeth, mucosa, alveolar bone), sclerae and B. THE USE OF DRUGS OF THE heart valves. Skin and oral pigmentation Central Nervous System Effects TETRACYCLINE-CLASS DURING has been reported to occur independently TOOTH DEVELOPMENT (LAST HALF OF Central nervous system side effects of time or amount of drug administration, PREGNANCY, INFANCY, AND CHILDHOOD including light-headedness, dizziness or vertigo have been reported with minocycline whereas other tissue pigmentation has UP TO THE AGE OF 8 YEARS) MAY been reported to occur upon prolonged therapy. Patients who experience these CAUSE PERMANENT DISCOLORATION administration. Skin pigmentation includes OFTHE TEETH (YELLOW-GRAY-BROWN). symptoms should be cautioned about diffuse pigmentation as well as over sites driving vehicles or using hazardous This adverse reaction is more common ofscars or injury. machinery while on minocycline therapy. during long-term use of the drug but These symptoms may disappear during Development of Drug Resistant has been observed following repeated therapy and usually rapidly disappear Bacteria short-term courses. Enamel hypoplasia whenthe drug is discontinued. Bacterial resistance to the tetracyclines has also been reported. TETRACYCLINE may develop in patients using SOLODYN, Benign Intracranial Hypertension DRUGS, THEREFORE, SHOULD NOT BE therefore, the susceptibility of bacteria Pseudotumor cerebri (benign intracranial USED DURING TOOTH DEVELOPMENT. associated with infection should be hypertension) in adults and adolescents C. All tetracyclines form a stable calcium considered in selecting antimicrobial has been associated with the use complex in any bone-forming tissue. A therapy. Because of the potential for of tetracyclines. Minocycline has decrease in fibula growth rate has been been reported to cause or precipitate drug-resistant bacteria to develop during observed in premature human infants the use of SOLODYN, it should be used only pseudotumor cerebri, the hallmark given oral tetracycline in doses of 25 as indicated. of whichis papilledema. Clinical mg/kg every 6 hours. This reaction was manifestations include headache and Superinfection shown to be reversible when the drug blurred vision. Bulging fontanels have been As with other antibiotic preparations, use was discontinued. associated with the use of tetracyclines of SOLODYN may result in overgrowth of Results of animal studies indicate that in infants. Although signs and symptoms nonsusceptible organisms, including fungi. tetracyclines cross the placenta, are of pseudotumor cerebri resolve after If superinfection occurs, the antibiotic found in fetal tissues, and can cause discontinuation of treatment, the possibility should be discontinued and appropriate retardation of skeletal development for permanent sequelae such as visual therapy instituted. on the developing fetus. Evidence of loss that may be permanent or severe embryotoxicity has been noted in animals exists. Patients should be questioned for
Autoimmune conditions: polyarthralgia, pericarditis, exacerbation of systemic lupus, pulmonary infiltrates with eosinophilia, transient lupus-like syndrome. Central nervous system: pseudotumor cerebri, bulging fontanels in infants, decreased hearing. Endocrine: thyroid discoloration, abnormal thyroid function. Oncology: papillary thyroid cancer. Oral: glossitis, dysphagia, tooth discoloration. Gastrointestinal: enterocolitis, pancreatitis, hepatitis, liver failure. Renal: reversible acute renal failure. Hematology: hemolytic anemia, thrombocytopenia, eosinophilia. Preliminary studies suggest that use of minocycline may have deleterious effects on human spermatogenesis (see Nonclinical Toxicology). DRUG INTERACTIONS Anticoagulants Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.
Penicillin Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline-class drugs in conjunction with penicillin. Methoxyflurane The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity. Antacids and Iron Preparations Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium and iron-containing preparations. Low Dose Oral Contraceptives In a multi-center study to evaluate the effect of SOLODYN on low dose oral contraceptives, hormone levels over one menstrual cycle with and without SOLODYN1 mg/kg once-daily were measured. Based on the results of this trial,minocycline-related changes in estradiol, progestinic hormone, FSH and LHplasma levels, of breakthrough bleeding,or of contraceptive failure, can notbe ruled out. To avoid contraceptive failure, female patients are advised to use asecond form of contraceptive during treatment with minocycline. Drug/Laboratory Test Interactions False elevations of urinary catecholamine levels may occur due to interference with the fluorescence test. USE IN SPECIFIC POPULATIONS Pregnancy Teratogenic Effects: Pregnancy category D (see Warnings and Precautions) SOLODYN should not be used during pregnancy. If the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus and stop treatment immediately. There are no adequate and well-controlled studies on the use of minocycline in pregnant women. Minocycline, like other tetracycline-class drugs, crosses the placenta and may cause fetal harm when administered to a pregnant woman. Rare spontaneous reports of congenital anomalies including limb reduction have been reported with minocycline use in pregnancy in post-marketing experience. Only limited information is available regarding these reports; therefore, no conclusion on causal association can beestablished. Minocycline induced skeletal malformations (bent limb bones) in fetuses when administered to pregnant rats and rabbits in doses of 30 mg/kg/day and 100 mg/kg/day, respectively, (resulting in approximately 3times and 2 times, respectively, the systemic exposure to minocycline observedin patients as a result of use of SOLODYN). Reduced mean fetal body weight was observed in studies in which minocycline was administered to pregnant rats at a dose of 10 mg/kg/day (which resulted in approximately the same level of systemic exposure to minocycline as that observed in patients who use SOLODYN).
Minocycline was assessed for effects on peri- and post-natal development of rats in a study that involved oral administration to pregnant rats from day 6 of gestation through the period of lactation (postpartum day 20), at dosages of 5, 10, or 50 mg/kg/day. In this study, body weight gain was significantly reduced in pregnant females that received 50 mg/kg/day (resulting in approximately 2.5 times the systemic exposure to minocycline observed in patients as a result of use of SOLODYN). No effects of treatment on the duration of the gestation period or the number of live pups born per litter were observed. Gross external anomalies observed in F1 pups (offspring of animals that received minocycline) included reducedbody size, improperly rotated forelimbs, and reduced size of extremities. No effects were observed on the physical development, behavior, learning ability, or reproduction ofF1 pups, and there was no effect on gross appearance of F2 pups (offspring ofF1 animals).
evaluate the carcinogenic potential of minocycline. A structurally related compound, oxytetracycline, was found toproduce adrenal and pituitary tumors inrats. MutagenesisMinocycline was not mutagenic in vitro in a bacterial reverse mutation assay (Ames test) or CHO/HGPRT mammalian cell assay in the presence or absence of metabolic activation. Minocycline was not clastogenic in vitro using human peripheral blood lymphocytes or in vivo in a mouse micronucleus test.
contains minocycline hydrochloride equivalent to 65 mg minocycline, supplied as follows: NDC 99207-463-30 Bottle of 30 The 80 mg extended release tablets are gray, unscored, coated, and debossed with DYN-080 on one side. Each tablet contains minocycline hydrochloride equivalent to 80 mg minocycline, supplied as follows: NDC 99207-466-30 Bottle of 30
The 90 mg extended release tablets are Impairment of FertilityMale and yellow, unscored, coated, and debossed female reproductive performance in with DYN-090 on one side. Each tablet rats was unaffected by oral doses of contains minocycline hydrochloride minocycline of up to 300 mg/kg/day (which equivalent to 90 mg minocycline, supplied resulted in up to approximately 40 times the as follows: level of systemic exposure to minocycline observed in patients as a result of use of NDC 99207-461-30 Bottle of 30 SOLODYN). However, oral administration of NDC 99207-461-10 Bottle of 100 100 or 300 mg/kg/day of minocycline to The 105 mg extended release tablets are male rats (resulting in approximately 15 to 40 times the level of systemic exposure to purple, unscored, coated, and debossed minocycline observedin patients as a result with DYN-105 on one side. Each tablet contains minocycline hydrochloride Nursing Mothers of use of SOLODYN) adversely affected Tetracycline-class antibiotics are excreted spermatogenesis. Effectsobserved at 300 equivalent to 105 mg minocycline, supplied as follows: in human milk. Because of the potential for mg/kg/day included a reduced number serious adverse effects on bone and tooth of sperm cells per gram of epididymis, NDC 99207-467-30 Bottle of 30 development in nursing infants from the an apparent reduction in the percentage tetracycline-class antibiotics, a decision The 115 mg extended release tablets are of sperm that were motile, and (at 100 should be made whether to discontinue green, unscored, coated, and debossed and 300 mg/kg/day) increased numbers nursing or discontinue the drug, taking into of morphologically abnormal sperm cells. with DYN-115 on one side. Each tablet account the importance of the drug to the Morphological abnormalities observed in contains minocycline hydrochloride mother (see Warnings and Precautions). equivalent to 115 mg minocycline, sperm samples included absent heads, suppliedas follows: misshapen heads, and abnormal flagella. Pediatric Use SOLODYN is indicated to treat only NDC 99207-464-30 Bottle of 30 Limited human studies suggest that inflammatory lesions of non-nodular minocycline may have a deleterious effect The 135 mg extended release tablets are moderate to severe acne vulgaris on spermatogenesis. pink (orange-brown), unscored, coated, in patients 12 years and older. SOLODYN should not be used by individuals and debossed with DYN-135 on one Safety and effectiveness in pediatric of either gender who are attempting to side. Each tablet contains minocycline patientsbelow the age of 12 has not conceive a child. hydrochloride equivalent to 135 mg been established. minocycline, supplied as follows: Use of tetracycline-class antibiotics below HOW SUPPLIED/STORAGE AND HANDLING NDC 99207-462-30 Bottle of 30 the age of 8 is not recommended due to How Supplied NDC 99207-462-10 Bottle of 100 the potential for tooth discoloration (see SOLODYN (minocycline HCl, USP) Extended Warnings and Precautions). Storage Release Tablets are supplied as aqueous Geriatric Use film coated tablets containing minocycline Store at 25C (77F); excursions are Clinical studies of SOLODYN did not hydrochloride equivalent to 45mg, 55 mg, permitted to 15-30C (59-86F) [See USP Controlled Room Temperature]. include sufficient numbers of subjects aged 65 mg, 80 mg, 90 mg, 105mg, 115 mg 65 and over to determine whether they or135 mg minocycline, are supplied Handling respond differently from younger subjects. asfollows. Keep out of reach of children Other reported clinical experience has not Protect from light, moisture, and identified differences in responses between The 45 mg extended release tablets are excessiveheat. the elderly and younger patients. In general, gray, unscored, coated, and debossed dose selection for an elderly patient should with DYN-045 on one side. Each tablet Dispense in tight, light-resistant container be cautious, usually starting at the low end contains minocycline hydrochloride with child-resistant closure. equivalent to 45 mg minocycline, supplied of the dosing range, reflecting the greater as follows: U.S. Patent 5,908,838* and Patents Pending frequency of decreased hepatic, renal, or *90 mg is also covered by U.S. Patents cardiac function, and concomitant disease NDC 99207-460-30 Bottle of 30 7,541,347 and 7,544,373 or other drug therapy. NDC 99207-460-10 Bottle of 100 Manufactured for: OVERDOSAGE The 55 mg extended release tablets are Medicis, The Dermatology Company In case of overdosage, discontinue pink, unscored, coated, and debossed Scottsdale, AZ 85256 medication, treat symptomatically and with DYN-055 on one side. Each tablet institute supportive measures. Minocycline contains minocycline hydrochloride August 2010 is not removed in significant quantities by equivalent to 55 mg minocycline, supplied 17110163 hemodialysis or peritoneal dialysis. as follows: NONCLINICAL TOXICOLOGY NDC 99207-465-30 Bottle of 30 Carcinogenesis, Mutagenesis, The 65 mg extended release tablets are Impairment of Fertility blue, unscored, coated, and debossed CarcinogenesisLong-term animal with DYN-065 on one side. Each tablet studies have not been performed to
cme information
SUMMER ACADEMy MEETING 2011 DIRECTLy SPONSORED By The American Academy Of Dermatology
STATEMENT OF NEED
The American Academy of Dermatologys Summer Academy Meeting 2011 is planned to comprehensively address the nine content areas within the Dermatologic Core Curriculum and provide dermatologists and other dermatology health care professionals with high quality educational opportunities for the optimization of dermatologic knowledge, competence and performance.
TARGET AUDIENCE
The primary target audience of the American Academy of Dermatologys Summer Academy Meeting is its members. Secondary audiences for the Summer Academy Meeting 2011 include dermatology residents and other dermatology health care professionals.
DISCLOSURES
PLANNER DISCLOSURE OF RELEvANT FINANCIAL RELATIONSHIP(S)
The following planning committee members reported they have no relationship(s) with commercial interest(s) to disclose relevant to the content of this CME activity: Michael E. Ming, M.D. Erik J. Stratman, M.D. Janet A. Fairley, M.D. Robert David Greenberg, M.D. Suzanne Olbricht, M.D. The following planning committee members reported they do have relationship(s) with commercial interest(s) to be disclosed to learners:
Planner Robert T. Brodell, M.D. Role Honoraria Speaker Commercial Interest 3 M/Graceway Pharmaceuticals, Allergan, Dermik/BenzaClin, GlaxoSmithKline, Novartis Pharmaceuticals, Galderma Laboratories, L.P., Medicis, SanofiAventis, PharmaDerm/Veregen Abbott Laboratories, Centocor Ortho Biotech, Genentech Dow Pharmaceuticals Sciences, Promius Coria Galderma, Johnson & Johnson, Ortho Dermatologics Elsevier, Wiley-Blackwell Allerderm, Amgen, Astellas, Galderma, Johnson & Johnson, Novartis, Stiefel Pierre Fabre Dermatology Bristol-Myers Squibb, Genzyme Astellas Eisai, Yaupon American College of Physicians, Elsevier, WebMD Elsevier Advanced Biohealing, Healthpoint, Tissue Repair Company Molynecke, National Healing Board, Organogenesis GlaxoSmithKline Mosaic Clinuvel, La Roche-Posay, Orfagen Lumenis, Medicis Inamed Suneva CLRS Technology
cme information
Lawrence F. Eichenfield, M.D. Ilona J. Frieden, M.D. Joan Guitart, M.D. William D. James, M.D. Robert S. Kirsner, M.D. Henry W. Lim, M.D. Ronald L. Moy, M.D.
Honoraria Investigator Honoraria Consultant Honoraria Speaker Honoraria Consultant Royalty Investigator No Compensation Received Honoraria Consultant Honoraria Consultant Honoraria Advisory Board Grants Investigator Honoraria Other Royalty Grants Investigator Honoraria Advisory Board Honoraria Other Advisory Board No Compensation Received Honoraria Consultant Honoraria Speaker Investigator No Compensation Received Grants Investigator Stockholder Investigator
The Academy staff involved with this CME activity and all content validation/peer reviewers of this CME activity have reported no relevant financial relationships with commercial interest(s).
12 | AmericAn AcAdemy of dermAtology SUmmer AcAdemy meeting 2011
cme information
FACULTy DISCLOSURE OF RELEvANT FINANCIAL RELATIONSHIP(S)
UNAPPROvED USE DISCLOSURE
The American Academy of Dermatology requires CME faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label (not approved for the indications being discussed), unlabeled (not approved for any indications), experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. This information is intended solely for continuing medical education and is not intended to promote off-label use of these products/procedures. If you have questions, contact the medical affairs department of the manufacturer for the most recent approval information. Faculty at this meeting will be discussing information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.
It is the policy of AAD that all faculty participating in a CME-certified activity are required to disclose to AAD and to learners relevant financial relationships with any commercial interest(s) that they or their first-degree relative (spouse, parent, sibling, or child). Relevant financial relationships include financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Typically, such relationships would be with companies that sell health care products or services that are consumed by or used in the treatment of patients. The intent of this disclosure is not to prevent participation in CMEcertified educational activities by individuals with a relevant financial relationship with commercial interest(s), but rather to provide learners with information on which they can make their own determination whether or not said relationship(s) influenced the content of the educational activity. Session director and faculty disclosure information is located within the Program-at-a-Glance book after the scientific schedule. Faculty have been asked to also make a verbal disclosure at the start of their presentations supplemented by a disclosure slide in order to verify the accuracy of the disclosure information printed in the Program-at-a-Glance and ensure their disclosure information is shared with the learners PRIOR to the presentation taking place.
The following commercial interests provided in-kind support for the Summer Academy Meeting 2011:
cme information
DISCLAIMER
In accordance with the ACCME Standards for Commercial Support of CME, the American Academy of Dermatology has implemented mechanisms, prior to the planning and implementation of this CME activity, to identify and mitigate conflicts of interest for all individuals in a position to control the content of this CME activity.
The American Academy of Dermatology is not responsible for statements made by faculty. Statements or opinions expressed in this program reflect the views of the faculty and do not reflect the official policy of the American Academy of Dermatology. The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to the diagnostic, management and treatment options of a specific patients medical condition.
ACCREDITATION
The American Academy of Dermatology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
www.aad.org
13
cme information
AMA PRA CATEGORY 1 CREDIT TM DESIGNATION NON-MEMBER PHySICIAN CME CREDIT CERTIFICATE
The American Academy of Dermatology designates this live activity for a maximum of 30 AMA PRA Category 1 CreditsTM. Physicians should claim the credit commensurate only with the extent of their participation in the activity.
The American Academy of Dermatologys Summer Academy Meeting 2011 is recognized by the American Academy of Dermatology for 30 AAD Recognized Category 1 CME Credits and may be used toward the American Academy of Dermatologys Continuing Medical Education Award. All Summer Academy Meeting 2011 activities, unless otherwise specified, are approved for direct-sponsored AAD Category 1 CME Credit.
Non-member physicians who attend the meeting can receive a CME Credit Certificate which includes documentation of the total CME credits claimed. If you are a physician and would like to receive a CME Credit Certificate, please submit a copy of the CME Claim Form and check yes where asked if you would like to receive the CME Credit Certificate.
CME Credit is awarded based on actual participation in the learning activities. An overall evaluation form and CME credit claim form will be provided in the registration bag distributed on-site at registration. Learners should complete the session evaluation forms and drop them into the boxes labeled CME Evaluations throughout the duration of the meeting. Prior to departure, learners should complete the CME credit claim form and drop it into the CME Evaluations boxes for processing. CME credits can also be claimed online at www.aad.org/cme/claim. The online claim system is available for 2 weeks post meeting. Credit is calculated on a 1/4-hour basis and will be reflected on member transcripts within four to six weeks after the meeting.
14
EXAMPLE B
POWERFUL EFFICACY
From baseline to week 12, lesion reduction (total, noninammatory, and inammatory) was similar to tazarotene gel, 0.1%1*
*A phase 3b, 12-week, noninferiority, multicenter, investigator-blinded, controlled clinical study of patients 12 to 35 years of age with acne vulgaris (N=172). At the end of 12 weeks, neither product was found to be inferior. 160 patients participated in the satisfaction survey.
A single-center, randomized, investigator/evaluator-blinded, bilateral (split-face) comparison of healthy subjects 18 years of age (N=30). Subjects received Differin Gel, 0.3% on one half of the face and tretinoin gel microsphere, 0.04% on the other half for 22 days.
Important Safety Information Of the patients who experienced cutaneous irritation (erythema, scaling, dryness, and/or stinging/burning) during the clinical trial, the majority of cases were mild to moderate in severity, occurred early in treatment, and decreased thereafter. Adverse events that occurred in greater than 1% of the subjects included dry skin (14.0%), skin discomfort (5.8%), pruritus (1.9%), desquamation (1.6%), and sunburn (1.2%). Pregnancy Category C. Concomitant use of potentially irritating products or overexposure to sunlight or sunlamps, extreme wind or cold, may increase the potential for irritation. Use of sunscreen and protective clothing over treated areas are recommended when exposure cannot be avoided.
www.differin.com
D ug Interactions: As D FFER Ge 0.3% h DIFFERIN (adapalene)NGel, 0.3% tan u SUMMARY BRIEF e o other pot
e patien Rx only
su ur resorcinol, USAGE DIFFERIN G l, 0 3% ndi FFER N Ge , 0.3% ese of ac t vulgar s been used IND CATIONS AND or salic ic acid in comb nation i th D ated for the topic l tr a mentprepa e ons hav in patients it years s age and older. 12 is adv of b e not to star Carcinogenesis, Mutagenesis Gel, 0.3% of Fertility: rc no tered s nd v a s adap l e have been con CONTRAINDICATIONS: DIFFERINImpa rment should not beC dmin enicityto udie dwi h who r hyp rsens t ve to a uctedn om ce at the al doses of in he gel nd 4.0 apal ny of op omponents 0 , .3, ehicle mg/kg/day. Th PRECAUTIONS: at the m x rta n taneou huma dose (MRHD a treatment such a D ema, Gel 0 d yness, Gene al: C mum ommen digns a d symp oms of sumed to e 2.5 gr sry FFER scaling, 3%. In th a da s udy, increased inc be experienced and use of DIFFERIN omocytom s in he adrena likely as of male rats wa stinging/burning may dence of benign with mal gnant pheoch Gel, 0 3%. These are most medulto occur during the fiob four weeks of treatment, are mostly mild to moderate in intensity, and usually lessen with continued use of the st erved. No cation D ogen city stud es ev ty duct d. An ffe ud es ents m d photoc rc pending upon he wer rco of th se sid al ts, pat have wn an creased rto eo sk use a mo s ld be structed sk ther n n oplasm w er, red e pharm o y ic y s on of DIFFERIN ino 0.3% o exposed to use tur h the u ceothe freq n o of ppli it ar drugs e.g., re G l,ds) when di cont nue UV If o rea ght s ggesting sens ti vity ce of thes al u tation occ ns, use of th ar, pat e on shouldbe advi ed to a o a un tion A hough the s g ica or chemi s r es to um use i n c med cat ts hould be d s on nu d or minim ze exposu to either sunlight o artif cial UV irradiation sources. Exposure to sunlight, including sunlamps, should be minimized during use of adapalene. Patients who normally Ad p len gh no e h sun xpo n and th se with ects in v nsi Am s est, Chinese h arn d to y cel s exp ri nce hdid levels of bit utag ur , or ge otoxic e nherent s tro iv ty to sun should be mst r ov xercise a mouse mphoma TK products and protec ve m onucl treated tion Us of suns reen assay) and in vivo (mou lothcng over us test).areas is recommended when exposure cannot R product function tremes, such s were o old, d o ats be i ered a doses o adap re in amounts be avo ded eWeath r e nd fe til y stud e wind c duct al n mayadm rr tat ng oto pati nts under enetment with up to 20 adapalene on the reproductive performanc or fe t of of he F and mucous membranes. The product should e e be applied Avoid con act with the eyes, lips, angles lit the nose, males or females There were also no etec ab not fects on the offspr g. g uts, abra lopm nt and sub e u t reproduct func ion of t to owth, dev ions, czemato s or s nbur ed skinveAs wi h other r tFnoids u e of waxing as a depilatory method Pregnancy: eratogenic t fects th nancy C should be avo ded on sk n e eated wPre dapalene pregnant for Pat e pa P ti as using DIFFERIN eratogenic ats rec bbits follo mi stere oral (see An c Info matiowomen. Ad ts e e ntsbeen shown o be Gel, 0 3%, houldand ve thewhen ng nform tion nd instr m Dat tions s This in pregn n o be used on y as directed by justi ies the 1. d du m dicat on is y on y if the potential benefit the physician. R N el 0.3% only . is for xternal usein pre . Avo d Da 3.Humancon ct with the eyes, lips, angles of the nose, and mucous membranes. n Cle set aff cted ar a w t FFER orGel, 0.3%cleansertreat en of acne ulga catiwo 4. lin l ia invol ng a mi soapless in the befo applying thi med is, n n ated urize nt on be used v nec d a n g w ver, p ancy c nta ning alp a ydro y or n ycoli asu sshould 5 Mo s reat may y ter h f g h sary; h ive pr g ducts s and used e e ve b t c g rol m ac d dur n apy How be avoided. he Expos ecy, two p ye to el medi o babi sresult n ea t nsy stwo s swelling, con prem tur nd deye 6 pregn of the ien s th ed h h may by n m d e ch t nts de iv ed unct s, a th e rm rr ta io nimal Dat 7. Th s med c tion should not be applied to cuts, abrasions, eczematous, or sunburned skin. t or n d e o 0 potential sk kg o d 8 o te ep lat o should s wereperfo med oa str ated k doses to the 15 to 5.0o mg n e d yo s Wax atogen ef ec not be seen in 6 im s e maximu re ommended human exacerbation b acne may m c pari may A due n ha 9. oDuring thet early weeks of therapy, an apparent ose (MRHD of sed on m occur. This ons. be apa to the eeno own o m di at ogen p n ats a d abb leswh aad n s er not b c t do red a 5 mg/ to d scont n n act of the b ra n on ev ously un een s on d ho ld d ora nsid es eas n g epresen e 2 and therapy. m crophthalmia cephalocele nd ske h l the po li in the r nd u ti c Drug Interactions Ae DIFFERIN G l, 0.3% et s abnorm nti el to nduce o al irr t b n ln erni pat en s, concom om exophthalmos a tan id y other po nt ally ima ng top calrab ducts (medicated or abrasive soaps and cleansers, soaps and cos u of nd skelet l abno r t es n the pr t. Cut neous te stro tudies in ra and rabbits with high concentrations 6 alco ol, ast exhib d no to metics that have a olog g drying effect, and products at doses of 0.6, 2 0, and of 0 mg/kg/da ingents, spices, or to icity and appro n ma incr aution Particular caution in d be ex rc and sing prepa icat on in abb ts lime) should be only m ched with ases n super umerary r b houboth sp ci ed n e ayed oss at ons conta n ng Syst sorc nol, or e AUC 2 d to adapal e with gel at topica doses If 6.0 prepa a y n ts and abbit sulfur, r mic expos salicyl c 0ac h) in combin t on 0.3% DIFFERIN Ge , 0 3% o thesemg/kg d ions h ve be n used, it isrepre ab e not 7 and 28 7 times, espectively Gel, exposure inth ne pat en ut h pr pwra ons h ene 0.3% g advi ented 5 to start therapy with DIFFERIN the 0 3%, until a effects of eated t ad p e subsided applied to the M tagenesis, back (2 g t f Fert lity 1000 cm2 of acne in s with dapalene have been con Carcinogenesis, fa e, chest an Impairme a s applied t Carc nogenicity stud olved s n). Nu sing mice rs It is not known 0.4, er and ug mg/kg/day, and in rats at Bec use man drugs ar exc e ed ducted n Moth at topical doses ofwhe 1.3,his d 4.0 s excreted n human m k. oral doses of 0.15, 0.5, and 1.5 in human T ese doses re up to 3 erc s (mic DIFFE IN (rats) in terms of stered ursing wom n. mg/kg/day m k, caution hould be e tim s d wh )nand 2 imes Gel 0 3% s admi mg/m dtoyathe pot nt al e posure Pediatric Use: r omm ef ecti eness in pediatric p ients be ow the age of 12 have not Gel, 0 3%. ed at the maximum S ety andnd d h man dose (MRHD), ssumed to be 2.5 grams DIFFERINbeen estab n the oral Geria ric Use inc cal s s of DIFFERIN Gel 3% did not inc oma in the 65 yea s of ge nd o l ts wa study, ncreasedCl n d nceudif benign and malignan0 pheochromocy ude ub ectsadrenal med llas of m d r o dete m erv d ob ne wh and above have not be studies were No photocarcinogenicity n estab ished conducted. Animal studies have shown an increased risk of skin neoplasms with the use of pharmacologically similar drugs (e.g., retinoids) when exposed to UV irradiation in the laboratory or to sunlight. Although the significance of these studies to human use is not clear, patients should be advised to avoid or minimize exposure to either sunlight or artificial UV irradiation sources. Adapalene did not exhibit mutagenic or genotoxic effects in vitro (Ames test, Chinese hamster ovary cell assay, mouse lymphoma TK assay) and in vivo (mouse micronucleus test). Reproductive function and fertility studies were conducted in rats administered oral doses of adapalene in amounts up to 20 mg/kg/day (up to 26 times the MRHD based on mg/m comparisons). No effects of adapalene were found on the reproductive performance or fertility of the F0 males or females. There were also no detectable effects on the growth, development and subsequent reproductive function of the F1 offspring. Pregnancy: Teratogenic effects. Pregnancy Category C. Retinoids may cause fetal harm, when administered to pregnant women. Adapalene has been shown to be teratogenic in rats and rabbits when administered orally (see Animal Data below). There are no adequate and well controlled studies in pregnant women. DIFFERIN Gel, 0.3% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. The safety and efficacy of DIFFERIN Gel, 0.3% in pregnancy has not been established. 1 Human Data In clinical trials involving DIFFERIN Gel, 0.3% in the treatment of acne vulgaris, women of chi d bearing potential initiated treatment only after having had a negative pregnancy test and used effective birth control measures during therapy. However, 6 women treated with DIFFERIN Gel, 0.3% became pregnant. One patient elected o terminate the pregnancy, two patients delivered healthy babies by normal delivery, two patients delivered prematurely and the babies remained in intensive care until reaching a healthy state and one patient was lost to follow up. 2. Animal Data No teratogenic effects were seen in rats at oral doses of 0.15 to 5.0 mg/kg/day adapalene representing up to 6 times the maximum recommended human dose (MRHD) based on mg/m comparisons. Adapalene has been shown to be teratogenic in rats and rabbits when administered orally at doses 25 mg/kg representing 32 and 65 times, respectively, the MRHD based on mg/m comparisons. Findings included cleft palate, microphthalmia, encephalocele and skeletal abnormalities in the rat and umbilical hernia, exophthalmos and kidney and skeletal abnormalities in the rabbit. Cutaneous teratology studies in rats and rabbits at doses of 0.6, 2.0, and 6.0 mg/kg/day exhibited no feto toxicity and only minimal increases in supernumerary ribs in both species and delayed ossification in rabbits. Systemic exposure (AUC0 24h) to adapalene 0.3% gel at topical doses of 6.0 mg/kg/day in rats and rabbits represented 5.7 and 28.7 times, respectively, the exposure in acne patients treated with adapalene 0.3% gel applied to the face, chest and back (2 grams applied to 1000 cm2 of acne involved skin). Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when DIFFERIN Gel, 0.3% is administered to a nursing woman. Pediatric Use: Safety and effectiveness in pediatric patients below the age of 12 have not been established. Geriatric Use: Clinical studies of DIFFERIN Gel, 0.3% did not include subjects 65 years of age and older to deter mine whether they respond differently than younger subjects. Safety and effectiveness in geriatric patients age 65 and above have not been established.
For topical use only roa for ophthalmic, oral or cular ca t onuse li e) should be ap Not hed wi h caution Part intravaginal sh
ADVERSE REACTIONS: In the multi center, controlled clinical trial, signs and symptoms of local cutaneous irritation were monitored in 258 acne patients who used DIFFERIN Gel, 0.3% once daily for 12 weeks. Of the patients who experienced cutaneous irritation (erythema, scaling, dryness, and/or burning/stinging), the majority of cases were mild to moderate in severity, occurred early in treatment and decreased thereafter. The incidence of local cutaneous irritation with DIFFERIN Gel, 0.3% from the controlled clinical study is provided in the following table: Table 2: Physician assessed local cutaneous irritation with DIFFERIN Gel Incidence of Local Cutaneous Irritation with DIFFERIN Gel, 0.3% from Controlled Clinical Study (N 253*) Maximum Severity Scores Higher Than Baseline Erythema Scaling Dryness Burning/Stinging Mild 66 (26.1%) 110 (43.5%) 113 (44.7%) 72 (28.5%) Moderate 33 (13.0%) 47 (18.6%) 43 (17.0%) 36 (14.2%) Severe 1 (0.4%) 3 (1.2%) 2 (0.8%) 9 (3.6%)
* Total number of subjects with local cutaneous data for at least one post Baseline evaluation. Table 3: Patient reported local cutaneous adverse events with DIFFERIN Gel DIFFERIN (adapalene) Gel, 0.3% N 258 Related* Adverse Events Dry Skin Skin Discomfort Desquamation 57 (22.1%) 36 (14%) 15 (5.8%) 4 (1.6%) Vehicle Gel N 134 6 (4.5%) 2 (1.5%) 0 (0.0%) 0 (0.0%)
* Selected adverse events defined by investigator as Possibly, Probably or Definitely Related Related adverse events from the controlled clinical trial that occurred in greater than 1% of patients who used DIFFERIN Gel, 0.3% once daily included: dry skin (14.0%), skin discomfort (5.8%), pruritus (1.9%), desquamation (1.6%), and sunburn (1.2%). The following selected adverse events occurred in less than 1% of patients: acne flare, contact dermatitis, eyelid edema, conjunctivitis, erythema, pruritus, skin discoloration, rash, and eczema. In a one year, open label safety study of 551 patients with acne who received DIFFERIN Gel, 0.3%, the pattern of adverse events was similar to the 12 week controlled study. OVERDOSAGE: DIFFERIN Gel, 0.3% is intended for topical use only. If the medication is applied excessively, no f P p l f more rapid or better results will be obtained and marked redness, scaling or skin discomfort may occur. Chronic t t e t of l lt t d d b b d, t l d h II t A ingestion of 2006;54:242 lead to the same side effects as those associated with excessive oral intake of vitamin A. Dermatol the drug may 50 Marketed by: GALDERMA LABORATORIES, L.P. Fort Worth, Texas 76177 USA Manufactured by: DPT Laboratories, Ltd. San Antonio, Texas 78215 USA GALDERMA is a registered trademark. Revised: June 2007 325089-0607
References: 1. Thiboutot D, Arsonnaud S, Soto P. Efficacy and tolerability of adapalene 0.3% gel compared to tazarotene 0.1% gel in the treatment of acne vulgaris. J Drugs Dermatol. 2008;7 (6)(suppl):S3-S10. 2. Data on file. Galderma Laboratories, L.P. A 3-week, single-center, randomized, investigator/evaluator-blinded, bilateral (split-face) comparison, clinical study of adults 18 years of age and older with healthy skin (N=30). Galderma is a registered trademark. 2010 Galderma Laboratories, L.P. Galderma Laboratories, L.P. 14501 N. Freeway Fort Worth, TX 76177 DIFF-088 03/10
www.differin.com
Program overview
Restricted Session open to dermatologist and adjunct (researcher, corporate) members. A ticket is required for admittance
M O C
This activity has been approved by the ABD to satisfy component 2 of MOC-D Leadership Institute addresses leadership competencies specific to dermatologists
Practice Management Session open to eligible office staff/registered nurses Patient Safety Session Audience Response System Session
Thursday, August 4
Focus Sessions 7:15 a.m. to 8:45 a.m. U001 Your True Colors: Know Yourself and Understand Others . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .38 U002 Asian American Skin . . . . . . . . . . . . . . . . . . . . . . . .38 Hidradenitis Suppurativa: An Update. . . . . . . . . . . .38 U003 U004 Medical Management of Actinic Keratoses . . . . . . . .38 Forums 9:00 a.m. to 11:00 a.m. F001 Nails . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .39 Photoprotection . . . . . . . . . . . . . . . . . . . . . . . . . . . .39 F002 F003 Case-Based Challenges in Consultative Dermatology . . . . . . . . . . . . . . . . . . . .40 F004 Face to Face: Management of Facial Dermatoses . . . . . . . . . . . . . . . . . . . . . . . . . . .40 workshop 9:00 a.m. to 11:00 a.m. W001 MOC Self-Assessment: Skin Cancer . . . . . . . . . . . .41 Symposia S001 S002 S003 9:00 a.m. to 12:00 p.m. EADV/AAD Joint Symposium . . . . . . . . . . . . . . . . .41 E.H.R. Physician Demonstration . . . . . . . . . . . . . . .42 Negotiating Your Way to Great Leadership . . . . . . .42
Focus Sessions 2:30 p.m. to 4:00 p.m. U008 Quality and Customer Service for a Better Practice. . . . . . . . . . . . . . . . . . . . . . . . . .48 U009 Smoking and the Skin . . . . . . . . . . . . . . . . . . . . . . .48 U010 Skin of Color . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .49 U011 From the Dermatology-Rheumatology Clinic: Practical Tips and Advances in Management . . . . . .49 Forums 3:00 p.m. to 5:00 p.m. F009 Review and Update of Regional Reconstruction . . . .50 F010 Legal Dilemmas in Dermatology . . . . . . . . . . . . . . .50
Program overview
workshops 3:00 p.m. to 5:00 p.m. W003 MOC Self-Assessment: Acne, Psoriasis, Eczema and Inflammatory Dermatosis . . . . . . . . . .51 Dermoscopy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .51 W004
Friday, August 5
Forums 12:00 p.m. to 2:00 p.m. F005 Infectious Disease and Infestation Update . . . . . . . .43 Whats Boiling Over: Atopic Dermatitis and Other F006 Eczematous Conditions . . . . . . . . . . . . . . . . . . . . . .43 F007 Case-Based Controversies: Procedural . . . . . . . . . . .44 F008 Case-Based Controversies: Medical . . . . . . . . . . . . . .44 workshop 12:00 p.m. to 2:00 p.m. W002 MOC Self-Assessment: Office-Based Safety . . .45 Focus Sessions 12:15 p.m. to 1:45 p.m. U005 Pitfalls in Dermatopathology . . . . . . . . . . . . . . . . . .45 U006 Bringing out the Best in Others . . . . . . . . . . . . . . . .46 U007 Neonatal Dermatology . . . . . . . . . . . . . . . . . . . . . . .46 Course 2:00 p.m. to 5:00 p.m. C001 Live Patient Demonstration: Botulinum Toxin and Fillers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .47 Symposia 2:00 p.m. to 5:00 p.m. S004 Leading High Performance Teams . . . . . . . . . . . . . .47 S005 Medication Monitoring and Complications . . . . . . .48
Focus Sessions 7:15 a.m. to 8:45 a.m. U012 Patients Satisfaction: Measurement and Improvement . . . . . . . . . . . . . . .53 U013 Whats New in Non-Melanoma Skin Cancer . . . . . .53 U014 Mastering Moles in Pediatric Patients . . . . . . . . . . . .53 U015 Laser Update . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .53 Plenary Session 9:00 a.m. to 12:00 p.m. 9:00 a.m. Chairs Welcome / Henry W. Lim, M.D. . . . . . . . 54 9:05 a.m. Presidents Address / Ronald L. Moy, M.D. . . . . . 54 9:20 a.m. Everett C. Fox, M.D., Memorial Lectureship: Sentinel Node Biopsy: Just the Facts, you Decide! / Timothy M. Johnson, M.D. . . . . . . . . . . . . . . . . 54 9:50 a.m. Guest Speaker / Don Tapscott . . . . . . . . . . . . . . . . 54 10:30 a.m. Overhauling CME and Dermatology Education: Laps, Gaps, Maps, and Traps / Erik J. Stratman, M.D. . . . . . . . . . . . . . . . . . . . 55 10:45 a.m. Contact Dermatitis / David Eric Cohen, M.D. . . . . . . 55 11:00 a.m. Update in CTCL: A Tale of Two Kinds of T-Cells / Sam T. Hwang, M.D., Ph.D. . . . . . . . . . . . . . . . 55 11:15 a.m. Comparative Effectiveness / David J. Margolis, M.D. . . . . . . . . . . . . . . . . . . 55 11:30 a.m. Non-Ablative and Ablative Fractional Resurfacing: Cosmetic and Medical Indications / Roy G. Geronemus, M.D. . . . . . . . . . . . . . . . . . . 56
www.aad.org
17
Program overview
Course 2:00 p.m. to 5:00 p.m. C002 Live Patient Demoonstration - Neurotoxins and Soft Tissue Augmentation . . . . . . . . . . . . . . . . .57 Symposia 2:00 p.m. to 5:00 p.m. S006 Whats Hot in Dermatopathology . . . . . . . . . . . . . .57 S007 Effective Communications: Delivering Key Messages . . . . . . . . . . . . . . . . . . . . .58 Focus Sessions 2:30 p.m. to 4:00 p.m. U016 From Bench to Bedside: Important Clinical Advances . . . . . . . . . . . . . . . . . .58 U017 Photodynamic Therapy. . . . . . . . . . . . . . . . . . . . . . .58 U018 Dermoscopy for the Non-Dermoscopist . . . . . . . . . .59 Cellulitis: A Common (Mis)Diagnosis? . . . . . . . . . .59 U019 Forums 3:00 p.m. to 5:00 p.m. F011 Using Technology to Improve Dermatology Access . . . . . . . . . . . . . . . . . . . . . . . . .59 F012 Case-Based Challenges for PA/NPs . . . . . . . . . . . . .60 Melanoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .60 F013 F014 Finessing Surgical Technique . . . . . . . . . . . . . . . . . .61 Forums 12:00 p.m. to 2:00 p.m. F018 Hypercoagulability, Purpura and the Skin . . . . . . . .69 F019 Oral Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .69 F020 Tumor Board . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .70 workshop 12:00 p.m. to 2:00 p.m. W006 Practical Approaches to Patient Problems . . . . . . . .70 Focus Session 12:15 p.m. to 1:45 p.m. U024 When Clinical and Histological Findings Converge: Great Cases From a Dermatopathologists Perspective . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .71 U025 Impact of Nanotechnology and Dermatology. . . . . .71 U026 Pediatric Dermatology Jeopardy . . . . . . . . . . . . . . . .71 Symposium 2:00 p.m. to 5:00 p.m. S010 Cutting Edge Surgery and Oncology . . . . . . . . . . . .72 Focus Sessions 2:30 p.m. to 4:00 p.m. U027 Practical Dermoscopy . . . . . . . . . . . . . . . . . . . . . . . .72 U028 Morphea: Not Just for Adults Anymore . . . . . . . . . .72 Forums 3:00 p.m. to 5:00 p.m. F021 New Technologies in Minimally Invasive Skin Rejuvenation . . . . . . . . . . . . . . . . . . . .73 Psoriasis Guidelines: Implementing F022 them in Your Practice . . . . . . . . . . . . . . . . . . . . . . . .73 workshop 3:00 p.m. to 5:00 p.m. W007 Coding and Documentation . . . . . . . . . . . . . . .74
Program overview
workshop 3:00 p.m. to 5:00 p.m. W005 MOC Self-Assessment: Pediatric Dermatology . . . .62
Saturday, August 6
Focus Sessions 7:15 a.m. to 8:45 a.m. U020 Exploring Evidence Based Cosmeceuticals . . . . . . . .64 Controversies in Dysplastic Nevi . . . . . . . . . . . . . .64 U021 U022 Patch Test Allergens 101: A Detectives Toolkit . . . . . . . . . . . . . . . . . . . . . . . . .65 Use of Light for Diagnosis and U023 Treatment in Dermatology . . . . . . . . . . . . . . . . . . . .65 Forums 9:00 a.m. to 11:00 a.m. F015 Alopecia and Hair Loss. . . . . . . . . . . . . . . . . . . . . . .66 Consultative Dermatology . . . . . . . . . . . . . . . . . . . .66 F016 F017 Case-Based Controversies: Dermatopathology . . . . . . . . . . . . . . . . . . . . . . . . . .66 Symposia 9:00 a.m. to 12:00 p.m. S008 Whats Hot in Womens Dermatology . . . . . . . . . . .67 S009 Dermatology Grand Rounds: A Discussion of CaseBased Dilemmas . . . . . . . . . . . . . . . . . . . . . . . . . . . .68 Course 9:00 a.m. to 5:00 p.m. C003 Derm Exam Prep Course: Refresher . . . . . . . . . . . . .68
Sunday, August 7
Focus Sessions 7:15 a.m. to 8:45 a.m. U029 Leprosy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .76 Optimizing Management of Melanoma: U030 Recognizing and Responding to Common Dilemmas in Patient Care . . . . . . . . . . . .76 U031 The Interface of Skin and Psyche . . . . . . . . . . . . . . .76 U032 Spitzs Genodermatoses . . . . . . . . . . . . . . . . . . . . . . .76 U033 Infectious Disease Update: What I Wouldnt Have Known Without Evidence-Based Medicine . . . . . . .77 Forum 9:00 a.m. to 11:00 a.m. F023 Pathology and Procedures of the Aging Hand . . . . .77 Symposia 9:00 a.m. to 12:00 a.m. S011 Whats Hot in Pediatric Dermatology. . . . . . . . . . . .78 S012 Whats Breaking Out: Acne and Rosacea . . . . . . . . .78
18
SATURDAy, AUGUST 6
7:15 a.m. to 8:45 a.m. 9:00 a.m. to 11:00 a.m. 9:00 a.m. to 12:00 p.m. 9:00 a.m. to 5:00 p.m. 12:00 p.m. to 2:00 p.m. 12:15 p.m. to 1:45 p.m. 2:00 p.m. to 5:00 p.m. 2:30 p.m. to 4:00 p.m. 3:00 p.m. to 5:00 p.m.
FRIDAy, AUGUST 5
7:15 a.m. to 8:45 a.m. 9:00 a.m. to 12:00 p.m. 2:00 p.m. to 5:00 p.m. 2:30 p.m. to 4:00 p.m. 3:00 p.m. to 5:00 p.m.
SUNDAy, AUGUST 7
7:15 a.m. to 8:45 a.m. 9:00 a.m. to 11:00 a.m. 9:00 a.m. to 12:00 p.m.
NOTES
www.aad.org
19
general information
MEETING LOCATION
NON-MEMBER REGISTRATION
Summer Academy Meeting 2011 will take place August 3-7 in New York, N.Y. On-site offices, exhibits, services, and all educational sessions will be located at: Hilton New York 1335 Avenue of the Americas New York, NY 10019 www.hilton.com
Non-members must submit an online request form for registration approval and access ID number. See the chart on page 23 for a list of non-member registration categories. New this year, non-member requests and required documentation will only be accepted via the online submission page located in the attendee registration area at www.aad.org/meetings-and-events/summer-meeting. Once approved, the registration and housing brochure will be sent via U.S. mail and an access ID number will be sent to the e-mail address supplied online. The deadline for submission and approval is Friday, July 15, 2011 at 12 p.m. (CT). Please allow 10-12 days for approval, processing, and receipt of materials, including access ID number. Note: In an effort to make the meeting more environmentally friendly, program books will no longer be mailed out to non-member registrants. The complete program book can be accessed online. Program books will be available on-site for reference. Questions: E-mail: mrc@aad.org or registration@aad.org (866) 503-SKIN (7546) Toll-free phone:
REGISTRATION INFORMATION
Early registration
Early registration and housing for Summer Academy Meeting 2011 begins at 12:00 p.m. (CT), Wednesday, May 11, 2011, according to the schedule below. Registration and housing forms faxed in prior to the opening of early registration will be held and processed based on the date and time received and the schedule listed below. Allow 3-5 business days for the processing of faxed forms. Physician, life, and honorary members .......................Wednesday, May 11 Graduate members, residents, research fellows, and medical students ...........................Wednesday, May 18 Adjunct members, physician assistants and nurse practitioners, office staff, registered nurses, and non-members ...............................Wednesday, May 25 Early registration for members and approved non-members closes at 12:00 p.m. (CT) on Wednesday, July 6, 2011. After this date and time late registration will apply. Between July 27 at 12 p.m. (CT) August 3 at 12 p.m. (CT) all registration systems will be closed. On-site registration will begin at 12 p.m. (CT) on Wednesday, August 3, 2011.
general information
Spouse/Guest registration includes spouses, family members (children 16 years or older), and guests accompanying registrants. A guest is defined as a significant other, friend, or a child 16 years or older. Photo ID and proof of age (drivers license, student ID, birth certificate) will be required. A co-worker or an associate within the industry does not qualify for the guest registration category. Spouse/Guest registration is available for one person per physician registrant. Registrants in this category may attend non-restricted symposia, plenary sessions, electronic posters and technical exhibits. This category will not be issued an ExpoCard or a Certificate of Attendance.
www.aad.org
21
general information
Registration instructions
Registration and housing for the Summer Academy Meeting 2011 may be completed online, by fax, or by mail. Registration, including enrollment in specific sessions, is on a first-come, first-served basis. Registration forms are enclosed with this book. All forms are non-transferable.
REGISTRATION TyPE ONLINE REGISTRATION REGISTRATION INSTRUCTIONS To register and book housing online for Summer Academy Meeting 2011, go to: www.aad.org/meetings-and-events/summer-meeting click on Attendee Registration and Housing and follow the instructions. You will need to input the ID number that is preprinted above your name on the back of the registration and housing brochure. FAX REGISTRATION To register by fax, complete all registration and housing forms and fax to: (800) 521-6017 (U.S. and Canada) Credit card Three to five business days from receipt PAyMENT METHOD Credit card only
(Visa, Mastercard, or American Express)
general information
CUSTOMER SERvICE For additional assistance in completing your registration call the AAD Registration Office at (847) 996-5876 or (800) 974-3084 or call the AAD Meetings and Conventions Department at (847) 330-0230. ADA / SPECIAL ASSISTANCE Academy staff will be available to help individuals with any special needs (i.e., physical). Please complete the appropriate section on the registration form and a staff member will contact you. TICkETED EvENTS Registrants should identify sessions for which they are requesting tickets when they complete general registration (see chart page 24 for information on session categories, including ticket requirements and tuition fees). Enrollment in ticketed sessions is on a first-come, first-served basis. Alternate choices should be identified. Enrollment in multiple sessions during the same time slot is not permitted.
Confirmation letters will be sent to all registrants who register prior to the start of on-site registation. If an e-mail address is provided, confirmation will be sent via e-mail. If no e-mail address is provided, the confirmation will be sent via fax. If neither an e-mail address or fax number is supplied, confirmation will be sent via U.S. mail. Once you have received a confirmation letter, you may review and print registration information online. To do so, take the following steps: 1. Visit www.aad.org/meetings-and-events/summer-meeting 2. Click on Attendee Registration and Housing 3. Click on Already Registered 4. Enter registration confirmation number and last name, then click Find Me Once in your personal record, you may print a copy of your receipt, pay a balance due, or make changes to your registration and housing. An updated confirmation will be sent after changes are processed.
22
general information
REGISTRATION CATEGORIES, ACCESS, AND FEES
The chart below details fees and sessions access for all categories eligible to register for Summer Academy Meeting 2011. For further information on membership eligibility, please refer to www.aad.org/member-tools-and-benefits/become-a-member or e-mail mrc@aad.org.
Member categories
REGISTRATION FEES REGISTRATION CATEGORy Physician member Adjunct (researcher, corporate)** Adjunct other** Life member Honorary member Graduate member/Resident/Research Fellow**
5/11/11 7/6/11 at 12:00 p.m. (CT)
EARLy
LATE
Y Y Y
Non-member categories
REGISTRATION CATEGORy Medical student* ** Non-dermatology resident**
(See page 21 for information on obtaining a non-member request form for registration approval)
general information
REGISTRATION FEES
5/11/11 7/6/11 at 12:00 p.m. (CT)
EARLy
LATE
Non-member physician + (treating patients in an office-like setting) Physician assistant/nurse practitioner* ** (working in an AAD member dermatologists office) Resident/Research Fellow** (outside U.S. and Canadian program) Office staff/registered nurse* (working in a dermatologists office) Non-member, non-physician (Non-member corporate individuals and industry representatives or scientists working in field of the dermatology)* **++ Spouse/guest ++
$1,285
$1,410
$65
$85
* This category is not eligible to register a spouse/guest along with registation. ** This category is not eligible to register office staff/RN along with registration. + Only dermatologists in this category may register office staff/RN along with registration. ++ This category of registration will not be issued an ExpoCard with registration.
www.aad.org
23
general information
SESSION CATEGORIES, ACCESS AND FEES
The chart below details session types at Summer Academy Meeting 2011 as well as session fees where applicable. Meeting attendees should register for specific sessions requiring tickets when completing general registration. See page 25 for details on distribution of tickets and other meeting materials.
TUITION FEE SESSION TyPE Derm Exam Prep Course: Refresher** SESSION DESCRIPTION This couse is targeted at the Board Certified Dermatologist preparing for the American Board of Dermatology (ABD) Maintenance of Certification in Dermatology (MOC-D) exam. Residents preparing for their Board exam may also benefit, but this course is not designed as a Prep for initial board certification. Live patient demonstration** Interactive session presenting live demonstrations of botulinum toxin and soft tissue filler injections; open to dermatologists and adjunct (research, corporate) members only Sessions comprised of individual presentations focused on a specific subject; open to dermatologists and adjunct (research, corporate) members only Sessions comprised of individual presentations focused on a specific subject Sessions emphasizing media training, clinical care, and technical skills Sessions exploring a single subject Sessions with an emphasis on discussion and participant interaction Y $100 $400 $60 TICkET REQUIRED Y Members and PAs/NPs $300 Non-Members and Office Staff/RNs N/A Medical Students and Residents $150
Restricted symposia*
No fee
No fee
No fee
Non-restricted symposia*
No fee
No fee
No fee
general information
Y Y Y
* ickets for sessions with no fee will hold a seat for 15 minutes after the official start time, after which seats will be T available on a first-come first-served basis for eligible categories. ** Attendees attending sessions with a fee must have a ticket for admittance.
In addition to the regularly scheduled exhibit hours: Thursday .............................................. 12 p.m. to 6 p.m. Friday .................................................. 12 p.m. to 6 p.m. Saturday ............................................... 10 a.m. to 2 p.m. the Academy is offering two hours of unopposed exhibit hours on: Friday, August 5 ..............................12 p.m. to 2 p.m. During this time, physicians may visit the technical exhibits, without conflicts to their educational session schedule.
24
general information
CANCELLATIONS
General registration
MEETING MATERIALS
Registrants who wish to cancel all of their general registration should send a letter of cancellation via one of the following methods: E-mail: Fax: Deadline: aad@experient-inc.com (847) 996-5401 or (800) 521-6017 12 p.m. (CT), Wednesday, July 27, 2011; no refund will be given for cancellations received after this date. No exceptions will be made. $75 (fee will be deducted from refund amount); $25 (fee will be deducted for all spouse/guest cancellations) Cancellations received by 12 p.m. (CT), Wednesday, July 27, 2011 will be processed and refunds issued prior to the meeting.
U.S. and Canadian registrants who complete registration by 12 p.m. (CT), on Wednesday, July 6, 2011, will have their badges, tickets, and attendance verification/meeting bag voucher sent by U.S. mail to U.S. registrants, and via special courier service to Canadian registrants between July 11 and July 15, 2011. Materials will be mailed to the address listed on your registration record, which will also be listed on your ExpoCard. In the event that you do not receive your materials prior to the meeting, a new set can be picked up at the on-site registration counters. Ticketed event changes/cancellations for U.S. and Canadian registrants who will be receiving their materials by mail will only be accepted until Wednesday, July 6, 2011 at 12 p.m. (CT). After this date and time, ticket cancellations and changes will need to be made on site at the meeting. For housing changes/cancellations, refer to the hotel and travel information section of the program book page 27.
INTERNATIONAL REGISTRANTS AND INDIvIDUALS wHO REGISTER AFTER wEDNESDAy, JULy 6, 2011 AT 12 P.M. (CT)
Fee:
Processing:
Tickets returned on-site will be processed and refunds issued four to six weeks after the meeting. No-shows: No-shows are considered to have missed the Wednesday, July 27, 2011 deadline and are not eligible for a refund. No refunds will be issued for on-site registration. Registration is non-transferable. If you cannot attend the meeting, you must submit a cancellation; you may not change the name on your registration.
general information
All international registrants and U.S. and Canadian registrants who register after 12 p.m. (CT) on July 6, 2011, will need to pick up badges, tickets, and vouchers on site at the On-site Registration Counters. See page 28 for locations.
CORRECTIONS
For hotel reservation cancellation, please see hotel and travel information section on page 26.
Upon receipt, please review materials for accuracy. If a discrepancy or error is found, send an e-mail to registration@aad.org by 12 p.m. (CT), Wednesday, July 27, 2011 with the following information: Full name Registration confirmation number Error or discrepancy found The AAD will make every attempt to make corrections received by the deadline prior to the start of the meeting. Corrected tickets must be picked up at the On-site Registration Counter (see page 28 for locations and times). Corrections received after the deadline must be made On-site at the Registration Counter.
ATTENDANCE vERIFICATION, MEETING BAGS, OTHER MATERIALS
Session tickets must be returned prior to the start time of the session in order to obtain a refund. To return session tickets prior to the meeting, refer to the Meeting Materials section. Session tickets may be returned on site at the On-site Registration Counter. Tickets cannot be returned or exchanged after the start of the session. Refunds will not be issued for late arrival or for non-attendance.
Those who registered during the early registration phase and received their meeting packet may redeem their attendance verification/meeting bag voucher on site at the Attendance Verification/Meeting Bag Counter. The attendance verification/meeting bag voucher must be presented so that attendance can be verified and CME credit claimed. See page 28 for counter times and location.
www.aad.org
| 25
general information
BADGE IDENTIFICATION
Registration categories will be indicated by badge color as described below. Specific categories will appear in bold at the bottom of each badge.
BADGE TyPE
CHARITABLE CONTRIBUTIONS
You can make a tax-deductible contribution when you register for the Summer Academy Meeting 2011, or at the AAD Resource Center located in Booth 906 in the Technical Exhibit Hall. AAD Camp Discovery Endowment Children with chronic skin conditions enjoy AAD Camp Discovery, a summer camp where they can meet others with similar conditions. You can help support this unique summer camp opportunity! Six week-long sessions serve more than 300 children each year. AAD Shade Structure Program You can be a part of the Academys efforts to reduce skin cancer occurrences. More than 200 protective shade structures have been built through this program, sheltering more than 158,000 people from harmful UV rays each day. Your help is needed to expand this important component of our skin cancer prevention efforts.
Thank you for Furthering Excellence in DermatologyToday and Tomorrow
BLUE
Medical personnel
Physician members, life members, honorary members, graduate members, residents, research fellows, physician assistants/nurse practitioners, non-dermatology residents, medical students, non-member physicians Adjunct members, office staff/registered nurses, and non-member non-physicians Spouses/guests (note: no badge will be issued to children under 16 years) Exhibitors Press AAD staff
yELLOw
general information
Separate registration counters will be set up for medical personnel and allied health personnel. Please utilize the appropriate designated counters based on your registration type. Please refer to the listing above.
Letters of Invitation
If you require a Letter of Invitation, please submit a written request via e-mail to registration@aad.org once you have completed your registration. Letters will be sent once registration verification is complete. Due to security concerns, letters will only be issued to registrants who have completed their registration by the Wednesday, July 27, 2011, 12 p.m. (CT) deadline.
Certificate of Attendance
International registrants, physician assistants/nurse practitioners, office staff/registered nurses, medical students, and adjunct members may print a Certificate of Attendance on site. To do so, take your ExpoCard to the registration area located on the 2nd Floor Promenade of the Hilton New York. Certificate of Attendance stations will be available beginning Friday, August 5, 2011. Certificates will not be issued for the spouse/guest & non-member nonphysician categories.
Guest rooms are being held for Summer Academy Meeting 2011 registrants at the Hilton New York, Sheraton New York, and The London, at AAD discounted meeting rates for those booking through the AAD Housing Office. These rates are lower than available hotel rack rates. See the registration and housing brochure for information on hotel reservations. Individuals who book reservations directly with the hotel are not guaranteed the AAD discount. Additional hotels may be added if needed. Reservations may be made online, by fax, or by mail through the AAD Housing Office in conjunction with registration for the meeting and according to the registration schedule on page 23. Hotel reservations for those not registered for the meeting cannot be accommodated. Be prepared to finalize your travel plans immediately as hotel rooms go quickly. Availability cannot be guaranteed for reservation requests received after the housing deadline of July 12, 2011 at 12 p.m. (CT).
PAyMENT INFORMATION
Registration and housing fees may be paid by credit card (Visa, Mastercard, or American Express) or by check, payable to AAD Registration and Housing.
26 | AmericAn AcAdemy of dermAtology SUmmer AcAdemy meeting 2011
general information
HOTEL RESERvATION CANCELLATION
Deadline Tuesday, July 12, 2011 at 12 p.m. (CT) Send a letter of cancellation to: E-mail: aad@experient-inc.com or Fax to AAD Housing Office: (847) 996-5401 or (800) 521-6017 A full refund of your deposit will be issued. After Tuesday, July 12, 2011 at 12 p.m. (CT) Requests for changes or cancellations will NOT be processed by the AAD Housing Office after 12 p.m. (CT), July 12, 2011. Refunds of deposits will NOT be issued for cancellations received after 12 p.m. (CT), Tuesday, July 12, 2011 regardless of method of cancellation Between Tuesday, July 12, 2011 and Friday, July 15, 2011 The Academy will be transferring reservation information to hotels, and hotels will be processing reservations into their systems. Refund of deposits will NOT be issued for cancellations received after 12 p.m. (CT), Tuesday, July 12, 2011 regardless of method of cancellation. Starting July 16, 2011 Contact the hotel directly to cancel or change a reservation. Refunds of deposits will NOT be issued for cancellations received after 12 p.m. (CT), Tuesday, July 12, 2011 regardless of method of cancellation. No late check-in Failure to check in on the scheduled date of arrival will result in the loss of deposit and cancellation of the room.
Association Travel Concepts Registrants may book online, by phone or e-mail with the AADs official travel agency, Association Travel Concepts Online: E-mail: Phone: Hours: Booking fees: www.atcmeetings.com/aad reservations@atcmeetings.com (800) 458-9383 Monday Friday, 7:30 a.m. to 6 p.m. (CT) Online: $7 e-mail: $35 phone: $35 (Fees apply to ticketed reservations) New Users click Create a New Account to get started.
United and American You may also book through your own agency or contact the airlines directly. Refer to the ID numbers indicated below to receive applicable discounts. United Airlines: 800) 521-4041 ID: 510CK
general information
Discounts on vehicle rentals with Avis and Hertz are available to meeting registrants. Avis Contact Avis directly and provide the Avis World Wide discount number A723900 when making your reservation. Reservations may be made on the Web or by phone. Website: Phone: www.avis.com (800) 831-8000 (U.S.) (800) 879-2847 (Canada)
Travel information
AIR TRAvEL
The following discounts and services have been negotiated for registrants traveling to the Summer Academy Meeting 2011 in New York, N.Y. through the Academys official travel agency, Association Travel Concepts (ATC), on United Airlines and American Airlines: Up to 5 percent off applicable classes of service for United Airlines tickets purchased more than 30 days prior to the meeting. Restrictions apply. 5 percent off applicable classes of service for American Airlines tickets purchased prior to the meeting. Personalized services. Low fare options. Advanced seat assignment and special meal requests. Frequent flyer program updates. The above discounts apply for flights between July 31- August 10, 2011 to or from John F. Kennedy or LaGuardia Airports. Additional services are available through Association Travel Concepts when booking online, including airport parking, event tickets, dining reservations, mobile device alerts, personal profile, 24/7 online access, powerful search options, hold trips, low fares search options.
(Those outside U.S. and Canada should contact their local Avis office.)
Hertz Contact Hertz directly and provide the discount code 0010533 when making your reservation or submit a coupon or promotional coupon number. Reservations may be made on the Web or by phone. Website: Phone: www.hertz.com (800) 654-2210 (U.S.) (800) 263-0600 (Canada)
(Those outside U.S. and Canada should contact their local Hertz office.)
www.aad.org
27
general information
ON-SITE SERvICES AND EXHIBITS
ACADEMy OFFICES/EXHIBITS
All locations are in the Hilton New York unless otherwise indicated. Additional information, including hours of operation, for these and other offices, exhibits, and services on site at Summer Academy Meeting 2011 follows. AAD Resource Center ..............................................................................................................................................Booth 906 Board of Directors Office ....................................................................................................................................Harlem Suite Business Center .......................................................................................................................................................... 2nd floor Convention Office ..................................................................................................................................... Gramercy Suite AB Development Office ............................................................................................................................................ Hudson Suite Cyber Center ...........................................................................................................................................2nd floor Promenade Poster Exhibits ......................................................................................................................................... 3rd floor Promenade Registration .............................................................................................................................................2nd floor Promenade Press Registration .....................................................................................................................................2nd floor Promenade Speaker Ready Room ................................................................................................................................ Murray Hill Suite A Technical Exhibits ........................................................................................... Rhinelander Gallery & Americas Halls I and II
general information
Registration services
ON-SITE REGISTRATION COUNTER: 2ND FLOOR PROMENADE
Exhibits
TECHNICAL EXHIBITS: RHINELANDER GALLERy & AMERICAS HALLS I AND II
On-site Registration will open on Wednesday, August 3 at 12 p.m. For those who have not registered prior to this date, tickets for available sessions may be selected here. A photo ID must be presented. Each individual can pick up ONLY his or her own materials, with the exception of the spouse/guest badge. The On-site Registration Counter will be open during the following hours: Wednesday, August 3 ................................12 p.m. 6 p.m. Thursday, August 4...................................... 7 a.m. 6 p.m. Friday, August 5 .......................................... 7 a.m. 6 p.m. Saturday, August 6 ...................................... 7 a.m. 5 p.m. Sunday, August 7 ...................................... 7 a.m. 12 p.m.
ATTENDANCE vERIFICATION/MEETING BAG PICkUP COUNTER: 2ND FLOOR PROMENADE
The Technical Exhibit Hall will be open during the following hours: Thursday, August 4....................................12 p.m. 6 p.m. Reception .............................................. 5 p.m. 6 p.m. Friday, August 5 ........................................12 p.m. 6 p.m. Unopposed Exhibit Hours ................... 12 p.m. 2 p.m. Saturday, August 6 .................................... 10 a.m. 2 p.m. Infants and children under age 16 will not be admitted to the Technical Exhibit Hall. This policy was created for the safety of the children of Academy members and guests. Your compliance is appreciated.
AAD RESOURCE CENTER: BOOTH #906
All registrants should redeem their attendance verification/ meeting bag voucher at the Attendance Verification/Meeting Bag Counter during the on-site registration hours listed above. This voucher must be redeemed in order to claim CME credit.
The AAD Resource Center contains information on Academy membership as well as applications, and information on Academy services and products. Staff will be available during regular exhibit hours to answer questions.
28
general information
ELECTRONIC POSTER EXHIBITS/POSTER PRESENTATIONS: 3RD FLOOR PROMENADE BUSINESS SERvICE CENTER: 2ND FLOOR
Electronic Poster Exhibits viewing stations will be open during the following hours: Thursday, August 4...................................... 7 a.m. 6 p.m. Friday, August 5 .......................................... 7 a.m. 6 p.m. Saturday, August 6 ...................................... 7 a.m. 5 p.m. Poster authors will conduct brief presentations of their electronic posters at the Poster Presentation Centers in the 3rd floor Promenade during the meeting. A full schedule of presentations will be available on the Summer Academy Meeting 2011 website at www.aad.org in June, and posted on-site at the meeting.
The Business Service Center is available to all meeting registrants. Available services include photocopying, transparencies, fax transmissions and receipts, and FedEx and U.S. mail drop-off. Payment is required at time of service; major credit cards are accepted. The Business Center will be open during the following hours: Wednesday, August 3 ................................12 p.m. 6 p.m. Thursday, August 4...................................... 8 a.m. 5 p.m. Friday, August 5 .......................................... 8 a.m. 5 p.m. Saturday, August 6 ...................................... 8 a.m. 5 p.m. Sunday, August 7 ...................................... 8 a.m. 12 p.m.
CyBER CENTER: 2ND FLOOR PROMENADE
Other Services
EvALUATION AND CME vERIFICATION
The Cyber Center will be open during the following hours: Wednesday, August 3 ................................12 p.m. 6 p.m. Thursday, August 4...................................... 7 a.m. 6 p.m. Friday, August 5 .......................................... 7 a.m. 6 p.m. Saturday, August 6 ...................................... 7 a.m. 5 p.m. Sunday, August 7 ...................................... 7 a.m. 12 p.m.
The overall evaluation form and CME credit reporting form will be provided in the registration bag distributed on site. Only those who have submitted their Attendance Verification/Meeting Bag voucher are eligible to claim CME credit.
SPEAkER READy ROOM: MURRAy HILL SUITE A
general information
The Speaker Ready Room will be open during the following hours: Wednesday, August 3 ................................12 p.m. 6 p.m. Thursday, August 4............................ 6:30 a.m. 5:30 p.m. Friday, August 5 ................................ 6:30 a.m. 5:30 p.m. Saturday, August 6 ............................ 6:30 a.m. 5:30 p.m. Sunday, August 7 ................................. 6:30 a.m. 12 p.m.
www.aad.org
29
general information
PRESS REGISTRATION: 2ND FLOOR PROMENADE
Journalists who are working for and representing recognized news organizations are encouraged to register to attend the meeting as Press. Press may register to attend the Summer Academy Meeting 2011 in advance or at the On-site Press Registration Desk. To register, journalists must provide a business card and samples of their work. All freelancers must present a letter of assignment. Please note, the Academy will not be hosting a Press Office at the Summer Academy Meeting 2011.
MOBILITy SERvICE
Twenty-four hour mobility service is available by contacting ScootAround, Inc. Toll-free phone: E-mail: Fax: (888) 441-7575 info@scootaround.com (204) 478-1172
Mobility service during Summer Academy Meeting 2011 official meeting hours is available. Should your needs require mobility service strictly during official meeting hours, you may reserve a scooter through the Academy, free of charge. To do so, check the ADA Mobile box under the Personal Information page of your online registration. You will be required to pick up and drop off your scooter in the AAD Convention Office, Gramercy Suite AB, each meeting day.
TOURS
general information
The concierge at your hotel can assist with arrangements for sightseeing tours. Should you require tour information after you have arrived at the hotel, the Concierge Desk can be reached from any house phone or sleeping room. The Academy has no control over and assumes no responsibility for the tours that are provided by independent tour operators. This information is provided solely to assist Summer Academy Meeting 2011 participants.
CHILD CARE SERvICES
Contact the Concierge Desk at your hotel to arrange for child care services. Arrangements should be made as early as possible prior to your anticipated arrival. The Academy has no control over and assumes no responsibility for the care provided through the hotels. This information is provided solely as a service to help registrants identify possible resources for child care services.
MEETING HANDOUTS
Meeting handouts will be available beginning July 1, 2011 on the Academys Website at www.aad.org/meetings-andevents/summer-meeting. Handouts will no longer be distributed on site via DVD for Summer Academy Meeting 2011.
30
general information
It is the responsibility of the session director to ensure balance with regards to disclosure of potential conflicts of interest. In addition, all speakers are required to complete the speaker attestation form indicating compliance with these policies. Content Validation Academy-sponsored educational activities are designed to promote improvements or quality in health care and not promote a specific proprietary business interest or a commercial interest. Presentations and related materials must be based on scientific methods generally accepted by the medical community. Presentations should be evidence-based and discuss the validity of the evidence upon which they base the opinion(s). (See Sackett et al, BMJ 1996;312:71-2.) This ensures the audience that the recommendations are supported by the evidence and contributes to management of any potential conflicts of interest. Further, if the presentation includes discussion of unlabeled or investigational use of a commercial product, this also must be disclosed to the participants. CME must give a balanced view of therapeutic options. Use of generic names will contribute to this impartiality. If CME educational material or content includes trade names, trade names from several companies should be used where available, as opposed to using trade names from just a single company. Educational materials such as slides, abstracts, and handouts cannot contain any advertising or product-group messages. Outcomes Measurement Several methods of evaluation are utilized in assessing the educational program. Session directors, speakers, attendees, and formal observers are all given the opportunity to evaluate the educational content and speaker performance. Included in this process are measures to rate the success of the Academys policies regarding independence in continuing medical education activities with particular focus on the absence of commercial bias. In addition, the Academy may review speaker presentations stored on the meeting servers to collect aggregate data regarding disclosure. These data are only used to determine effectiveness of the Academys policies and procedures regarding disclosure. Should it be determined that a member of the Academys educational program violated the Academys Policy to Ensure Independence in Continuing Medical Education, the individual may not be asked to participate in future educational programs.
AGE LIMITS
Infants and children under the age of 16 are not allowed into educational sessions or the Technical Exhibit Hall. This policy is due to the nature of some presentations and to ensure the safety of registrants children. Your support and compliance are appreciated.
CAMERA/vIDEO RECORDING
Use of cameras, camera phones, and video cameras is prohibited in all educational sessions. Violations of this policy will result in removal from the session and confiscation of equipment. Directors and room monitors will be closely monitoring adherence to this policy.
CELL PHONES
Cell phone usage during education sessions is disruptive and is therefore prohibited. Session attendees are asked to turn off cell phones or place them on vibrate prior to entering a session room. Violations of the policy will result in removal from the session room. Session directors and room monitors will be closely monitoring adherence to this policy.
general information
SMOkING
All AAD educational programs within meeting rooms and seated functions occurring during the meeting are smoke free. Please also comply with the smoking policy of each individual facility.
ALCOHOLIC BEvERAGES
The Academys official policy regarding the minimum age for alcohol consumption is the age applicable to the jurisdiction of the event venue.
www.aad.org
31
general information
OFFICIAL LANGUAGE
AAD Staff
MEETINGS AND CONvENTIONS DEPARTMENT
The Meetings and Conventions Department administers the Summer Academy Meeting 2011. For further information, please contact the following staff members by phone at (847) 330-0230, fax (847) 330-1090 or e-mail mrc@aad.org. Timothy Moses, CMP...... Director, Meetings and Conventions Debra Barrett ..............................Senior Manager, Meetings Robin Downey ....................... Senior Manager, Registration Sara Peterson, CEM ..................... Senior Manager, Exhibits Amanda Sage, CMP ....................Senior Manager, Meetings Tamara Pundsack ........................Senior Meetings Specialist Joni Taylor .............................................. Exhibits Specialist Susan Jackson ................................ Administrative Specialist Krysten Zarembski ............................Meetings Coordinator Rachel Jamieson ................................. Registration Assistant
Please be aware that the room locations listed in this program book may change prior to the meeting. Refer to the Program Book Update under the Summer Academy Meeting 2011 section of the AAD website at www.aad.org. When on site, the Program-at-a-Glance will have updated room changes. The Program-at-a-Glance will be distributed to all registrants in the meeting bag.
SCIENTIFIC SESSIONS/TICkETED SESSION LATE ARRIvALS
Tickets for sessions with no fee will hold a seat for a registered attendee until 15 minutes after the official start time of the session. After the first 15 minutes, seats will be available on a first-come, first-serve basis to eligible categories. Individuals attending sessions with a fee must have a ticket for admittance.
general information
EDUCATION DEPARTMENT
The Education Department develops and administers the educational program for the Summer Academy Meeting 2011. For further information, please contact the following staff members by phone at (847)330-0230, Fax (847)330-1135, or e-mail mrc@aad.org. Debra L. Gist, MPH, FACME............. Director, Education Jennifer Thompson, MS ...... Senior Manager, Live Education Jennifer Wahl ....................................... Education Specialist Michelle Michelotti ......................... Education Coordinator
CREATIvE AND PUBLISHING DEPARTMENT
The Creative and Publishing Department designs, edits, and produces the Summer Academy Meeting 2011 Program Book. Lara Lowery .................... Director, Creative and Publishing Ed Wantuch ...............................................Design Manager Nicole Torling ............................................... Lead Designer Joe Miller .................................................Graphic Designer Katie Domanowski................... Senior Manager, Publishing Dean Monti ............ Managing Editor, Special Publications Nate Jenkins ........................................ Production Manager Carrie Parratt ..................................... Advertising Specialist Jon Dudek ..........................................Production Specialist
32 | AmericAn AcAdemy of dermAtology SUmmer AcAdemy meeting 2011
The American Academy of Dermatology extends its most sincere appreciation to our Sustaining Fund Donors!
Your support helps us expand and enhance our educational and humanitarian mission. Thank you for Furthering Excellence in DermatologyToday and Tomorrow!
Receive 5% off
AAD Apparel including scrubs and lab coats! Personalize it!
NEw Patient
Communication Surveys learn how to improve your practice and help satisfy Component 4 of MOC-D. Peer Communication Surveys coming soon!
Save $25 on
Dermoscopy: A Guide for the Physician.
1% CMS bonus!
Cetaphil RESTORADERM Skin Restoring Moisturizer and Body Wash formulated for atopic dermatitis
Patented technology helps restore hydration in atopic skin1,2: Ceramides help replenish the skins natural lipids Filaggrin technology helps restore moisture to help rebuild the damaged skin barrier Clinically proven to help soothe itch and reduce redness, dryness and irritation2 Highly tolerable; preservative and fragrance free2
cetaphil.com
References: 1. Sugarman JL. The epidermal barrier in atopic dermatitis. Semin Cutan Med Surg. 2008;27:108-114. 2. Data on file. Galderma Laboratories. Galderma, Cetaphil and RESTORADERM are registered trademarks. 2011 Galderma Laboratories, L.P. Galderma Laboratories, L.P., 14501 N. Freeway, Fort Worth, TX 76177 CETA-278 Printed in USA 03/11
scientific sessions
For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information.
Restricted Session open to dermatologist and adjunct (researcher, corporate) members. A ticket is required for admittance
M O C
This activity has been approved by the ABD to satisfy component 2 of MOC-D Leadership Institute addresses leadership competencies specific to dermatologists
Practice Management Session open to eligible office staff/registered nurses Patient Safety Session Audience Response System Session
Thursday, August 4
Focus Sessions 7:15 a.m. to 8:45 a.m. U001 Your True Colors: Know Yourself and Understand Others .....................................................................38 U002 Asian American Skin ...............................................38 Hidradenitis Suppurativa: An Update......................38 U003 U004 Medical Management of Actinic Keratoses ..............38 Forums F001 F002 F003 F004 9:00 a.m. to 11:00 a.m. Nails ........................................................................39 Photoprotection.......................................................39 Case-Based Challenges in Consultative Dermatology .......................................40 Face to Face: Management of Facial Dermatoses ....................................................40
Focus Sessions 12:15 p.m. to 1:45 p.m. U005 Pitfalls in Dermatopathology ...................................45 U006 Bringing out the Best in Others ..............................46 Neonatal Dermatology ............................................46 U007 Course 2:00 p.m. to 5:00 p.m. C001 Live Patient Demonstration: Botulinum Toxin and Fillers ................................................................47 Symposia 2:00 p.m. to 5:00 p.m. S004 Leading High Performance Teams ...........................47 Medication Monitoring and Complications ............48 S005 Focus Sessions 2:30 p.m. to 4:00 p.m. U008 Quality and Customer Service for a Better Practice ...48 Smoking and the Skin .............................................48 U009 U010 Skin of Color...........................................................49 U011 From the Dermatology-Rheumatology Clinic: Practical Tips and Advances in Management ...........49 Forums 3:00 p.m. to 5:00 p.m. F009 Review and Update of Regional Reconstruction..........................................50 F010 Legal Dilemmas in Dermatology .............................50 Workshops 3:00 p.m. to 5:00 p.m. W003 MOC Self-Assessment: Acne, Psoriasis, Eczema and Inflammatory Dermatosis ...................51 W004 Dermoscopy ............................................................51
Workshop 9:00 a.m. to 11:00 a.m. W001 MOC Self-Assessment: Skin Cancer ........................41 Symposia S001 S002 S003 9:00 a.m. to 12:00 p.m. EADV/AAD Joint Symposium ................................41 EHR Physician Demonstration ...............................42 Negotiating Your Way to Great Leadership..............42
Forums 12:00 p.m. to 2:00 p.m. F005 Infectious Disease and Infestation Update ...............43 F006 Whats Boiling Over: Atopic Dermatitis and Other Eczematous Conditions ...........................................43 F007 Case-Based Controversies: Procedural......................44 F008 Case-Based Controversies: Medical ..........................44 Workshop 12:00 p.m. to 2:00 p.m. W002 MOC Self-Assessment: Office-Based Safety ......45
www.aad.org
37
For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information.
scientific sessions
FOCuS SeSSIOnS
7:15 a.m. to 8:45 a.m. Ticket required for admission, no tuition fee. Ticket holds seat for only 15 minutes after the official start time.
u001
u003
DIReCTOR Robert A. Lee, M.D., Ph.D. LeARnIng OBjeCTIveS Following this focus session, the attendee should be able to: 1. Diagnose hidradenitis suppurativa, differentiate it from clinical simulator and categorize it based on severity. 2. Summarize current medical and surgical therapeutic options. 3. Formulate and prescribe a treatment plan based on current the medical literature. DeSCRIPTIOn Hidradenitis suppurativa is a chronic, recurrent, scarring inflammatory dermatosis. It is a common disease that is associated with considerable morbidity and often poses significant challenges for the practitioner. Its clinical presentation and corresponding histopathology will be reviewed. Standard and newer therapeutic options, including hormone therapy, immunomodulators, surgical and laser procedures, will be discussed. After this presentation, the audience will be able to diagnose and accurately stage the disease, describe its natural history, and summarize current therapies. They will be able to apply this information to develop a rational treatment algorithm for this often difficult to treat disease. 1.50 Category 1 CME Credits
DIReCTOR Elizabeth Shannon Martin, M.D. LeARnIng OBjeCTIveS Following this focus session, the attendee should be able to: 1. Identify his/her own leadership strengths and weaknesses. 2. Improve the effectiveness of communications with others. 3. Implement core leadership competencies into daily practice. DeSCRIPTIOn No matter the setting, dermatologists are faced with leadership opportunities every day. Whether it be everyday staff management, practice promotion/expansion, involvement in organized medicine, or advancing an academic career, strong leadership skills allow a physician to meet these challenges with aplomb. This interactive session will allow participants to perform a personality selfassessment and focus on how information learned allows the dermatologist to capitalize on his/her strengths and improve on his/her weaknesses. How to improve communications with others using personality assessment will also be discussed. This session addresses the Leadership Institute Competencies Increasing Self-Awareness and Communicating Effectively. 1.50 Category 1 CME Credits
u002
u004
DIReCTOR Melvin W. Chiu, M.D. LeARnIng OBjeCTIveS Following this focus session, the attendee should be able to: 1. Recognize the unique characteristics of Asian American skin. 2. Describe the presentation of particular dermatologic conditions as they present in Asian Americans. 3. Discuss special considerations when treating Asian American skin. DeSCRIPTIOn The Asian American population is one of the fastest growing segments of the U.S. population. An estimated 40 million Asian Americans will be living in the U.S. by 2050. This session will introduce the diversity of Asian skin, its unique characteristics, and some of the dermatologic conditions that can manifest differently in Asian skin. Furthermore, this session will cover therapeutic considerations when managing skin disease in Asian Americans. 1.50 Category 1 CME Credits
DIReCTOR Neal D. Bhatia, M.D. LeARnIng OBjeCTIveS Following this focus session, the attendee should be able to: 1. Review the fundamental pathogenesis and progression of photodamage to actinic keratosis. 2. Apply the mechanisms of action of therapeutics to the disease state and discuss current and future treatment options. 3. Identify the importance of incorporating medical management of actinic keratosis into a treatment regimen. DeSCRIPTIOn The medical management of actinic keratosis and the consequence of photodamage requires a fundamental understanding of the pathogenesis of mutations and the cutaneous neoplastic changes that occur over time, as well as a basic knowledge of the mechanisms of action of the many available therapeutic options. The goals of the session are to review these concepts as well as discuss current and future treatments, both topical and systemic, to serve as part of the clinicians regimen. 1.50 Category 1 CME Credits
38
scientific sessions
For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information.
FORuMS
9:00 a.m. to 11:00 a.m. Ticket required for admission, no tuition fee. Ticket holds seat for only 15 minutes after the official start time.
F001
nails
Room: Nassau Suite A/B
F002
Photoprotection
Room: Sutton North
DIReCTOR Phoebe Rich, M.D. InvITeD SPeAKeRS C. Ralph Daniel, M.D. Zoe Diana Draelos, M.D. Nathaniel J. Jellinek, M.D. Richard K. Scher, M.D. Dana W.K. Stern, M.D.
DIReCTOR Steven Q. Wang, M.D. InvITeD SPeAKeRS Zoe Diana Draelos, M.D. Allan C. Halpern, M.D. Henry W. Lim, M.D. Uli Osterwalder
LeARnIng OBjeCTIveS Following this forum, the attendee should be able to: 1. Apply techniques for performing a nail biopsy. 2. Diagnose and manage nail psoriasis, nail fungal infections and other nail conditions. 3. Recognize and treat cosmetic nail problems. DeSCRIPTIOn This session covers nail diagnosis, surgery and therapy, from soup to nuts. Nail experts will discuss common and uncommon nail problems with practical tips and strategies for management. Detailed nail surgery know-how for the novice and experienced will round out the program. There will be adequate time for questions and discussion. 2.00 Category 1 CME Credits SCHeDuLe 9:00 a.m. What You Need To Know About Nail Psoriasis and More / Dr. Scher 9:15 a.m. What You Need: A Nail Tool Kit / Dr. Stern 9:25 a.m. How To Do It: Nail Surgery Procedures / Dr. Jellinek 9:45 a.m. Questions and Answers / All faculty 10:00 a.m. Hot Nail Topics - Tumors, Fungus, New Therapy / Dr. Rich 10:15 a.m. What You Need To Know About Candida in the Nail / Dr. Daniel 10:30 a.m. The Latest and Greatest / Dr. Draelos 10:45 a.m. Questions and Answers / All faculty
LeARnIng OBjeCTIveS Following this forum, the attendee should be able to: 1. Discuss the current regulation and future trends in sunscreens formulation. 2. Evaluate the impact of sunscreens on skin cancer prevention and Vitamin D synthesis. 3. Explain the role of nanotechnology and antioxidants in sunscreens formulation. DeSCRIPTIOn Current technology and development in photoprotection, specifically the role of sunscreen will be discussed by leading experts in the field. The session will focus on the regulatory trends and scientific research in sunscreen formulation. A discussion of hot topics, such as skin cancer prevention and Vitamin D synthesis, in photoprotection will also be presented. 2.00 Category 1 CME Credits SCHeDuLe 9:00 a.m. Introduction / Dr. Wang 9:05 a.m. The Ideal Sunscreen - Global Understanding, Perspective and Direction on Sunscreen Regulation / Mr. Osterwalder 9:25 a.m. Photoprotection and Vitamin D: Whats New? / Dr. Lim 9:45 a.m. Does Sunscreen Prevent Skin Cancer? / Dr. Halpern 10:05 a.m. What is the Role of Antioxidants in Photoprotection? / Dr. Wang 10:25 a.m. The Impact of Nanotechnology in Photoprotection / Dr. Draelos 10:45 a.m. Questions and Answers / All faculty
www.aad.org
39
For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information.
scientific sessions
FORuMS
9:00 a.m. to 11:00 a.m. Ticket required for admission, no tuition fee. Ticket holds seat for only 15 minutes after the official start time.
F003
F004
DIReCTOR Lauren C. Hughey, M.D. InvITeD SPeAKeRS Jonathan Cotliar, M.D. Lindy Peta Fox, M.D. Kanade Shinkai, M.D., Ph.D. LeARnIng OBjeCTIveS Following this forum, the attendee should be able to: 1. Discuss controversies and challenges in the diagnosis of inpatient dermatology cases. 2. Identify controversies and challenges in the treatment of inpatient dermatology cases. DeSCRIPTIOn Inpatient dermatology offers us challenging cases. On a daily basis, we are making difficult decisions on rounds. This session is designed to examine some of these challenging situations and consider options for approaching these cases. 2.00 Category 1 CME Credits SCHeDuLe 9:00 a.m. Treatment of Inflammatory Skin Disease in the Setting of Active Infection or Underlying Malignancy / Dr. Kroshinsky 9:30 a.m. Diagnosing Patients With Fever and Rash in the Bone Marrow Unit / Dr. Cotliar 10:00 a.m. PCP Prophylaxis in Immunosuppressed Patient with Skin Disease / Dr. Shinkai 10:30 a.m. Ethical Issues in Treatment of Hospitalized Patients with Skin Disease / Dr. Fox
DIReCTOR Matthew Zirwas, M.D. InvITeD SPeAKeR Joseph B. Bikowski, M.D. LeARnIng OBjeCTIveS Following this forum, the attendee should be able to: 1. Diagnose unusual or unique presentations of facial dermatoses. 2. Develop unique treatment plans tailored to the presentation of each patient. DeSCRIPTIOn The session will consist of two lectures one on follicularly based facial dermatoses (demodex, acne, rosacea, pityrosporum folliculitis, etc) and one on eczematous facial dermatoses (seborrhea, atopic dermatitis, allergic contact, irritant contact, etc). The lectures will not discuss typical presentations and therapies it is assumed that attendees are competent to diagnose and treat these cases. Instead, the lectures will focus on difficult to diagnosis cases and on unique presentations that predict response to specific therapies. 2.00 Category 1 CME Credits SCHeDuLe 9:00 a.m. Follicularly Based Facial Dermatoses / Dr. Bikowski 10:00 a.m. Eczematous Facial Dermatoses / Dr. Zirwas
40
scientific sessions
For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information.
WORKSHOP
9:00 a.m. to 11:00 a.m. Tuition fee and ticket required for admission.
SYMPOSIuM
W001
M O C
S001
DIReCTOR Jerry D. Brewer, M.D. InvITeD SPeAKeRS Christian L. Baum, M.D. Michael J. Camilleri, M.D. Mark A. Cappel, M.D. Oscar Colegio, M.D., Ph.D. Shari Nemeth, M.D.
CO-DIReCTOR Jean L. Bolognia, M.D. CO-DIReCTOR Erwin Tschachler, M.D. InvITeD SPeAKeRS Simon Barton, M.D. Luca Borradori, M.D. Henry W. Lim, M.D. Rolf-Markus Szeimies, M.D. Kenneth J. Tomecki, M.D. Rein Willemze, M.D.
LeARnIng OBjeCTIveS Following this workshop, the attendee should be able to: 1. Identify strengths and weaknesses in knowledge of cutaneous oncology. 2. Demonstrate commitment to lifelong learning and selfassessment. 3. Practice increased self-directed learning to remain up-to-date on current trends and information relating to cutaneous malignancy. DeSCRIPTIOn This session will focus on the completion of 25 questions. Answers will be provided after the questions. The session is structured in a question and answer format utilizing an audience response system (ARS) and will cover skin cancer as a topic specific to MOC SelfAssessment. Participants will receive immediate feedback for each question and identify areas of weakness that require further selfdirected study. Specific topics that will be covered include: basal cell carcinoma, squamous cell carcinoma, malignant melanoma, Merkel cell carcinoma, adnexal tumors, and rare cutaneous malignancy (i.e. atypical fibroxanthoma, dermatofibrosarcoma protuberans, etc). 2.00 Category 1 CME Credits SCHeDuLe 9:00 a.m. 9:20 a.m. 9:40 a.m. 10:00 a.m. 10:20 a.m. 10:20 a.m. Questions on Basal Cell Carcinoma / Dr. Baum Questions on Squamous Cell Carcinoma / Dr. Colegio Questions on Malignant Melanoma / Dr. Nemeth Questions on Merkel Cell Carcinoma / Dr. Nemeth Questions on Adnexal Tumors / Dr. Camilleri Questions on Rare Cutaneous Malignancy / Dr. Cappel This session will be submitted to the American Board of Dermatology for approval to satisfy Component 2, commitment to lifelong learning and periodic self-assessment, of the MOC-D program.
LeARnIng OBjeCTIveS Following this symposium, the attendee should be able to: 1. Appreciate the bases for the new classification scheme for cutaneous B-cell lymphomas. 2. Have an evidence-based treatment approach to bullous pemphigoid. 3. Discuss new applications for photodynamic therapy. DeSCRIPTIOn The EADV and AAD have joined forces in an effort to compliment one another and provide the audience with an expanded perspective of topics of interest to dermatologists. Speakers representing the EADV will offer insights into the recent revisions in classification and prognoses of cutaneous B-cell lymphomas, based in large part upon the efforts of the EORTC. In addition to a review of newly developed rapid diagnostic tests for sexually transmitted infections, an evidence-based approach to the diagnosis and treatment of bullous pemphigoid will be presented. The use of photodynamic therapy for a range of disorders, from basal cell carcinomas to inflammatory diseases, will be covered, as well as new light sources and photosensitizers currently available in Europe. Because MRSA is a significantly greater problem in the USA than in Europe, speakers representing the AAD will provide an update on that topic in addition to a review and critique of the recent Institute of Medicines recommendations regarding vitamin D requirements. 3.00 Category 1 CME Credits ReFeRenCeS 1. Kirtschig G, Middleton P, Bennett C, et al. Interventions for bullous pemphigoid. Cochrane Database of Systematic Reviews 2010, Issue 10. Art. No.: CD002292. 2. Madan V, Lear JT, Szeimies R-M. Non-melanoma skin cancer. Lancet 2010;375:673-85. 3. www.iom.edu/Reports/2010/Dietary-Reference-Intakes-forCalcium-and-Vitamin-D.aspx SCHeDuLe 9:00 a.m. Bullous Pemphigoid: Clinical Spectrum and Evidence-Based Practical Management / Dr. Borradori 9:30 a.m. Bad Bugs and New Drugs: MRSA Infections / Dr. Tomecki 10:00 a.m. Sexually Transmitted Infections: Update on Rapid Diagnosis and Treatment / Mr. Barton 10:30 a.m. Cutaneous Lymphomas: What Dermatologists Should Know / Dr. Willemze 11:00 a.m. Photodynamic Therapy: A European Perspective / Dr. Szeimies 11:30 a.m. Institute of Medicines Recommendations Regarding Vitamin D Requirements / Dr. Lim www.aad.org
| 41
For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information.
scientific sessions
SYMPOSIA
9:00 a.m. to 12:00 p.m. Open admission, no tuition or ticket.
S002
S003
DIReCTOR Mark D. Kaufmann, M.D. LeARnIng OBjeCTIveS Following this symposium, the attendee should be able to: 1. Assess how other dermatologists in various practice settings successfully adopted EHR systems. 2. Implement an EHR utilizing best practices. 3. Discuss how to enhance patient safety, strengthen care coordination, and participate in quality improvements through EHR systems. DeSCRIPTIOn Live interactive physician-only (no vendors) demonstration of how EHR implementation was done and pearls on strategies that worked best. This session will provide members with an enhanced understanding of the experiences of EHR dermatology champions. 3.00 Category 1 CME Credits
DIReCTOR David J. Goldberg, M.D., JD InvITeD SPeAKeRS David E. Cohen, M.D., M.P.H. William P. Davey, M.D. Joseph S. Eastern, M.D. Michael H. Gold, M.D. Stephen P. Stone, M.D.
LeARnIng OBjeCTIveS Following this symposium, the attendee should be able to: 1. Demonstrate effective negotiation skills. 2. Recognize the perspective of others involved in the negotiation process; use alternative approaches to reach an optimal outcome. 3. Identify skills that make participation in board/committee meetings productive. DeSCRIPTIOn Getting the job done in our daily lives requires that we negotiate every day. Getting the job done at a committee level, on a board of directors, in our offices, or even with industry, the academic setting requires constant negotiation. Negotiation may be necessary to accomplish what you need to get done with an insurance contract, an academic department, a legislator, a building manager, industry, your office staff, and even our patients. Insight into skills that help you negotiate more effectively will be presented in this session. Working in our universities, communities and organizations we often serve on committees and boards. Skills that help you get the job done effectively will be reviewed. Building a team that works together to build strength, communication and efficiency for an effective outcome is necessary in all of our work. Join our panel of experts to learn from experience how to be an effective negotiator and get the job done. 3.00 Category 1 CME Credits SCHeDuLe 9:00 a.m. 9:25 a.m. 9:30 a.m. 9:55 a.m. 10:00 a.m. 10:25 a.m. 10:30 a.m. 10:55 a.m. 11:00 a.m. 11:25 a.m. 11:30 a.m. 11:55 a.m. Principles of Negotiation / Dr. Davey Questions and Answers / All faculty Negotiating with Providers: Make It Fair / Dr. Gold Questions and Answers / All faculty Negotiation with Patients: Control Your Day / Dr. Goldberg Questions and Answers / All faculty Negotiation to Simplify our Daily Practices / Dr. Eastern Questions and Answers / All faculty Negotiation with Influence on a Board of Directors / Dr. Stone Questions and Answers / All faculty Negotiation In Academics: The Art and the Science / Dr. Cohen Questions and Answers / All faculty
42
scientific sessions
For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information.
FORuMS
12:00 p.m. to 2:00 p.m. Ticket required for admission, no tuition fee. Ticket holds seat for only 15 minutes after the official start time.
F005
F006
DIReCTOR Kenneth J. Tomecki, M.D. InvITeD SPeAKeRS Anne E. Burdick, M.D., M.P.H Christopher C. Gasbarre, D.O. Jose Dario Martinez, M.D. Ronald P. Rapini, M.D. Theodore Rosen, M.D.
DIReCTOR Robert Sidbury, M.D. InvITeD SPeAKeRS Mary Wu Chang, M.D. Lawrence F. Eichenfield, M.D. Vincent Anthony DeLeo, M.D. Julie V. Schaffer, M.D. LeARnIng OBjeCTIveS Following this forum, the attendee should be able to: 1. Review the new NIAID food allergy guidelines and their relevance to AD care. 2. Discuss the differential diagnosis and appropriate management of severe infantile eczema. 3. Recognize the appropriate use of systemic therapy in atopic dermatitis. DeSCRIPTIOn This forum will update the learner on advances in the diagnosis and management of patients with atopic dermatitis and related conditions. We will specifically address the significance of new food allergy guidelines and how they relate to eczema patients, the unique challenges presented by infants with severe eczematous eruptions, the role of patch testing and contact allergy in atopic patients, and the appropriate use of systemic therapy. 2.00 Category 1 CME Credits SCHeDuLe 12:00 p.m. The Severely Affected Infant: What Should You Do Differently? / Dr. Chang 12:24 p.m. The New NIAID Food Allergy Guidelines: How Do They Affect my Practice? / Dr. Eichenfield 12:48 p.m. Contact Allergy and Patch Testing in Atopic Patients / Dr. DeLeo 1:12 p.m. The Appropriate Use of Systemic Therapy / Dr. Schaffer 1:36 p.m. The Rest of the Story / Dr. Sidbury
LeARnIng OBjeCTIveS Following this forum, the attendee should be able to: 1. Recognize recent trends and developments in infecttious diseases and infestations. 2. Evaluate and treat affected patients more knowledgeably and effectively. DeSCRIPTIOn This session, essentially an infectious whats new, will highlight the following topics: Selected infestations, including bed bugs; selected travel-related afflictions from the Americas; leprosy; resurgent diseases; and antimicrobials used in surgey. Presentations will emphasize trends and new developments, including diagnosis, therapy, and changing patterns of disease. Session will be clinically germane and directly applicable to patient care. 2 .00 Category 1 CME credits SCHeDuLe 12:00 p.m. Insect Assaults / Dr. Rapini 12:20 p.m. Travelers Buggy Maladies: The Americas / Dr. Martinez 12:40 p.m. Are There Bed Bugs in Your Bed? / Dr. Rosen 1:00 p.m. Germs And Steel: Antibiotics In Derm Surgery / Dr. Gasbarre 1:20 p.m. Leprosy 2011 / Dr. Burdick 1:40 p.m. Resurgent Diseases / Dr. Tomecki
www.aad.org
43
For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information.
scientific sessions
FORuMS
12:00 p.m. to 2:00 p.m. Ticket required for admission, no tuition fee. Ticket holds seat for only 15 minutes after the official start time.
F007
F008
DIReCTOR Victor Allen Neel, M.D., Ph.D. LeARnIng OBjeCTIveS Following this forum, the attendee should be able to: 1. Develop treatment strategies for challenging skin cancers. 2. Manage reconstruction conundrums. DeSCRIPTIOn The session is divided in two parts. The first part will focus on controversies in the management of melanoma, the use of adjuvant radiation in the treatment of SCC and role of dermatologists in treating Merkel cell carcinoma. The second part will highlight challenges in regional reconstruction. 2.00 Category 1 CME Credits
DIReCTOR Mark D. P. Davis, M.D. InvITeD SPeAKeRS Dawn M. R. Davis, M.D. Amer Nizar Kalaaji, M.D. Kathleen Julie Hectorne, M.D. Catherine Clayton Newman,M.D. David A. Wetter, M.D. LeARnIng OBjeCTIveS Following this forum, the attendee should be able to: 1. Describe controversies in diagnosis of selected dermatologic conditions. 2. Discuss controversies in the management of selected dermatologic conditions. DeSCRIPTIOn We will explore cases seen by medical dermatologists that led to some controversy either in diagnosis or management. 2.00 Category 1 CME Credits SCHeDuLe 12:00 p.m. Is Interstitial Granulomatous Dermatitis a Systemic Disorder? / Dr. Newman 12:20 p.m. The Patient is Starting Prednisone 30 mg Daily for Immunobullous Disease: Does PCP Prophylaxis Need to be Initiated? / Dr. Kalaaji 12:40 p.m. The Patient is on Biologics for Rheumatoid Arthritis. Now He has Developed What Looks Like Psoriasis on the Hands and Feet: What to do Now? / Dr. Wetter 1:00 p.m. Controversial Cases Seen by the Pediatric Dermatologist: A Pot-Pourri / Dr. Davis 1:20 p.m. This Male Patient Has Severe, Recalcitrant Nodulocystic Acne. He has a History of Psychiatric Illness: Should you Prescribe Isotretinoin? / Dr. Hectorne 1:40 p.m. The Patient Clearly has Delusions of Parasitosis: What Now? / Dr. Davis
44
scientific sessions
For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information.
WORKSHOP
12:00 p.m. to 2:00 p.m. Tuition fee and ticket required for admission.
FOCuS SeSSIOn
12:15 p.m. to 1:45 p.m. Ticket required for admission, no tuition fee. Ticket holds seat for only 15 minutes after the official start time.
W002
M O C
u005
Pitfalls in Dermatopathology
Room: Gibson Suite
DIReCTOR Aleodor A. Andea, M.D. LeARnIng OBjeCTIveS Following this focus session, the attendee should be able to: 1. Recognize a variety of dermatopathology cases that are prone to be misdiagnosed. 2. Identify histological features that are useful in preventing pitfalls in diagnosis. 3. Determine appropriate ancillary studies that help arrive at the correct diagnosis. DeSCRIPTIOn This session is directed towards residents, dermatologists with an interest in dermatopathology and dermatopathologists who enjoy challenging cases. Pitfalls in the diagnosis of cutaneous neoplasms that may result in diagnostic errors with significant clinical impact will be presented. The session focuses on histological mimickers: skin malignancies that resemble reactive conditions or benign neoplasms, benign conditions that masquerade as malignancies and tumors that are prone to be mistaken for other types of cutaneous malignancies. The audience will be presented with the salient features of each entity and with tips to avoid misdiagnosis. 1.50 Category 1 CME Credits
DIReCTOR Hillary Johnson-Jahangir, M.D., Ph.D. InvITeD SPeAKeRS Jacques Michael Casparian, M.D. Divya Srivastava, M.D. James Selwyn Taylor, M.D. Oliver J. Wisco, D.O. LeARnIng OBjeCTIveS Following this workshop, the attendee should be able to: 1. Identify strengths and weaknesses in ones knowledge of issues in patient safety that are relevant to dermatology. 2. Integrate and apply current concepts in patient safety to improve patient care. DeSCRIPTIOn This session will be structured as a question-and-answer format using an automated response system. Current concepts in patient safety that are relevant for dermatologists will be highlighted. Safety issues important in procedural and medical dermatologic practice will be addressed in order to better care for our patients. This session does not qualify as a Patient Safety Module for MOC Component 2: Commitment to Lifelong-Learning and Periodic Self-Assessment. 2.00 Category 1 CME Credits * Self-assessment questions utilized in this session are the same as those used for Workshop W013 offered at Annual Meeting 2011 and Workshop W004 offered at Summer Academy Meeting 2010. Physicians should not claim CME/MOC credit for attending this session if they attended Workshop W013 at Annual Meeting 2011 or Workshop W004 at Summer Academy Meeting 2010.
www.aad.org
45
For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information.
scientific sessions
FOCuS SeSSIOnS
12:15 p.m. to 1:45 p.m. Ticket required for admission, no tuition fee. Ticket holds seat for only 15 minutes after the official start time.
u006
DIReCTOR Kathryn Schwarzenberger, M.D. InvITeD SPeAKeRS Jane M. Grant-Kels, M.D. Joseph L. Jorizzo, M.D. LeARnIng OBjeCTIveS Following this focus session, the attendee should be able to: 1. Describe and utilize mentorship skills to build teams at all levels. 2. Identify and nurture qualities in individuals that help your team grow. DeSCRIPTIOn Regardless of practice setting, we all work closely with others: partners, residents, nurses, assistants, and staff. One of the most rewarding, and potentially difficult, aspects of leadership is helping others mature and grow into their full potential. Join several dedicated mentor-leaders in our field as they share their pearls about how to help others reach their full potential. Audience participation will be sought in this open-format session. 1.50 Category 1 CME Credits
u007
neonatal Dermatology
Room: Sutton South
DIReCTOR Tor A. Shwayder, M.D. LeARnIng OBjeCTIveS Following this focus session, the attendee should be able to: 1. Recognize normal newborn cutaneous variants so one can relax and reassure the parents. 2. Identify abnormal newborn cutaneous variants and when to yell for help! 3. Perform an examination on newborn skin at the hospital or office. DeSCRIPTIOn Love seeing those babies, but dread being asked about a rash? Confused about normal newborn skin variations? How does one approach the cutaneous signs of rare genetic diseases? And those marks with rare systemic associations, do they need imaging or follow up? Journey with me to explore the newborn skin, with special emphasis on the normal, practical, everyday office visit punctuated with only enough warnings to keep you on your toes. Included at no extra charge: Hints from 30 years of keeping my tie clear of poop and how to muffle ear-splitting cries. 1.50 Category 1 CME Credits
46
scientific sessions
For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information.
COuRSe
2:00 p.m. to 5:00 p.m. Tuition fee and ticket required for admission.
SYMPOSIuM
C001
S004
DIReCTOR Margaret E. Parsons, M.D. InvITeD SPeAKeRS Karen Collishaw, CAE Jennifer Lucas, M.D. Victor J. Marks, M.D. Erik J. Stratman, M.D.
DIReCTOR Thomas E. Rohrer, M.D. InvITeD SPeAKeRS Diane S. Berson, M.D. Doris J. Day, M.D. Lisa M. Donofrio, M.D. Michael Kane, M.D. Amy B. Lewis, M.D. Ellen S. Marmur, M.D. Alan Matarasso, M.D. Seth L. Matarasso, M.D. Roberta D. Sengelmann, M.D.
LeARnIng OBjeCTIveS Following this course, the attendee should be able to: 1. Assess the aging face and choose the most appropriate injection techniques. 2. Identify soft tissue fillers appropriate for a variety of facial areas and applications. 3. Identify new concepts in facial aging and how that applies to rejuvenating procedures. DeSCRIPTIOn This live interactive session will feature experts from around the country demonstrating and commenting on soft tissue filler and botulinum toxin injections. It is an opportunity for attendees to virtually step into the office of these expert injectors and see how they assess, interact with, and inject their patients. Each region of the face will be addressed by two faculty members and audience interaction is encouraged. 3.00 Category 1 CME Credits ReFeRenCeS 1. Kaminer M, Dover J, Arndt K, Rohrer T, eds. Atlas of Cosmetic Surgery. Philadelphia: Elsevier, 2008 2. Carruthers A, Carruthers J. Botulinum Toxin in Procedures in Cosmetic Dermatologic Surgery Series. Philadelphia: Elsevier, 2008 3. Carruthers A, Carruthers J. Soft Tissue Augmentation In Cosmetic Dermatology Series. Philadelphia: Elsevier, 2008 SCHeDuLe 2:00 p.m. Introduction 2:05 p.m. Upper Face Rejuvenation / Dr. Alan Matarasso / Dr. Seth Matarasso 2:30 p.m. Lower Face Rejuvenation / Dr. Marmur / Dr. Day 2:55 p.m. Filling the Temples / Dr. Berson / Dr. Marmur 3:20 p.m. Volumizing the Mid Face / Dr. Donofrio / Dr. Lewis 3:45 p.m. Creating the Perfect Lip / Dr. Seth Matarasso / Dr. Berson 4:10 p.m. Rejuvenating the Neck and Hands / Dr. Lewis / Dr. Day 4:30 p.m. Rejuvenating the Eyes and Tear Troughs / Dr. Kane / Dr. Donofrio 4:55 p.m. Questions and Answers
LeARnIng OBjeCTIveS Following this symposium, the attendee should be able to: 1. Identify key concepts of team-building. 2. Plan and execute effective team goals. 3. Utilize team member skills for effective outcomes. DeSCRIPTIOn Getting your team to work together for maximum performance requires insight, thought, preparation, and leadership. Join our experts in this area to learn concrete concepts and valuable insight and ideas on how to maximize your teams performance for an optimal result with a group that feels that they have worked together and enjoyed the process to achieve success. 3.00 Category 1 CME Credits ReFeRenCeS 1. Lencioni, P. The Five Dysfunctions of a Team. Jossey-Bass. 2002 SCHeDuLe 2:00 p.m. 2:05 p.m. 2:35 p.m. 2:40 p.m. 3:20 p.m. 3:30 p.m. 4:00 p.m. 4:05 p.m. 4:30 p.m. 4:35 p.m. 4:55 p.m. Introduction / Dr. Parsons Managing Teams: Principles / Ms.Collishaw Questions and Answers / Ms.Collishaw Leading Teams / Dr. Marks Questions and Answers / Dr. Marks Knowing the Personalities on Your Team / Dr. Stratman Questions and Answers / Dr. Stratman Being a Star Team Player / Dr. Lucas Questions and Answers / Dr. Lucas Getting the Work Done on Time / Dr. Parsons Questions and Answers/Conclusion / Dr. Parsons
www.aad.org
47
For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information.
scientific sessions
SYMPOSIuM
2:00 p.m. to 5:00 p.m. Open admission, no tuition or ticket.
FOCuS SeSSIOn
2:30 p.m. to 4:00 p.m. Ticket required for admission, no tuition fee. Ticket holds seat for only 15 minutes after the official start time.
S005
u008
DIReCTOR Stephen E. Wolverton, M.D. InvITeD SPeAKeRS James Q. Del Rosso, D.O. Julie Claire Harper, M.D. John A. Zic, M.D. LeARnIng OBjeCTIveS Following this symposium, the attendee should be able to: 1. Identify the safety issues concerning common systemic therapies in acne and rosacea. 2. Describe the clinical relevance of selected chemotherapy drugs in dermatology and the cutaneous risks of these drugs. 3. Assess the most current scientific information on the most serious isotretinoin complications, focusing most on the theoretical risk of inflammatory bowel disease. DeSCRIPTIOn This highly interactive symposium will address important up-todate scientific information, as well as relevant controversies and difficult questions concerning four common areas of systemic dermatologic therapy. Experts in each of the four areas will inform and challenge the audience concerning both the important complications and monitoring required in order to maximize drug safety. The schedule allows more than adequate time to answer questions from the audience. 3.00 Category 1 CME Credits ReFeRenCeS 1. Wolverton SE editor, Controversies in Dermatologic Drug Therapy. Dermatol Ther 22(5):397, 2009 Sep-Oct. (entire issue) SCHeDuLe 2:00 p.m. Systemic Agents Used to Treat Acne and Rosacea: Monitoring and Safety Consideration / Dr. Del Rosso 2:40 p.m. Questions and Answers / All faculty 2:45 p.m. Chemotherapy and Dermatologist: Some Dermatology Uses and Unique Skin Complications / Dr. Zic 3:25 p.m. Questions and Answers / Dr. Zic 3:30 p.m. Isotretinoin Adverse Effects: An Update on the Most Worrisome Complications / Dr. Harper 4:10 p.m. Questions and Answers / All faculty 4:15 p.m. Drug Causation: How Do We Know the Drug Did the Deed? / Dr. Wolverton 4:55 p.m. Questions and Answers / All faculty
DIReCTOR Charles N. Ellis, M.D. LeARnIng OBjeCTIveS Following this focus session, the attendee should be able to: 1. Recognize why Service Excellence is important and how it represents quality in medicine. 2. Evaluate great service in the office setting. 3. Implement Service Excellence in dermatology offices. DeSCRIPTIOn Service Excellence (also called customer service) is a critical competency for dermatologists. Studies show patient satisfaction is driven by patient experiences, even more than patient outcomes. There is evidence that patient satisfaction and quality medicine are one and the same. Training in providing great service leads to a more efficient and happier workforce. Service Excellence forms a foundation for other projects and safety improvements. After instituting Service Excellence, practitioners spend more time in medical care and less in office problem-solving. Understanding how to provide great service will be the best thing you ever did for yourself. (For all practitioners). 1.50 Category 1 CME Credits
u009
DIReCTOR Sergei A. Grando, M.D., Ph.D. LeARnIng OBjeCTIveS Following this focus session, the attendee should be able to: 1. Diagnose smoking-related skin and mucosal changes. 2. Diagnose skin and mucosal diseases related to smoking. DeSCRIPTIOn In addition to a well known harmful role of smoking in several inflammatory skin diseases, such as psoriasis and hidradenitis suppurativa, there is a high risk of developing skin cancers among first- and second-hand smokers. Increased skin cancer rate and precocious skin aging in smokers are the two arms of the same pathophysiologic mechanism. On the other hand, there is a negative association of smoking with certain skin diseases, such as pyoderma gangrenosum and pemphigus. The dichotomous effect of smoking can be explained through the nicotinic receptormediated action of nicotine on different cutaneous cell types involved in a particular disease. 1.50 Category 1 CME Credits
48
scientific sessions
For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information.
FOCuS SeSSIOnS
2:30 p.m. to 4:00 p.m. Ticket required for admission, no tuition fee. Ticket holds seat for only 15 minutes after the official start time.
u010
Skin of Color
Room: Clinton Suite
u011
DIReCTOR Wendy E. Roberts, M.D. LeARnIng OBjeCTIveS Following this focus session, the attendee should be able to: 1. Review the current peer reviewed literature in Ethnic Skin of Color. 2. Discuss skin cancer, alopecia and inflammatory disorders in Ethnic skin of Color. 3. Update our medical knowledgebase and treatments in Ethnic Skin of Color. DeSCRIPTIOn This session will overview pertinent and current peer review literature present regarding Skin and Hair of Color. Fact vs. fiction will be reviewed regarding description, detection and treatment options in persons with darker skin types. The session is targeted as a data resource for those who teach, research, or treat skin of color. 1.50 Category 1 CME Credits
DIReCTOR Abrar A. Qureshi, M.D., M.P.H. LeARnIng OBjeCTIveS Following this forum, the attendee should be able to: 1. Design a combined clinic with physicians from multiple specialties working together. 2. Evaluate and work up patients with cutaneous lupus, dermatomyositis, pyoderma gangrenosum, scleroderma/fibrosis and psoriasis/psoriatic arthritis in a multidisciplinary clinic environment. 3. Treat patients with cutaneous lupus, dermatomyositis, pyoderma gangrenosum, scleroderma/fibrosis and psoriasis/ psoriatic arthritis. DeSCRIPTIOn This session will consist of a summary of clinic set-up with a discussion of operational, patient flow and billing practices. I will discuss approaches to the patient with cutaneous lupus, dermatomyositis, pyoderma gangrenosum, scleroderma/fibrosis and psoriasis/psoriatic arthritis including taking a history and physical examination, laboratory investigations and therapy. As examples, case studies from our multidisciplinary clinics will be presented emphasizing management and decision making process and referral back to the referring dermatologist. Therapeutic approaches will focus on case examples to illustrate choice of systemic therapies including biologics. We will spend time on off-label treatment options and therapeutic pearls mainly, emphasizing the treatment of skin disease in patients who also have multi-organ disease. 1.50 Category 1 CME Credits
Adults
www.aad.org
49
For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information.
scientific sessions
FORuMS
3:00 p.m. to 5:00 p.m. Ticket required for admission, no tuition fee. Ticket holds seat for only 15 minutes after the official start time.
F009
F010
DIReCTOR Clifford Warren Lober, M.D., J.D. InvITeD SPeAKeRS Rebecca B. Campen, M.D., J.D. Jonathan Scott Sanders, M.D., J.D. LeARnIng OBjeCTIveS Following this forum, the attendee should be able to: 1. Analyze legal dilemmas to facilitate appropriate patient care. 2. Recognize legal implications of treatment alternatives. DeSCRIPTIOn You are online in a social Internet site and one of the other people starts to discuss the treatment of his unusual skin condition. You cant resist giving advice. Unfortunately, your advice is grossly incorrect. What is your liability? You see a patient who adamantly insists that his sutures be removed one week after they have been placed, but you know medically that the patient will have an unsatisfactory result if you comply with his demand. What should you do? These and other legal dilemmas will be discussed by a panel of MD/JDs, all of whom are practicing dermatologists. 2.00 Category 1 CME Credits SCHeDuLe 3:00 p.m. Presentation and Analysis of Legal Dilemmas / All faculty 4:00 p.m. Questions and Answers / All faculty 4:15 p.m. Presentation and Analysis of Legal Dilemmas / All faculty 4:45 p.m. Questions and Answers / All faculty
DIReCTOR Shang I. Brian Jiang, M.D. InvITeD SPeAKeRS Murad Alam, M.D. John A. Carucci, M.D., Ph.D. Hayes B. Gladstone, M.D. LeARnIng OBjeCTIveS Following this forum, the attendee should be able to: 1. Recognize the best reconstruction options for difficult anatomic areas. 2. Identify different reconstructive options for various anatomic locations. 3. Identify important recent literature related to regional reconstruction.
DeSCRIPTIOn This session will focus on regional reconstruction for Mohs surgery defects. The speakers will review and update different repair options for difficult anatomic locations such as the nose, ear, lip/ perioral area as well as staged procedures for these same locations. 2.00 Category 1 CME Credits SCHeDuLe 3:00 p.m. 3:05 p.m. 3:30 p.m. 3:55 p.m. 4:20 p.m. 4:45 p.m. Introduction / Dr. Jiang Reconstruction of Nasal Defects / Dr. Jiang Reconstruction of the Lip and Perioral Area / Dr. Alam Reconstruction of the Ear / Dr. Gladstone Staged Reconstruction: Regional Approach / Dr. Carucci Questions and Answers / All faculty
50
scientific sessions
For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information.
WORKSHOPS
3:00 p.m. to 5:00 p.m. Tuition fee and ticket required for admission.
W003
M O C
W004
Dermoscopy
Room: Sutton North
DIReCTOR Mary C. Martini, M.D. InvITeD SPeAKeR Ana M. Ciurea, M.D. LeARnIng OBjeCTIveS Following this workshop, the attendee should be able to: 1. Apply the two step method to identify melanocytic and nonmelanocytic skin lesions with dermoscopy. 2. Distinguish benign and malignant melanocytic lesions using dermoscopy. 3. Identify melanoma on dermoscopy. DeSCRIPTIOn This session is geared for both the beginner dermoscopist and also offers a good review for clinicians who incorporate dermoscopy in their practices. The session will review terminology, current dermatoscopes: polarized and non-polarized and the two step algorithm. Following these presentations, the attendee will view numerous images of benign and malignant melanocytic lesions, with emphasis on melanoma and dysplastic nevi. Non-melanocytic lesions will also be covered. The session will conclude with a series of dermoscopy unknowns. 2.00 Category 1 CME Credits SCHeDuLe 3:00 p.m. Dermoscopy Basics: Equipment and Terminology / Dr. Ciurea 3:20 p.m. Questions / Dr. Ciurea 3:30 p.m. The two Step Algorithm: Defining Melanocytic and Non-Melanocytic Lesions / Dr. Ciurea 3:50 p.m. Questions / Dr. Ciurea 4:00 p.m. Dysplastic Nevi and Melanoma / Dr. Martini 4:20 p.m. Questions / Dr. Martini 4:30 p.m. Dermoscopy Unknowns / Dr. Martini 4:50 p.m. Questions / Dr. Martini
DIReCTOR Joslyn S. Kirby, M.D. InvITeD SPeAKeRS Mark Lebwohl, M.D. Christen M. Mowad, M.D. Misha Rosenbach, M.D. Joshua Zeichner, M.D.
LeARnIng OBjeCTIveS Following this workshop, the attendee should be able to: 1. Identify the strengths and weaknesses in the attendees dermatology knowledge and to make improvements as needed. 2. Demonstrate commitment to lifelong learning and selfassessment via completion of 25 questions and answers with discussion. DeSCRIPTIOn This session is structured as a question and answer forum using an audience response system. This forum will allow for self-assessment with immediate feedback and allows for identification of areas that require further self-directed study. The forum will cover topics in acne, psoriasis, eczema, and other inflammatory dermatoses. Due to the timed framework of this session, please arrive on time. 2.00 Category 1 CME Credits This session will be submitted to the American Board of Dermatology for approval to satisfy Component 2, commitment to lifelong learning and periodic self-assessment, of the MOC-D program.
DERMOSCOPY
Learn a technique that is less invasive and yields faster results, both of which benefit the patient. View over 8,000 slides and 400 cases Identify and diagnose lesions of the skin Includes two DVDs basic and advanced
www.aad.org
51
scientific sessions
For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information.
Restricted Session open to dermatologist and adjunct (researcher, corporate) members. A ticket is required for admittance
M O C
This activity has been approved by the ABD to satisfy component 2 of MOC-D Leadership Institute addresses leadership competencies specific to dermatologists
Practice Management Session open to eligible office staff/registered nurses Patient Safety Session Audience Response System Session
Focus Sessions 7:15 a.m. to 8:45 a.m. U012 Patients Satisfaction: Measurement and Improvement . . . . . . . . . . . . . U013 Whats New in Non-Melanoma Skin Cancer . . . . U014 Mastering Moles in Pediatric Patients . . . . . . . . . U015 Laser Update . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Friday, August 5
53 53 53 53
Symposia 2:00 p.m. to 5:00 p.m. S006 Whats Hot in Dermatopathology . . . . . . . . . . . . 57 S007 Effective Communications: Delivering Key Messages . . . . . . . . . . . . . . . . . . . 58 Focus Sessions 2:30 p.m. to 4:00 p.m. U016 From Bench to Bedside: Important Clinical Advances . . . . . . . . . . . . . . . . U017 Photodynamic Therapy . . . . . . . . . . . . . . . . . . . . U018 Dermoscopy for the Non-Dermoscopist . . . . . . . Cellulitis: A Common (Mis)Diagnosis? . . . . . . . . U019 Forums F011 F012 F013 F014
Plenary Session 9:00 a.m. to 12:00 p.m. 9:00 a.m. Chairs Welcome / Henry W. Lim, M.D. . . . . . . . 54 9:05 a.m. Presidents Address / Ronald L. Moy, M.D. . . . . . 54 9:20 a.m. Everett C. Fox, M.D., Memorial Lectureship: Sentinel Node Biopsy: Just the Facts, You Decide / Timothy M. Johnson, M.D. . . . . . . . . . . . . . . . . 54 9:50 a.m. Guest Speaker / Don Tapscott . . . . . . . . . . . . . . . . 54 10:30 a.m. Overhauling CME and Dermatology Education: Laps, Gaps, Maps, and Traps / Erik J. Stratman, M.D. . . . . . . . . . . . . . . . . . . . 55 10:45 a.m. Contact Dermatitis / David Eric Cohen, M.D. . . . . .55 11:00 a.m. Update in CTCL: A Tale of Two Kinds of T-Cells / Sam T. Hwang, M.D., Ph.D. . . . . . . . . . . . . . . 55 11:15 a.m. Comparative Effectiveness / David J. Margolis, M.D. . . . . . . . . . . . . . . . . . . 55 11:30 a.m. Non-Ablative and Ablative Fractional Resurfacing: Cosmetic and Medical Indications / Roy G. Geronemus, M.D. . . . . . . . . . . . . . . . . . 56 Course 2:00 p.m. to 5:00 p.m. C002 Live Patient Demonstration: Neurotoxins and Soft Tissue Augmentation . . . . . . . . . . . . . . . . . . . . . . 57
58 58 59 59
3:00 p.m. to 5:00 p.m. Using Technology to Improve Dermatology Access . .59 Case-Based Challenges for PA/NPs . . . . . . . . . . . 60 Melanoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60 Finessing Surgical Technique . . . . . . . . . . . . . . . . 61
Workshop 3:00 p.m. to 5:00 p.m. W005 MOC Self-Assessment: Pediatric Dermatology . . . 62
52
scientific sessions
For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information.
FOCuS SeSSIOnS
7:15 a.m. to 8:45 a.m. Ticket required for admission, no tuition fee. Ticket holds seat for only 15 minutes after the official start time.
u012
u014
DIReCTOR Julie V. Schaffer, M.D. LeARnIng OBjeCTIveS Following this focus session, the attendee should be able to: 1. Recognize clinicopathologic variants of acquired and congenital melanocytic nevi in children and their typical patterns of evolution. 2. Identify and monitor children at risk for the development of melanoma or neurocutaneous melanocytosis. 3. Formulate an individualized approach to management of melanocytic nevi in children. DeSCRIPTIOn This session will review the clinical spectrum, natural history, and management of melanocytic nevi in children, including variants such as spitz, blue, and speckled lentiginous nevi. Current concepts of the risks associated with congenital melanocytic nevi of different sizes, numbers, and locations as well as individualized strategies for their management (e.g. considering cosmesis and ease of monitoring) will be discussed. Recent observations on the dermatoscopic features and molecular hallmarks of childhoodacquired and congenital melanocytic nevi will be examined, highlighting insights into pathways of melanocytic tumorigenesis. Data on clinical presentations and biologic behavior of prepubertal melanoma will also be presented. 1.50 Category 1 CME Credits
DIReCTOR Victor James Marks, M.D. LeARnIng OBjeCTIveS Following this focus session, the attendee should be able to: 1. Recognize the difference between patient and physician perception of excellence in care. 2. Apply Principles of Service Excellence to your practice setting. 3. Identify behavioral standards that can be adopted as office standards. DeSCRIPTIOn This session will focus on raising awareness of the importance of an exceptional experience by patients as the basis for office success. We will discuss patient versus physician perceptions of care, outline principles of service excellence, and elucidate the concept of behavioral (service) standards as a means of ensuring consistently personal service delivery by all personnel in the office. 1.50 Category 1 CME Credits
u013
DIReCTOR Gary Goldenberg, M.D. LeARnIng OBjeCTIveS Following this focus session, the attendee should be able to: 1. Identify and analyze new and important studies in nonmelanoma skin cancer. 2. Describe new findings in dermatopathology in relation to nonmelanoma skin cancer. 3. Identify new treatment approaches to non-melanoma skin cancer. DeSCRIPTIOn This session will focus on non-melanoma skin cancer, including actinic keratosis, squamous cell carcinoma, basal cell carcinoma, Merkel cell carcinoma, and Kaposis sarcoma. We will review and analyze new studies, focusing on pathogenesis, epidemiology, histopathology, and treatment. 1.50 Category 1 CME Credits
u015
Laser update
Room: Clinton Suite
DIReCTOR Jerome M. Garden, M.D. LeARnIng OBjeCTIveS Following this focus session, the attendee should be able to: 1. Choose appropriate laser systems for various conditions. 2. Determine a practical and safe approach for everyday practice. 3. Identify the latest developments in laser therapy. DeSCRIPTIOn With so many devices being promoted for the treatment of the skin, this forum will give an understanding to the science and clinical outcome including the latest developments. A greater skill as how to approach the patient will be developed. 1.50 Category 1 CME Credits
www.aad.org
53
scientific sessions
P151 PLenARY SeSSIOn
For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information. 9:00 a.m. to 12:00 p.m. Room: Grand Ballroom East/West Open admission, no tuition or ticket. Up to 2.00 Category 1 CME Credits 9:05 a.m.
9:00 a.m.
Welcome
Henry W. Lim, M.D. Chair, Scientific Assembly Committee
Presidents Address
Ronald L. Moy, M.D.
No CME Credit
To help us succeed in todays dynamic health care environment, the Academy has developed a detailed plan of strategic priorities aligned with our members top concerns including addressing challenges and opportunities that emerge as we work through the impending health care revolution, Dr. Moy stated earlier this year. For the Summer Academy Meeting 2011 in New York, Dr. Moy will discuss the progress of these efforts and address current issues affecting the profession. Dr. Moy will discuss how the Academy is helping its members manage change, and update attendees on plans for influencing positive change for the future. No CME Credit
9:20 a.m.
9:50 a.m.
everett C. Fox, M.D., Memorial Lectureship: Sentinel node Biopsy: just the Facts, You Decide!
Timothy M. Johnson, M.D
guest Speaker
Don Tapscott
Sentinel node biopsy for melanoma remains controversial within dermatology. This presentation will summarize the contemporary data, found by and large outside the core dermatology literature. It should be appreciated that variable interpretation of existing evidence is certain, and final interpretations and opinions may respectfully differ from one person to another. 0.50 Category 1 CME Credits
Don Tapscott is an internationally renowned authority on the strategic impact of information technology on innovation, marketing and talent. Tapscott consistently identifies and explains the next business imperatives and defines the business models and strategies required for success. Tapscott has authored or coauthored fourteen widely read books on technology, business and the Net Generation, including his newest book, Macrowikinomics: Rebooting Business and the World, co-authored with Anthony D. Williams. His other books include Grown Up Digital: How the Net Generation is Changing Your World and Wikinomics: How Mass Collaboration Changes Everything an international bestseller, appearing on the New York Times and BusinessWeek bestseller lists. No CME Credit
54
scientific sessions
For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information.
P151
9:00 a.m. to 12:00 p.m. Room: Grand Ballroom East/West Open admission, no tuition or ticket. Up to 2.00 Category 1 CME Credits 10:45 a.m.
PLenARY SeSSIOn
10:30 a.m.
Overhauling CMe and Dermatology education: Laps, gaps, Maps, and Traps
Erik J. Stratman, M.D.
Contact Dermatitis
David Eric Cohen, M.D.
Over 3 billion dollars is spent annually delivering CME education to physicians in the United States, or just over $3700 per US physician. Despite the expenditure, data suggest that the traditional lecture-based CME does little to change physician behavior when delivering subsequent patient care. With pressure mounting to provide more outcomes-driven impactful education during residency and during the continuing professional development of the practicing physician, medical education has begun to evolve. Residency training now has milestones in addition to competencies. In CME education, we see shifts in education delivery and focus, now with much greater emphasis in performance improvement, point of care education, and Maintenance of Certification. In many cases, these education changes are becoming less optional and an expected means to acquire education to maintain licensure and/or certification. This session will provide the dermatologist with a glimpse at changes underway and changes coming, and will explain how we all will be impacted through CME sessions of the near future. 0.25 Category 1 CME Credit 11:00 a.m.
The evaluation of contact dermatitis presents an often harrowing challenge in the daily care of patients with eczematous dermatitis. While the technique of patch testing has changed little in the past decades, our recognition of important provocative allergens and groups of chemicals regularly transforms and evolves, a consequence of the great flux in exposure patterns that patients experience through their work and routine daily activities. Consequently, we have seen the emergence of important and relevant allergens as participants in the genesis of cutaneous delayed type hypersensitivity and the vanishing role of previously commonly implicated chemicals. We will review the epidemiologic journey of contact dermatitis and current perspectives on the importance and relevance of patch testing. 0.25 Category 1 CME Credit
11:15 a.m.
Comparative effectiveness
David J. Margolis, M.D.
In the dermatologic literature, Szary syndrome (SS) is often described as a variant of mycosis fungoides (MF). New immunological data indicate that the malignant T cells in SS and MF are derived from two distinct populations of T cells. This information can help explain the clinical manifestations of these two diseases and provide avenues for selective therapy. 0.25 Category 1 CME Credit
Comparative effectiveness research is the comparison of existing therapeutic options in order to determine which therapy provides the greatest benefits, often in a real world setting. His presentation will include a basic primer on comparative effectiveness research and discuss why this type of research will impact the provision of healthcare. 0.25 Category 1 CME Credit
www.aad.org
55
scientific sessions
P151 PLenARY SeSSIOn
For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information. 9:00 a.m. to 12:00 p.m. Room: Grand Ballroom East/West Open admission, no tuition or ticket. Up to 2.00 Category 1 CME Credits
11:30 a.m.
Fractional resurfacing was developed in response to complications and prolonged healing associated with non fractional resurfacing for cosmetic conditions. Non-ablative fractional resurfacing involves the delivery of thousands of microthermal zones extending to various depths depending on the laser wavelength and energy. The non-ablative treatments have shown dramatic clinical benefit for rejuvenation, acne and surgical scars, dyschromia and actinic keratoses. 0.25 Category 1 CME Credit
The American Academy of Dermatology is pleased to announce a Call for Nominations for the 2013 Named Lectureships. These distinguished awards are given in recognition of outstanding dermatologic research. Recipients receive cash awards and will present their lecture at the 2013 Annual Meeting in Miami, Fla. Nominations are currently being accepted for the following awards:
Clarence S. Livingood, MD,
11:45 a.m.
If you would like to apply or nominate someone visit the Academy Resource Center Booth 906 or visit www.aad.org/namedlectureships
56
scientific sessions
For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information.
COuRSe
2:00 p.m. to 5:00 p.m. Tuition fee and ticket required for admission.
SYMPOSIuM
C002
S006
DIReCTOR Shane A. Meehan, M.D. InvITeD SPeAKeRS Tammie C. Ferringer, M.D. Gary Goldenberg, M.D. Rishi R. Patel, M.D. LeARnIng OBjeCTIveS Following this symposium, the attendee should be able to: 1. Discuss new developments in the understanding of various disease processes from the perspective of dermatopathology as they pertain to clinical practice of dermatology. 2. Describe advances in diagnostic studies as they pertain to the diagnosis and pathogenesis of a variety of infectious, neoplastic and inflammatory disease processes. DeSCRIPTIOn This course is designed to provide dermatologists and dermatopathologists with an overview of recent developments in the diagnosis and pathogenesis of a wide variety of neoplastic and inflammatory processes. Recently devised immunoperoxidase markers for the diagnosis of melanoma, non-melanoma skin cancers, and certain infectious diseases will be discussed. In addition, advances in molecular diagnostic studies as they pertain to the understanding and diagnosis of melanocytic neoplasms will be reviewed. The session will also encompass newly recognized inflammatory processes, such as cocaine-related retiform purpura and challenges pertaining to the diagnosis of pustular psoriasis versus acute generalized exanthematous pustulosis. 3.00 Category 1 CME Credits SCHeDuLe 2:00 p.m. 2:40 p.m. 2:45 p.m. 3:25 p.m. 3:30 p.m. Inflammatory Skin Disorders / Dr. Patel Discussion / Dr. Patel Todays Immunohistochemistry / Dr. Ferringer Discussion / Dr. Ferringer Whats New In Non-Melanoma Skin Cancer? / Dr. Goldenberg 4:10 p.m. Discussion / Dr. Goldenberg 4:15 p.m. Atypical Melanocytic Nevi And Melanoma / Dr. Meehan 4:55 p.m. Discussion / Dr. Meehan
DIReCTOR Heidi A. Waldorf, M.D. InvITeD SPeAKeRS Rebecca L. Fitzgerald, M.D. Jeannette O. Graf, M.D. Michael Kane, M.D. Seth L. Matarasso, M.D. Cameron K. Rokhsar, M.D. Neil S. Sadick, M.D. Susan H. Weinkle, M.D.
LeARnIng OBjeCTIveS Following this course, the attendee should be able to: 1. Evaluate the aging face. 2. Develop a therapeutic rejuvenation plan utilizing a combination of neurotoxin and soft tissue fillers and collagen stimulators. 3. Avoid and manage complications. DeSCRIPTIOn This session consists of live demonstrations of injectables for facial rejuvenation including neuromodulators, soft tissue fillers and collagen stimulators. During the demonstrations, the faculty will review patient evaluation, anatomic considerations, product selection, injection techniques and complications. Combination therapies to enhance outcomes will be discussed. 3.00 Category 1 CME Credits SCHeDuLe 2:00 p.m. Introduction / Dr. Waldorf 2:05 p.m. The Upper Face: Shaping the Brow / Dr. Kane / Dr. Graf 2:25 p.m. The Upper Face: Focus on the Eyes and Tear Trough / Dr. Graf / Dr. Matarasso 2:45 p.m. The Upper Face: The Atrophic Temple / Dr. Fitzgerald / Dr. Kane 3:05 p.m. The Mid-Face: Volumizing the Cheeks / Dr. Sadick / Dr. Fitzgerald 3:25 p.m. Questions and Answers / Faculty 3:35 p.m. The Mid-Face: Approaching the Perioral Area and Lips / Dr. Matarasso / Dr. Waldorf 3:55 p.m. The Lower Face: Managing Jowls and Jawline / Dr. Waldorf / Dr. Weinkle 4:15 p.m. The Hands: Rejuvenation / Dr. Weinkle / Dr. Rohksar 4:25 p.m. Refining the Nose / Dr. Rohksar / Dr. Sadick 4:45 p.m. Questions and Answers / Faculty
www.aad.org
57
scientific sessions
SYMPOSIuM
2:00 p.m. to 5:00 p.m. Open admission, no tuition or ticket.
For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information.
FOCuS SeSSIOn
2:30 p.m. to 4:00 p.m. Ticket required for admission, no tuition fee. Ticket holds seat for only 15 minutes after the official start time.
S007
u016
DIReCTOR Patricia Farris, M.D. InvITeD SPeAKeR Ruth Mugalian LeARnIng OBjeCTIveS Following this symposium, the attendee should be able to: 1. Prepare compelling and relatable key messages. 2. Communicate key messages clearly, concisely and effectively. 3. Apply strategies for staying focused on key messages in challenging situations such as media interviews. DeSCRIPTIOn The Academy has identified effective communication as a core competency for leadership in dermatology. Learning how to successfully craft and deliver key messages will help you communicate effectively in any situation. Attendees will have the opportunity to practice what theyve learned about message development in mock media interviews designed to challenge participants to stay focused while delivering their message. The course director is a previous chair of the council on communications. She will be assisted by a communications consultant. This session is recommended for dermatologists and graduate members. Seating will be limited to 30 and available on a first-come first-served basis. 3.00 Category 1 CME Credits SCHeDuLe 2:00 p.m. 2:05 p.m. 2:40 p.m. 3:00 p.m. 3:20 p.m. 4:50 p.m. Introduction / Dr. Farris Key Message Training / Dr. Farris Basics/Expectations of an Interview / Ms. Mugalian Develop Key Messages / Ms. Mugalian On-Camera Mock Media Interviews / Ms. Mugalian Questions and Answers / All Faculty
DIReCTOR Oscar Colegio, M.D., Ph.D. LeARnIng OBjeCTIveS Following this focus session, the attendee should be able to: 1. Describe molecular pathways recently discovered to be effective targets for treating melanoma, basal cell carcinoma and dermatofibrosarcoma protuberans. 2. Summarize the efficacy of recently approved therapies or therapies currently in trials for the treatment of skin cancers. DeSCRIPTIOn Systemic and topical targeted therapies are emerging as a rational approach to the management of skin cancers. In this session, the rationale behind and effectiveness of new molecules used in the treatment of melanoma, basal cell carcinoma, actinic keratoses, dermatofibrosarcoma protuberans and Kaposis sarcoma will be reviewed. This session is designed for a broad audience, from practicing dermatologists to basic scientists. 1.50 Category 1 CME Credits
u017
Photodynamic Therapy
Room: Regent Parlor
DIReCTOR Mollie A. MacCormack, M.D. LeARnIng OBjeCTIveS Following this focus session, the attendee should be able to: 1. Describe the mechanism of action of photodynamic therapy. 2. Identify conditions that respond well to photodynamic therapy as well as those that do not. 3. Incorporate photodynamic therapy into his or her practice. DeSCRIPTIOn Photodynamic therapy is rapidly becoming a mainstay of dermatologic therapy. Easily incorporated into clinical practice it adds a new dimension to dermatologic care. Yet, as with any recent advance, confusion exists regarding its actual efficacy for treating a variety of skin diseases. This session will cover the science behind photodynamic therapy, details on how the procedure is performed and how you can easily incorporate it into your own practice as well as an extensive review of the data supporting its efficacy in treating a wide range of dermatologic conditions. 1.50 Category 1 CME Credits
58
scientific sessions
For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information.
FOCuS SeSSIOnS
2:30 p.m. to 4:00 p.m. Ticket required for admission, no tuition fee. Ticket holds seat for only 15 minutes after the official start time.
FORuM
3:00 p.m. to 5:00 p.m. Ticket required for admission, no tuition fee. Ticket holds seat for only 15 minutes after the official start time.
u018
F011
DIReCTOR Jennifer A. Stein, M.D., Ph.D. LeARnIng OBjeCTIveS Following this focus session, the attendee should be able to: 1. Recognize characteristic dermoscopic structures of benign and malignant lesions. 2. Use dermoscopy to distinguish benign from suspicious lesions that require biopsy. 3. Formulate a simple pattern recognition system that can be used in general dermatologic practice to minimize unnecessary biopsies and improve detection of malignant lesions. DeSCRIPTIOn Novice dermoscopists will be taught recognizable dermoscopic patterns to assist in the diagnosis of pigmented lesions. We will discuss a simple pattern recognition system that can be incorporated into routine dermatologic practice. The session will also include dermoscopy of special sites, including the face and acral surfaces. Participants will be shown unknown cases throughout the session for self-assessment and the approach to diagnosis of these cases will be reviewed. By incorporating dermoscopy into everyday practice, participants will be able to improve their diagnostic accuracy in detecting melanoma and other skin cancers. 1.50 Category 1 CME Credits
DIReCTOR Claudia Hernandez, M.D. InvITeD SPeAKeRS April W. Armstrong, M.D. Jeffrey A. V. Benabio, M.D. Noah A. Craft, M.D. William D. James, M.D. Amit Pandya, M.D.
LeARnIng OBjeCTIveS Following this forum, the attendee should be able to: 1. Identify those who may have limited access to dermatologic care and to identify possible barriers to providing this care. 2. Review innovative means for providing dermatologic care to those in need, including use of online educational databases, and teledermatology. 3. Discuss access to care issues and consider future means for providing dermatologic care to underserved populations.
u019
DeSCRIPTIOn Though the problem of inequality of dermatologic care has been recognized, there is still a shortage of care. Inequality of care in different regions of the United States and globally needs to be addressed. With the increase in usage of teledermatology and other new technologies, access to care should increase. Understanding the tools available to dermatologist will help in closing this gap. This course will provide professional development to the attendees via new information on methods of providing care to those in need. New technologies will aid in delivery of care for underserved patients and communities. 2.00 Category 1 CME Credits
DIReCTOR Daniela Kroshinsky, M.D. LeARnIng OBjeCTIveS Following this focus session, the attendee should be able to: 1. Define the clinical patterns and symptoms associated with the different forms of true cellulitis. 2. Recognize the features that suggest another diagnosis, specifically in atypical presentations or in patients who fail to respond to routine therapy. 3. Formulate a broad differential diagnosis for healthy and immunosuppressed patients. DeSCRIPTIOn Dermatologists are often consulted to evaluate a patient with presumed cellulitis. For routine cellulitis, an accurate diagnosis can be obtained from the patients symptoms and clinical appearance. However, when the clinical presentation is somewhat atypical, or if the patient fails to respond to appropriate therapy for common bacterial cellulitis, the differential diagnosis should be rapidly expanded. This session will discuss the approach to the patient with presumed cellulitis, with an emphasis on the differential diagnosis of cellulitis in both healthy and immunocompromised patients. 1.50 Category 1 CME Credits
Transition into Practice: A Toolkit for Dermatologists Entering into the Workforce
Whether youre fresh out of residency or changing practices mid-career, this manual will guide you every step of the way into your new job. ! NEW Assessing Practice Options Interview Process Structuring Your Contract Co-ownership/Buy-in Marketing Yourself to Patients
scientific sessions
FORuMS
For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information. 3:00 p.m. to 5:00 p.m. Ticket required for admission, no tuition fee. Ticket holds seat for only 15 minutes after the official start time.
F012
F013
Melanoma
Room: Sutton Center
DIReCTOR Eva A. Hurst, M.D. InvITeD SPeAKeRS Lynn Anne Cornelius, M.D. Kimberly Dawn Morel, M.D. Kara S. Nunley, M.D. Manisha J. Patel, M.D.
DIReCTOR Martin A. Weinstock, M.D., Ph.D. InvITeD SPeAKeRS Richard Carvajal, M.D. Allan C. Halpern, M.D. Darrell S. Rigel, M.D. Nancy E. Thomas, M.D.
LeARnIng OBjeCTIveS Following this forum, the attendee should be able to: 1. Perform a broad differential diagnosis based on clinical findings and lesion morphology. 2. Identify clinical and pathologic features of common and challenging dermatologic diseases. 3. Identify the most appropriate management strategies and formulate a practical treatment plan. DeSCRIPTIOn This forum is designed for NPs and PAs practicing dermatology. Using challenging case examples, participants will be guided through differential diagnoses and therapeutic plans for a variety of complex cases. Specifically, thought processes leading to the differential diagnoses will be described, laboratory testing and dermatopathology will be reviewed, and management will be discussed. Related to presented cases, this session will review advances and practical approaches to treatment. Topic highlights include pigmented lesions and melanoma, pediatric dermatology, transplant dermatology, and complex medical dermatology cases. An audience response system will be used to facilitate learning. 2.00 Category 1 CME Credits SCHeDuLe 3:00 p.m. Introduction and Objectives / Dr. Hurst 3:10 p.m. Pediatric Dermatology Case Challenges / Dr. Morel 3:35 p.m. Pigmented Lesion and Melanoma Case Challenges / Dr. Cornelius 3:55 p.m. Transplant Dermatology Case Challenges / Dr. Patel 4:20 p.m. Complex Medical Dermatology Case Challenges / Dr. Nunley 4:45 p.m. Question and Answer / All faculty
LeARnIng OBjeCTIveS Following this forum, the attendee should be able to: 1. Assess and use technologies relevant to melanoma. 2. Identify the clinical features of genetically distinct types of melanoma. 3. Decribe new therapies for metastatic melanoma. DeSCRIPTIOn This session will focus on the interaction of technology and melanoma, including assessing its effect on risk, its use in diagnosis, and issues in its control. Melanoma is now recognized as a collection of diseases, and we will also discuss their clinical features and therapy in the metastatic setting. 2.00 Category 1 CME Credits SCHeDuLe 3:00 p.m. Assessing Impact of New Technology on Melanoma Risk / Dr. Weinstock 3:12 p.m. Technological Aids to Melanoma Diagnosis / Dr. Halpern 3:39 p.m. BRAF and NRAS Mutant Melanomas: Clinical Features, Risk, and Outcome / Dr. Thomas 4:06 p.m. A New Era in the Management of Metastatic Melanoma / Dr. Carvajal 4:33 p.m. Indoor Tanning: Current Issues and Future Challenges / Dr. Rigel
60
scientific sessions
FORuM
For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information. 3:00 p.m. to 5:00 p.m. Ticket required for admission, no tuition fee. Ticket holds seat for only 15 minutes after the official start time.
F014
DIReCTOR David M. Ozog, M.D. InvITeD SPeAKeRS Brett M. Coldiron, M.D. Emily J. Fisher, M.D. Hayes B. Gladstone, M.D. Hugh M. Gloster Jr., M.D. Christopher James Miller, M.D. Suzanne Olbricht, M.D.
LeARnIng OBjeCTIveS Following this forum, the attendee should be able to: 1. Demonstrate simple yet essential surgical techniques to achieve optimal cosmetic and functional outcomes. 2. Utilize proper surgical instruments and materials to enhance healing and repair outcomes. 3. Assess common mistakes made when coding for surgical procedures and how to avoid them. DeSCRIPTIOn This session provides essential surgical pearls for the general dermatologist and intermediate dermatologic surgeon. A myriad of topics will be discussed including tips for anesthesia, optimizing suturing techniques and wound aversion, and the best use of surgical instruments, wound dressings and suture materials. Practical topics will be discussed, including surgical coding and tips to avoid and treat wound complications. 2.00 Category 1 CME Credits SCHeDuLe 3:00 p.m. Painless Anesthesia Before Difficult Closures Made Simple / Dr. Ozog 3:15 p.m. Instruments That Make My Day Easier / Dr. Gloster 3:30 p.m. When Aversion Aint Happening: Tips for Optimal Suture Placement / Dr. Miller 3:45 p.m. The Ear of the Dog: Hangover Remedies / Dr. Olbricht 4:00 p.m. Essential Suturing Techniques: Beyond The Simple Interrupted Stitch / Dr. Gladstone 4:15 p.m. Good Closures Gone Bad: A Short Story Of Blood, Pus, And Tears / Dr. Fisher 4:30 p.m. I Can Get Paid for That? Tips To Optimize Surgical Coding / Dr. Coldiron 4:45 p.m. Questions and Answers / All faculty
www.aad.org
61
scientific sessions
WORKSHOP
For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information. 3:00 p.m. to 5:00 p.m. Tuition fee and ticket required for admission.
W005
M O C
DIReCTOR Katherine B. Puttgen, M.D. InvITeD SPeAKeRS Bernard Cohen, M.D. Moise L. Levy, M.D. Teresa S. Wright, M.D. LeARnIng OBjeCTIveS Following this workshop, the attendee should be able to: 1. Identify features of neurofibromatosis type 1 in the pediatric population. 2. Differentiate among treatment options for function-threatening infantile hemangiomas. 3. Discuss causes of and therapies for tinea capitis.
DeSCRIPTIOn Attendees will review clinical findings of important genodermatoses in children including tuberous sclerosis, neurofibramotosis type 1, and Rothmund-Thomson. An update on vascular anomalies in children including infantile hemangiomas and congenital hemangiomas will be reviewed. Epidemiology of important pediatric dermatology infections and infestations will be discussed. 2.00 Category 1 CME Credits SCHeDuLe 3:00 p.m. 3:30 p.m. 4:00 p.m. 4:30 p.m. Questions and Answers: 1st Portion / Dr. Wright Questions and Answers: 2nd Portion / Dr. Puttgen Questions and Answers: 3rd Portion / Dr. Cohen Questions and Answers: 4th Portion / Dr. Levy * Self-assessment questions utilized in this session are the same as those used for Workshop W002 and W005 offered at Annual Meeting 2010 and 2011 and Workshop W008 at Summer Academy Meeting 2010. Physicians should not claim CME/MOC credit for attending this session if they attended any of the sessions listed above.
! NEW
Volume 4
Volume 3
Dou que ble th stio e ns!
62
scientific sessions
For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information.
Restricted Session open to dermatologist and adjunct (researcher, corporate) members. A ticket is required for admittance
M O C
This activity has been approved by the ABD to satisfy component 2 of MOC-D Leadership Institute addresses leadership competencies specific to dermatologists
Practice Management Session open to eligible office staff/registered nurses Patient Safety Session Audience Response System Session
Saturday, August 6
Focus Sessions 7:15 a.m. to 8:45 a.m. Exploring Evidence-Based Cosmeceuticals.............. 64 U020 Controversies in Dysplastic Nevi ......................... 64 U021 Patch Test Allergens 101: A Detectives Toolkit....... 65 U022 U023 Use of Light for Diagnosis and Treatment in Dermatology ..................................... 65 Forums F015 F016 F017 9:00 a.m. to 11:00 a.m. Alopecia and Hair Loss........................................... 66 Consultative Dermatology ...................................... 66 Case-Based Controversies: Dermatopathology.................................................. 66
Focus Session 12:15 p.m. to 1:45 p.m. U024 When Clinical and Histological Findings Converge: Great Cases From a Dermatopathologists Perspective .............................................................. 71 Impact of Nanotechnology and Dermatology......... 71 U025 Pediatric Dermatology Jeopardy ............................. 71 U026 Symposium 2:00 p.m. to 5:00 p.m. S010 Cutting Edge Surgery and Oncology ...................... 72 Focus Sessions 2:30 p.m. to 4:00 p.m. U027 Practical Dermoscopy ............................................. 72 Morphea: Not Just for Adults Anymore.................. 72 U028 Forums 3:00 p.m. to 5:00 p.m. F021 New Technologies in Minimally Invasive Skin Rejuvenation ..................................... 73 F022 Psoriasis Guidelines: Implementing them in Your Practice ............................................. 73 Workshop 3:00 p.m. to 5:00 p.m. W007 Coding and Documentation ............................ 74
Symposia 9:00 a.m. to 12:00 p.m. S008 Whats Hot in Womens Dermatology .................... 67 S009 Dermatology Grand Rounds: A Discussion of Case-Based Dilemmas ............................................ 68 Course 9:00 a.m. to 5:00 p.m. C003 Derm Exam Prep Course: Refresher ....................... 68 Forums 12:00 p.m. to 2:00 p.m. F018 Hypercoagulability, Purpura and the Skin .............. 69 F019 Oral Disease ........................................................... 69 F020 Tumor Board .......................................................... 70 Workshop 12:00 p.m. to 2:00 p.m. W006 Practical Approaches to Patient Problems .............. 70
www.aad.org
63
scientific sessions
For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information.
FOCuS SeSSIOn
7:15 a.m. to 8:45 a.m. Ticket required for admission, no tuition fee. Ticket holds seat for only 15 minutes after the official start time.
u020
u021
DIReCTOR Payam Abrishami, M.D. LeARnIng OBjeCTIveS Following this focus session, the attendee should be able to: 1. Examine historically the concept of the lentiginous and dysplastic nevi. 2. Analyze the criteria for the lentiginous, dysplastic, Clarks, and architecturally disordered nevi. 3. Discuss recommendations for terminology to be adopted by our specialty. DeSCRIPTIOn Through a series of original photomicrographs the session will validate the concept of the lentiginous nevus for the attendee. The terms dysplastic nevus, atypical nevus, architecturally disordered nevus, Clarks nevus, and degrees of atypia will be explored through historical review. The attendee will be empowered to decide the legitimacy of these concepts, which have emerged over the last 30 years; this session will promote a new direction in the understanding of these common melanocytic nevi. 1.50 Category 1 CME Credits
DIReCTOR Zoe Diana Draelos, M.D. LeARnIng OBjeCTIveS Following this focus session, the attendee should be able to: 1. Demonstrate an understanding of how cosmeceuticals can be used meaningfully in dermatology. 2. Examine new research directing development of cosmeceuticals. 3. Recognize the different categories of cosmeceuticals and their efficacy parameters. DeSCRIPTIOn Cosmeceuticals can be of value in dermatology for the prevention and maintenance of skin disease, in addition to addressing photoaging issues. This session will examine the evidence behind cosmeceuticals in the current marketplace while presenting new research leading to cosmeceutical development in the future. Each of the basic categories of cosmeceuticals will be discussed with attention to the efficacy of individual technologies. 1.50 Category 1 CME Credits
With a database of goods and services that are continually purchased by dermatologists, the AAD Buyers Guide allows members to quickly nd what they need without the clutter of general purpose search engines.
64
scientific sessions
For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information.
FOCuS SeSSIOn
7:15 a.m. to 8:45 a.m. Ticket required for admission, no tuition fee. Ticket holds seat for only 15 minutes after the official start time.
u022
u023
DIReCTOR Peter C. Schalock, M.D. LeARnIng OBjeCTIveS Following this focus session, the attendee should be able to: 1. Recognize common allergens on product labels. 2. Counsel patients on likely sources of allergen exposures. 3. Determine an appropriate array of allergens to adequately test your patients. DeSCRIPTIOn The baseline series of patch tests encompass many compounds to which patients are exposed on a daily basis. Having knowledge of potential allergens and their prospective sources of exposure is essential for assessing those with suspected allergic contact dermatitis in a general dermatology practice. This session is for those interested in learning more about the most common allergens. We will review the T.R.U.E. Test as well as the 50 Chemotechnique North American Standard Series allergens. Sources of these allergens and patient counseling tips will be suggested. Illustrative questions and cases will be discussed. 1.50 Category 1 CME Credits
DIReCTOR Iltefat H. Hamzavi, M.D. LeARnIng OBjeCTIveS Following this focus session, the attendee should be able to: 1. Demonstrate a basic understanding of skin optics. 2. Demonstrate the ability to formulate treatment plans using different light sources. 3. Identify the staff and skills needed to administer light-based treatments in your office. DeSCRIPTIOn Light has become a more important part of treatment options for dermatologists. A basic understanding of skin optics is needed to implement light based treatments in any practice. With this understanding complex diseases can be managed more effectively with phototherapy, PDT and lasers. This course will explain the theory behind photomedicine and then develop an approach to customize treatment modalities to the needs of the patient. Lastly, suggestions will be made on how to organize an office to start or improve phototherapy options. 1.50 Category 1 CME Credits
aa Measurement Tools
www.aad.org
65
scientific sessions
For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information.
FORuM
9:00 a.m. to 11:00 a.m. Ticket required for admission, no tuition fee. Ticket holds seat for only 15 minutes after the official start time.
F015
F017
DIReCTOR Dirk Michael Elston, M.D. LeARnIng OBjeCTIveS Following this forum, the attendee should be able to: 1. Perform an appropriate evaluation for non-scarring alopecia. 2. Perform an appropriate evaluation for scarring alopecia. 3. Manage alopecia effectively. DeSCRIPTIOn The evaluation and management of hair disorders can be challenging. This session presents a practical, efficient and costeffective approach to the evaluation and management of alopecia and hirsutism. 2.00 Category 1 CME Credits
DIReCTOR Jacqueline M. Junkins-Hopkins, M.D. InvITeD SPeAKeRS Aleodor A. Andea, M.D. John Andrew Carlson, M.D. Leonard C. Sperling, M.D. LeARnIng OBjeCTIveS Following this forum, the attendee should be able to: 1. 1. Identify management options for cases with problematic histopathologic findings. 2. Recognize limitations in the histopathologic assessment of certain entities. 3. Identify controversial topics that may be encountered in Dermatopathology. DeSCRIPTIOn Some entities in Dermatopathology may be considered controversial with regard to diagnosis, reporting and/or recommendations supplied by the dermatopathologist. Many of these issues have an impact on patient management. Selected topics, such as alopecia biopsies, management and reporting of atypical but non-malignant proliferations, including melanocytic lesions, atypical spindle cell tumors, and atypical dermal lymphocytic infiltrates, will be discussed by a panel of experienced dermatopathologists. Audience participation is welcomed and encouraged. This session will benefit both dermatologists and dermatopathologists. 2.00 Category 1 CME Credits SCHeDuLe 9:00 a.m. 9:25 a.m. 9:30 a.m. 9:55 a.m. 10:00 a.m. 10:25 a.m. 10:30 a.m. 10:55 a.m. Case Presentation / Dr. Carlson Questions and Answers / Dr. Carlson Case Presentation / Dr. Andea Questions and Answers / Dr. Andea Case Presentation / Dr. Sperling Questions and Answers / Dr. Sperling Case Presentation / Dr. Junkins-Hopkins Questions and Answers / Dr. Junkins-Hopkins
F016
Consultative Dermatology
Room: Sutton Center
DIReCTOR Jonathan Cotliar, M.D. InvITeD SPeAKeRS Lindy Peta Fox, M.D. Lauren C. Hughey, M.D. Daniela Kroshinsky, M.D. Kanade Shinkai, M.D., Ph.D.
LeARnIng OBjeCTIveS Following this forum, the attendee should be able to: 1. Recognize unique cutaneous toxicities associated with cancer therapy. 2. Recognize unique paraneoplastic dermatoses. 3. Recognize cutaneous complications of stem cell transplantation. DeSCRIPTIOn This case-based session is intended for physicians with an interest in the consultative care of cancer in patients with skin disease. Special attention will be paid to unique reactions to cancer therapy, new and unusual paraneoplastic dermatoses, unique presentations of neutrophilic dermatoses, as well as common and uncommon complications of stem cell transplantation. 2.00 Category 1 CME Credits SCHeDuLe 9:00 a.m. Unique Paraneoplastic Dermatoses / Dr. Hughey 9:25 a.m. Unique Reactions to Cancer Therapy / Dr. Fox 9:50 a.m. Unusual Dermatoses in Cancer Patients / Dr. Kroshinsky 10:15 a.m. Neutrophilic Dermatoses / Dr. Shinkai 10:40 a.m. Dermatoses Associated with Stem Cell Transplantation / Dr. Cotliar
66
scientific sessions
For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information.
SYMPOSIuM
S008
DIReCTOR Boni E. Elewski, M.D. InvITeD SPeAKeRS Craig A. Elmets, M.D. Marian Elizabeth Northington, M.D. Vlada Groysman, M.D. Darrell S. Rigel, M.D. Mark Lebwohl, M.D. Richard K. Scher, M.D. Mary Gail Mercurio, M.D. LeARnIng OBjeCTIveS Following this symposium, the attendee should be able to: 1. Discuss management of melanoma in women, vulvodynia and vulvar dermatoses; recognize contact dermatitis in women and pregnancy related dermatoses. 2. Effectively diagnose and treat women with nail disorders. 3. Select the best medical and aesthetic approach for management of the aging female face.
DeSCRIPTIOn Certain skin diseases occur more commonly in women. This symposium will focus on select skin disorders emphasizing diagnostic clues, therapeutic challenges, and treatment. Additionally, nail disorders, melanoma, diseases of pregnancy, best medical and aesthetic approach for the aging face, and psoriasis will be highlighted. Finally, there will be a discussion of vulvodynia and vulvar dermatoses as well as contact dermatitis in women. 3.00 Category 1 CME Credits SCHeDuLe 9:00 a.m. 9:05 a.m. 9:30 a.m. 9:55 a.m. 10:20 a.m. Introduction / Dr. Elewski Nail Tips for Women / Dr. Scher Treating Psoriasis in Women / Dr. Lebwohl Dermatoses of Pregnancy / Dr. Mercurio A Medical and Aesthetic Approach to the Aging Face / Dr. Northington 10:45 a.m. Management of Vulvodynia and Vulvar Dermatoses / Dr. Groysman 11:05 a.m. Contact Dermatitis in Women / Dr. Elmets 11:30 a.m. Melanoma in Women: Special Concerns / Dr. Rigel
www.aad.org
67
scientific sessions
For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information.
SYMPOSIuM
COuRSe
9:00 a.m. to 5:00 p.m. Tuition fee and ticket required for admission.
S009
C003
DIReCTOR Jeffrey J. Miller, M.D. InvITeD SPeAKeRS Bryan Erik Anderson, M.D. Victor J. Marks, M.D. Christopher James Miller, M.D. Bethanee Jean Schlosser, M.D. Andrea L. Zaenglein, M.D.
DIReCTOR Amit Garg, M.D. InvITeD SPeAKeRS Jeffrey Phillip Callen, M.D. Jennie T. Clarke, M.D. Lindy Peta Fox, M.D. Jane M. Grant-Kels, M.D. Fiona OReilly Zwald, M.D.
LeARnIng OBjeCTIveS Following this symposium, the attendee should be able to: 1. Develop skills in differential diagnosis and evaluation of complex dermatologic diseases, many with interdisciplinary considerations. 2. Discuss the use of advanced systemic therapies for the management of refractory dermatologic conditions.
DeSCRIPTIOn This session will offer a Grand Rounds style discussion. Evidenceand experience-based commentary among panelists and audience members will be presented to offer practical considerations in the diagnosis, specific evaluation, and advanced therapeutic management of challenging clinical cases and representing a breadth of complex diseases. An interactive case-based approach will be utilized to highlight relevance for the experienced clinician. 3.00 Category 1 CME Credits
LeARnIng OBjeCTIveS Following this course, the attendee should be able to: 1. Review the 150 dermatologic diseases and conditions listed by the American Board of Dermatology (ABD) as required for the General Dermatology module of the Maintenance of Certification in Dermatology (MOC). 2. Identify areas needing additional study in preparation for the General Dermatology module of the MOC-D exam. 3. Recognize the format used on the MOC-D exam. DeSCRIPTIOn This course is targeted to dermatologists preparing for the American Board of Dermatology (ABD) Maintenance of Certification in Dermatology (MOC-D) exam. Residents preparing for their Board exam may also benefit. The course will review the 150 diagnoses listed as covered in the General Dermatology module of the MOC-D exam in a format similar to the one used on the exam. 6.00 Category 1 CME Credits
68
scientific sessions
For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information.
FORuM
12:00 p.m. to 2:00 p.m. Ticket required for admission, no tuition fee. Ticket holds seat for only 15 minutes after the official start time.
F018
F019
Oral Disease
Room: Sutton North
DIReCTOR Warren W. Piette, M.D. LeARnIng OBjeCTIveS Following this forum, the attendee should be able to: 1. Recognize typical presentations of microvascular occlusion syndromes in the skin. 2. Choose relevant laboratory screening exams critical for diagnosis. 3. Define mechanisms of cutaneous occlusion. DeSCRIPTIOn This session begins with an outline of the differences in diagnoses between venous thromboembolism and microvascular occlusion. A brief discussion of relevant clotting and clot inhibition pathways is followed by a targeted review of pertinent laboratory testing. The session concludes with a presentation of unknown purpura cases including simple hemorrhage, inflammatory hemorrhage, and occlusion. 2.00 Category 1 CME Credits
DIReCTOR Ginat W. Mirowski, M.D., D.M.D. InvITeD SPeAKeRS Nasim Fazel, M.D. Bethanee Jean Schlosser, M.D., Ph.D. Janellen Smith, M.D. Rochelle R. Torgerson, M.D., Ph.D. LeARnIng OBjeCTIveS Following this forum, the attendee should be able to: 1. Evaluate the various presentations of common erosive/ ulcerative oral conditions including acute oral ulcers and erosive lichen planus. 2. Evaluate and treat conditions of the tongue including burning mouth. 3. Evaluate the various presentations of challenging conditions in immunocompromised hosts. DeSCRIPTIOn The session will cover the evaluation and treatment of numerous oral conditions. The faculty will share with the audience their approach and treatment of many common oral dermatoses including oral ulcers, oral erosive lichen planus, burning mouth, oral conditions in the immunocompromised host, as well as tongue lesions. 2.00 Category 1 CME Credits SCHeDuLe 12:00 p.m. 12:20 p.m. 12:40 p.m. 1:00 p.m. 1:20 p.m. 1:40 p.m. Acute Oral Ulceration / Dr. Fazel Oral Lichen Planus / Dr. Schlosser Update on Burning Mouth Syndrome / Dr. Torgerson Tongue Lesions / Dr. Smith Challenging Oral Cases / Dr. Mirowski Questions and Answers / All faculty
www.aad.org
69
scientific sessions
For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information.
FORuM
12:00 p.m. to 2:00 p.m. Ticket required for admission, no tuition fee. Ticket holds seat for only 15 minutes after the official start time.
WORKSHOP
12:00 p.m. to 2:00 p.m. Tuition fee and ticket required for admission.
F020
Tumor Board
Room: Sutton Center
W006
DIReCTOR Chrysalyne Delling Schmults, M.D. LeARnIng OBjeCTIveS Following this forum, the attendee should be able to: 1. Summarize available evidence that impacts management of cutaneous cancers. 2. Apply current treatment recommendations to patient care as appropriate. 3. Develop appropriate management strategies when scientific evidence is lacking. DeSCRIPTIOn Cases of cutaneous malignancy will be presented by the moderator and discussed by a multi-disciplinary panel comprised of experts in dermatology, dermatologic surgery, dermatopathology, oncology, and radiation/surgical oncology. Audience questions and participation will be encouraged. Cases will focus on common tumors such as melanoma and SCC but will also include more unusual tumors and interesting clinical scenarios. Available evidence and current treatment recommendations will be reviewed. Areas where data is lacking will be highlighted and panelists will discuss how to make management decisions when clear evidence does not exist. 2.00 Category 1 CME Credits
DIReCTOR Jeffrey Phillip Callen, M.D. InvITeD SPeAKeRS Jerry D. Brewer, M.D. Joseph L. Jorizzo, M.D. Julie V. Schaffer, M.D. Erik J. Stratman, M.D.
LeARnIng OBjeCTIveS Following this workshop, the attendee should be able to: 1. Construct a plan for evaluation of patients with cutaneous disease. 2. Develop a therapeutic ladder based upon the best evidence available. 3. Diagnose systemic manifestations of skin disease. DeSCRIPTIOn This session is an interactive session in which we will utilize an audience response system. Patient cases will be presented followed by a series of questions upon which audience input will be sought. Following polling, an expert panel will discuss their approach to the problem. 2.00 Category 1 CME Credits
70
scientific sessions
For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information.
FOCuS SeSSIOn
12:15 p.m. to 1:45 p.m. Ticket required for admission, no tuition fee. Ticket holds seat for only 15 minutes after the official start time.
u024
When Clinical and Histological Findings Converge: great Cases From a Dermatopathologists Perspective
Room: Regent Parlor
u026
DIReCTOR Victoria R. Barrio, M.D. LeARnIng OBjeCTIveS Following this focus session, the attendee should be able to: 1. Recognize several important pediatric dermatology conditions. 2. Formulate appropriate treatment plans for certain pediatric skin diseases. DeSCRIPTIOn This will be an interactive review of important new and fundamental concepts in pediatric dermatology. The format will follow that of the popular game show Jeopardy, such that each audience member can test their current knowledge in selected areas. The session should both reinforce the audience members previous knowledge and help work through scenarios that may present in their future practice. It is aimed toward the dermatology resident and the private practitioner. 1.50 Category 1 CME Credits
DIReCTOR Paolo Romanelli, M.D. LeARnIng OBjeCTIveS Following this focus session, the attendee should be able to: 1. Recognize the importance of representative skin biopsy to diagnose skin disease more effectively. 2. Better communicate to their dermatopathologist for the ultimate benefit of the patients. 3. Order appropriate IHC markers to optimize the therapeutic approach. DeSCRIPTIOn We will cover multiple clinically difficult cases that needed a representative skin biopsy to obtain a correct diagnostic clinicopathological correlation. Together with most of the cases, some immunohistochemistry studies as potential therapeutic biomarkers will also be discussed, in the effort to develop and optimize an effective future tailor-made treatment for every patient. 1.50 Category 1 CME Credits
u025
DIReCTOR Adnan Nasir, M.D., Ph.D. LeARnIng OBjeCTIveS Following this focus session, the attendee should be able to: 1. Recognize the importance of nanotechnology in dermatology. 2. Identify the key benefits of nanotechnology for consumers and patients in dermatology. 3. Identify potential hazards of nanotechnology. DeSCRIPTIOn Nanotechnology is a burgeoning field with tremendous potential for society and medicine. Currently, it is entering an exponential growth phase in the number and variety of products soon to be or already available for consumers and patients. The skin is the first point of contact and the first line of defense for nanomaterials. This presentation serves to educate attendees about the benefits and pitfalls of a new and exciting technology with enormous promise for the diagnosis and management of skin disease and for the maintenance of skin health. 1.50 Category 1 CME Credits
www.aad.org
71
scientific sessions
For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information.
SYMPOSIuM
2:00 p.m. to 5:00 p.m. Ticket required for admission, no tuition fee. Ticket holds seat for only 15 minutes after the official start time.
FOCuS SeSSIOn
2:30 p.m. to 4:00 p.m. Ticket required for admission, no tuition fee. Ticket holds seat for only 15 minutes after the official start time.
S010
DIReCTOR
u027
DIReCTOR
Practical Dermoscopy
Room: Regent Parlor Steven Q. Wang, M.D.
InvITeD SPeAKeRS Murad Alam, M.D. Christopher K. Bichakjian, M.D. Jerry D. Brewer, M.D.
LeARnIng OBjeCTIveS Following this focus session, the attendee should be able to: 1. Recognize the language of dermoscopy. 2. Recognize all of the global patterns and local criteria essential to become a proficient dermoscopist. 3. Assess their ability to put the dermoscopic essentials into practice. DeSCRIPTIOn There will be a complete review of the classic and not so classic global patterns and local criteria used to diagnose melanocytic, non-melanocytic, benign and malignant lesions. A self-assessment quiz will also be presented. 1.50 Category 1 CME Credits
LeARnIng OBjeCTIveS Following this symposium, the attendee should be able to: 1. Diagnose and treat skin cancer more effectively. 2. Differentiate and utilize newer techniques and therapies in surgical dermatology. DeSCRIPTIOn The objective of this symposium is to update attendees on cutting edge topics in dermatology related to the diagnosis and treatment of skin cancer and surgical techniques. This session is directed to surgically oriented dermatologists. 3.00 Category 1 CME Credits SCHeDuLe 2:00 p.m. Introduction / Dr. Bordeaux 2:05 p.m. Treatment of High Risk Squamous Cell Carcinoma With Cetuximab / Dr. Ratner 2:25 p.m. Update On Merkel Cell Carcinoma / Dr. Bichakjian 2:45 p.m. In Situ Photoimmunotherapy for Metastatic Melanoma / Dr. Alam 3:05 p.m. Melanoma of the Head and Neck: Practical Challenges Based on a Review of Greater Than 300 Cases at Penn / Dr. Miller 3:25 p.m. Questions 3:40 p.m. Non-Hodgkins Lymphoma and Skin Cancer / Dr. Brewer 4:00 p.m. Treatment of Basal Cell Carcinoma and Squamous Cell Carcinoma In Situ With the Pulsed Dye Laser / Dr. Jian 4:20 p.m. Whats New In Translational Research of Skin Cancer / Dr. Carucci 4:40 p.m. Reconstructing a Full-Thickness Defect of the Eyelid / Dr. Bordeaux 4:50 p.m. Questions and Answers
u028
DIReCTOR
LeARnIng OBjeCTIveS Following this focus session, the attendee should be able to: 1. Recognize the clinical variants of morphea in the pediatric patient. 2. Formulate a multidisciplinary approach to patient evaluation and management. 3. Select appropriate treatment methods. DeSCRIPTIOn The recognition and management of morphea in the pediatric population is primarily performed by dermatologists. This session will review the various forms of morphea and discuss their similarities and unique attributes as it pertains to children and adolescents. The opportunity to coordinate a multidisciplinary approach to patient care to optimize outcomes and satisfaction will be reviewed. A case portfolio will provide interactive discussion of typical and difficult issues often encountered by morphea patients and their physicians. 1.50 Category 1 CME Credits
S013
DIReCTOR
LeARnIng OBjeCTIveS Following this symposium, the attendee should be able to: 1. Recognize the problem of occupational exposures within the field of medicine and those employees most suscept ble to percutaneous injuries and mucocutaneous splashes. 2. Identify the procedures and behaviors that place dermatologists at highest risk for occupational exposures. 3. Describe strategies to implement in daily practice that will help eliminate the risk of occupational exposures. DeSCRIPTIOn The number of needlesticks and mucocutaneous splashes that occur in the United States is staggering. Dermatologists and their staff are particularly at risk due to the high number of in-office procedures performed. Attendees of this session will be able to identify and correct behaviors that place the practitioner and their staff at risk before, during, and after in-office procedures. The subject of bloodborne pathogen transmission will be discussed in detail. Additionally, the large problem of underreporting occupational exposures among students, residents, and physicians will be addressed. 1.5 Category 1 CME Credits
72 | amerIcan academy oF dermatoLogy sUmmer academy meetIng 2011
scientific sessions
For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information.
FORuM
3:00 p.m. to 5:00 p.m. Ticket required for admission, no tuition fee. Ticket holds seat for only 15 minutes after the official start time.
F021
F022
DIReCTOR Brooke A. Jackson, M.D. InvITeD SPeAKeRS Cheryl M. Burgess, M.D. Wendy E. Roberts, M.D. Hema A. Sundaram, M.D. Heidi A. Waldorf, M.D.
DIReCTOR Mark Lebwohl, M.D. InvITeD SPeAKeRS Henry W. Lim, M.D. Bruce Elliot Strober, M.D., Ph.D. Abby S. Van Voorhees, M.D. LeARnIng OBjeCTIveS 1. Develop skills to manage patients with psoriasis and psoriatic arthritis with an emphasis on decision making criteria that will enable the clinician to individualize therapy based upon disease type, extent, response to previous treatments, quality of life issues, and co-morbidities. 2. Recognize and diagnose challenging clinical cases and select evidence-based treatment using the recently published AAD psoriasis evidence-based guidelines, which includes best practices. 3. Address gaps in clinical knowledge and care. DeSCRIPTIOn The session will be helpful in expanding physician knowledge base and improving clinical confidence and effectiveness in treating psoriasis patients with a wide range of clinical presentations including psoriatic arthritis. The session will consist of four presentations, with time available after each talk for interaction with the attendees. It will be structured in a questionand-answer format when case studies are discussed. A short survey will be conducted before and after the session, and a follow-up survey will be conducted six months later to gauge and evaluate if guidelines/ implementation products and presentations were easy to translate into daily clinical practice. Studies have shown that high-quality guidelines can make important contribution to improving medical care. 2.00 Category 1 CME Credits SCHeDuLe 3:00 p.m. Introduction and overview with survey / Dr. Lebwohl 3:10 p.m. Topical Therapy for Psoriasis with case study / Dr. Van Voorhees 3:35 p.m. Phototherapy for Psoriasis with case study / Dr. Lim 4:00 p.m. Systemic Therapy with case study / Dr. Lebwohl 4:25 p.m. Biologic Therapy with case study / Dr. Strober 4:50 p.m. Panel Discussion with survey / All Faculty
LeARnIng OBjeCTIveS Following this forum, the attendee should be able to: 1. Describe new and emerging technologies in minimally invasive skin rejuvenation. 2. Discuss the role of these new technologies in the physicians armamentarium of treatment options. 3. Recognize the latest research supporting or negating these emerging technologies. DeSCRIPTIOn With the rapid proliferation of rejuvenation technologies, it is important for the physician to be familiar with these emerging technologies and their possible roles in the armamentarium of treatment modalities offered to patients. 2.00 Category 1 CME Credits SCHeDuLe 3:00 p.m. 3:35 p.m. 3:55 p.m. 4:15 p.m. 4:40 p.m. Fillers / Dr. Burgess Lotions, Potions and Other Devices / Dr. Jackson Neurotoxins / Dr. Roberts Lasers / Dr. Waldorf Fat / Dr. Sundaram
www.aad.org
73
scientific sessions
For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information.
WORKSHOP
3:00 p.m. to 5:00 p.m. Tuition fee and ticket required for admission.
W007
DIReCTOR Allan S. Wirtzer, M.D. InvITeD SPeAKeRS Paul Lizzul, M.D., Ph.D. Wayne M. Marley, M.D. Howard Woodling Rogers, M.D. LeARnIng OBjeCTIveS Following this workshop, the attendee should be able to: 1. Reduce errors in CPT coding. 2. Develop the necessary documentation required for CPT codes. 3. Identify how the audit process can affect your practice. DeSCRIPTIOn Inappropriate and inaccurate coding can adversely affect your practices financial well-being. This session will provide information that will not only guide you in the selection of proper CPT codes but, through the use of audited records, provide insight into what constitutes acceptable documentation of your services. 2.00 Category 1 CME Credits
This forum will provide the opportunity to learn best practices in the complex management of psoriasis and psoriatic arthritis. Experts in the field will review the latest clinical guidelines with four question-and-answer presentations. Attendees receive a full set of recently published AAD Guidelines together with implementation products, which will assist in using the evidence-based AAD psoriasis guidelines in practice FREE of charge!
Visit www.aad.org/ meetings-and-events/ summer-meeting to register.
Visit www.aad.org/webinars for a schedule of upcoming webinars as well as a list of those past.
74
scientific sessions
For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information.
Restricted Session open to dermatologist and adjunct (researcher, corporate) members. A ticket is required for admittance
M O C
This activity has been approved by the ABD to satisfy component 2 of MOC-D Leadership Institute addresses leadership competencies specific to dermatologists
Practice Management Session open to eligible office staff/registered nurses Patient Safety Session Audience Response System Session
Sunday, August 7
Focus Sessions 7:15 a.m. to 8:45 a.m. U029 Leprosy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76 U030 Optimizing Management of Melanoma: Recognizing and Responding to Common Dilemmas in Patient Care . . . . . . . . . . . . . . 76 U031 The Interface of Skin and Psyche . . . . . . . . . . . . . . . . . 76 U032 Spitzs Genodermatoses . . . . . . . . . . . . . . . . . . . . . . . . 76 U033 Infectious Disease Update: What I Wouldnt Have Known Without Evidence-Based Medicine . . . . . . . . . 77
Forum 9:00 a.m. to 11:00 a.m. F023 Pathology and Procedures of the Aging Hand . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77 Symposia 9:00 a.m. to 12:00 p.m. Whats Hot in Pediatric Dermatology . . . . . . . . . . . . . 78 S011 S012 Whats Breaking Out: Acne and Rosacea . . . . . . . . . . . 78
Learn more at the Academy Resource Center Booth 906 or visit www.AADdevelopment.org
www.aad.org
|
75
scientific sessions
For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information.
FOCuS SeSSIOn
7:15 a.m. to 8:45 a.m. Ticket required for admission, no tuition fee. Ticket holds seat for only 15 minutes after the official start time.
u029
Leprosy
Room: Gibson Suite
u031
DIReCTOR Danielle M. Miller, M.D., Ph.D. LeARnIng OBjeCTIveS Following this focus session, the attendee should be able to: 1. Diagnose the different presentations of Hansens Disease. 2. Treat the reactions seen in Hansens Disease. 3. Manage the disabilities and comorbidities seen in Leprosy. DeSCRIPTIOn The Leprosy Focus Session describes the clinical spectrum of Hansens disease and its diagnosis. Standard treatment protocols developed by the WHO and the National Hansens Disease Program will be presented. The reactions seen in Hansens disease and their treatment and management will be described. Also presented will be the comorbidities and long term disabilities that are encountered in this patient population and the surrounding socio-economic challenges associated with Leprosy. 1.50 Category 1 CME Credits
DIReCTOR Richard G. Fried, M.D., Ph.D. LeARnIng OBjeCTIveS Following this focus session, the attendee should be able to: 1. Discuss the common burden of chronic skin disease and its contributors to psychological distress in adults. 2. Define different types of stressors. DeSCRIPTIOn There is an abundant and ever growing body of research documenting the inextricable link between the skin and psyche. Common skin disorders such as eczema, rosacea, psoriasis, acne, urticaria, itch, and aging can all be influenced by the skin-psyche connection. This session will review the most compelling data and provide suggestions on how patients can incorporate mind-body techniques. 1.50 Category 1 CME Credits
u030
Optimizing Management of Melanoma: Recognizing and Responding to Common Dilemmas in Patient Care
Room: Regent Parlor
u032
Spitzs genodermatoses
Room: Sutton Center
DIReCTOR Joel L. Spitz, M.D. LeARnIng OBjeCTIveS Following this focus session, the attendee should be able to: 1. Recognize the main clinical features and be able to diagnose the more common genodermatoses. 2. Treat and manage the most common genodermatoses. DeSCRIPTIOn This session will be a clinical overview of genodermatoses directed towards residents, clinicians, and physician extenders. Clinical photos, mutation updates and management will be stressed in this session based on Spitzs Genodermatoses textbook. The presentation will be in an interactive, fun, game-show format to maximize learning and retention for board preparation and to gain a better understanding of these syndromes. 1.50 Category 1 CME Credits
DIReCTOR Christopher James Miller, M.D. LeARnIng OBjeCTIveS Following this focus session, the attendee should be able to: 1. Develop effective management strategies to optimize outcomes of patients with melanoma. 2. Recognize and respond to common dilemmas in which adherence to consensus guidelines is not possible. 3. Evaluate the most current evidence to identify opportunities to enhance management of patients with melanoma. DeSCRIPTIOn Dermatologists frequently assume the primary role in managing patients with melanoma. Although consensus guidelines are useful for most steps of the management process, dermatologists frequently encounter patients that challenge the simplicity of treatment algorithms. This session will use case studies to demonstrate common dilemmas encountered while managing patients with melanoma and review current literature to develop evidence-based responses. Controversial topics addressed in this session will include biopsy technique, the role of sentinel lymph node biopsy, the necessity of bloodwork or imaging, the role of Mohs surgery, and optimal follow-up strategies. 1.50 Category 1 CME Credits
76
scientific sessions
For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information.
FOCuS SeSSIOn
7:15 a.m. to 8:45 a.m. Ticket required for admission, no tuition fee. Ticket holds seat for only 15 minutes after the official start time.
FORuM
9:00 a.m. to 11:00 a.m. Ticket required for admission, no tuition fee. Ticket holds seat for only 15 minutes after the official start time.
u033
Infectious Disease update: What I Wouldnt Have Known Without evidenceBased Medicine
Room: Clinton Suite
F023
DIReCTOR Emily J. Fisher, M.D. InvITeD SPeAKeRS Dee Anna Glaser, M.D. Hugh M. Gloster, Jr., M.D. Ann G. Neff, M.D. LeARnIng OBjeCTIveS Following this forum, the attendee should be able to: 1. Diagnose common benign and malignant tumors of the hand and formulate treatment plans. 2. Describe key anatomic features of the hands and utilize appropriate surgical techniques. 3. Discuss methods for the treatment of common cosmetic concerns of the aging hand as well as evaluating and treating hyperhidrosis. DeSCRIPTIOn Following this session, the participant should be able to identify, diagnose and formulate appropriate treatment plans based on outcomes for the most common benign and malignant tumors found on the hands. Participants should be able to describe the anatomy of the hand, as well as utilize appropriate anesthetic and surgical techniques when performing surgery on the hand to avoid potential complications. Participants should be able to address common cosmetic concerns of the aging hand and various methods for treating and improving these changes. Finally the treatment of hyperhidrosis of the hands will be covered. 2.00 Category 1 CME Credits SCHeDuLe 9:00 a.m. 9:20 a.m. 9:50 a.m. 10:20 a.m. Benign Tumors of the Hand / Dr. Neff Malignant Tumors of the Hand / Dr. Gloster Surgical Procedures of the Hand / Dr. Fisher Cosmetic Procedures for the Aging Hand and Hyperhidrosis Treatment / Dr. Glaser 10:50 a.m. Questions and Answers / All faculty
DIReCTOR Miguel R. Sanchez, M.D. LeARnIng OBjeCTIveS Following this focus session, the attendee should be able to: 1. Examine data from studies of infectious diseases affecting the skin and mucous membranes. 2. Use information to develop best practices to diagnose and treat mucocutaneous infectious diseases. 3. Evaluate evidence behind new therapeutic strategies. DeSCRIPTIOn From antibiotic resistance, to vaccines, to impending epidemics, infectious diseases often capture the headlines of medical news. But there is hardly another subspecialty in medicine or dermatology in which differentiating fact from anecdote is more crucial. This session will review evidence from scientific studies to update the laboratory diagnosis and guide empirically supported treatment of bacterial, fungal, viral and parasitic infections, as well as develop more effective strategies to manage these diseases. 1.50 Category 1 CME Credits
www.aad.org
77
scientific sessions
For a description of session categories, access and fees, see page 24. Please note: meeting room locations are subject to change. See page 32 for more information.
SYMPOSIuM
S011
S012
DIReCTOR Nanette Blythe Silverberg, M.D. InvITeD SPeAKeRS Helen Shin, M.D. Robert Sidbury, M.D. Robert Silverberg, M.D. Jonathan I. Silverberg, M.D.
DIReCTOR Jonette Elizabeth Keri, M.D., Ph.D. InvITeD SPeAKeRS Hilary E. Baldwin, M.D. Alan R. Shalita, M.D. James Q. Del Rosso, D.O. Heather Clare Woolery-Lloyd, M.D. Joely Anne Kaufman, M.D. Andrea L. Zaenglein, M.D. LeARnIng OBjeCTIveS Following this symposium, the attendee should be able to: 1. Apply the latest evidence to treat acne and rosacea patients with conventional and emerging therapies. 2. Treat acne in special populations including younger patients and ethnic skin patients. 3. Identify common patient questions regarding diet and over the counter products. DeSCRIPTIOn The goal of this symposium will be to make practitioners better able to treat all acne and rosacea patients with an emphasis on providing good answers to commonly asked questions in day to day practice. The session will begin with an update of the latest information on these conditions and will follow with specific insight into the role of diet in acne. A good review of sunscreens and cosmetics as well as other non-prescription products will be reviewed including home based light technology. A thorough review on lasers/lights for acne and rosacea will be done, as well as lecture on specific populations of early and ethnic acne patients. Finally, a review of clinical pearls from contact dermatitis in these patients to acne surgery hints will complete the symposium. 3.00 Category 1 CME Credits SCHeDuLe 9:00 a.m. Perspectives on the Management of Acne and Rosacea: A Glance At The Past and A Peek At The Future / Dr. Del Rosso 9:25 a.m. The Role of Diet in Acne and Rosacea / Dr. Shalita 9:50 a.m. Ethnic Skin Acne and Rosacea / Dr. Woolery-Lloyd 10:15 a.m. Cosmetics, Sunscreens, and Other Interesting Topicals for Acne and Rosacea / Dr. Baldwin 10:40 a.m. Update on Lasers and Lights for Acne and Rosacea / Dr. Kaufman 11:05 a.m. Treating Early Acne: From Neonate to Adolescent / Dr. Zaenglein 11:30 a.m. Acne and Rosacea Treatment Pearls: Lessons from Challenging Patients / Dr. Keri
LeARnIng OBjeCTIveS Following this symposium, the attendee should be able to: 1. Analyze recent data on the role of diet and weight in pediatric skin disease. 2. Identify new diagnostic and therapeutic paradigms for hemangiomas of infancy. 3. Analyze recent data on the role of genetics in pediatric skin disease and new techniques in the therapy of genetic illnesses of childhood. DeSCRIPTIOn The session will cover several newer concepts and therapies in pediatric dermatology. The lectures will include newer diagnostic paradigms and therapeutic options in hemangiomas of infancy. The role of diet, vitamins, and weight in pediatric skin disease will be reviewed in light of recent literature. A lecture will review the data on recent controversies in isotretinoin usage. There will also be a lecture on new disease findings and pediatric dermatological implications. 3.00 Category 1 CME Credits ReFeRenCeS 1. Iacobas I, Burrows PE, Frieden IJ, Liang MG, Mulliken JB, Mancini AJ, Kramer D, Paller AS, Silverman R, Wagner AM, Metry DW. LUMBAR: association between cutaneous infantile hemangiomas of the lower body and regional congenital anomalies. J Pediatr. 2010; 157: 795-801. 2. Murray CS, Canoy D, Buchan I, Woodcock A, Simpson A, Custovic A. Body mass index in young children and allergic disease: gender differences in a longitudinal study. Clin Exp Allergy. 2011; 41: 78-85. 3. Crockett SD, Porter CQ, Martin CF, Sandler RS, Kappelman MD. Isotretinoin use and the risk of inflammatory bowel disease: a case-control study. Am J Gastroenterol. 2010; 105:1986-93. SCHeDuLe 9:00 a.m. Acne, Isotretinoin And Autoimmunity / Dr. Silverberg 9:30 a.m. The Role Of Obesity In Atopic Dermatitis / Dr. Silverberg 10:10 a.m. Whats New In The World Of Pediatric Dermatology / Dr. Sidbury 10:45 a.m. New Concepts In Clinical Pediatric Dermatology / Dr. Silverman 11:20 a.m. Acne And Diet / Dr. Shin
78
Oracea (doxycycline, USP) is indicated for the treatment of only inammatory lesions (papules and pustules) of rosacea in adult patients. In clinical trials, the most common adverse events reported were gastrointestinal upsets, nasopharyngitis/pain, and nasal congestion/sinusitis. Oracea should not be used to treat microbial infections, and should be used only as indicated. This drug is contraindicated in people who have shown hypersensitivity to any of the tetracyclines, and, like other tetracycline drugs, may cause fetal harm when administered to a pregnant woman. Oracea should not be used during pregnancy, by nursing mothers, or during tooth development (up to the age of 8 years). Although photosensitivity was not observed in clinical trials, Oracea patients should minimize or avoid exposure to natural or articial sunlight. All contraindications, warnings, and precautions associated with tetracyclines must be considered before prescribing Oracea. The safety of Oracea treatment beyond 9 months has not been established. Please see brief summary of Prescribing Information on next page.
References: 1. Del Rosso JQ, Webster GF, Jackson M, et al. Two randomized phase III clinical trials evaluating anti-inammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol. 2007;56(5):791-802. 2. Data on le. Galderma Laboratories, L.P. 3. Webster GF. An open label, community-based, 12-week assessment of the effectiveness and safety of monotherapy with doxycycline 40-mg (30-mg immediate-release and 10-mg delayed-release beads). Cutis. 2010;86(suppl 5[i]):7-15. 4. Del Rosso JQ, Schlessinger J, Werschler P. Comparison of anti-inammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea. J Drugs Dermatol. 2008;7(6):573-576. 5. Preshaw PM, Novak MJ, Mellonig J, et al. Modied-release subantimicrobial dose doxycycline enhances scaling and root planing in subjects with periodontal disease. J Periodontol. 2008;79(3):440-452.
Oracea and Galderma are registered trademarks of Galderma Laboratories, L.P. 2011 Galderma Laboratories, L.P. Galderma Laboratories, L.P. 14501 N. Freeway Fort Worth, TX 76177 ORA-525 Printed in USA 01/11
hcp.oracea.com
Rx Only
MICROBIOLOGY The plasma concentrations of doxycycline achieved with ORACEA during administration (see DOSAGE AND ADMINISTRATION) are less than the concentration required to treat bacterial diseases. In vivo microbiological studies utilizing a similar drug exposure for up to 18 months demonstrated no detectable long-term effects on bacterial ora of the oral cavity, skin, intestinal tract, and vagina. Carcinogenesis, Mutagenesis, Impairment of Fertility: Doxycycline was assessed for potential to induce carcinogenesis in a study in which the compound was administered to Sprague-Dawley rats by gavage at dosages of 20, 75, and 200 mg/kg/day for two years. An increased incidence of uterine polyps was observed in female rats that received 200 mg/kg/day, a dosage that resulted in a systemic exposure to doxycycline approximately 12.2 times that observed in female humans who use ORACEA (exposure comparison based upon area under the curve (AUC) values). No impact upon tumor incidence was observed in male rats at 200 mg/kg/ day, or in either gender at the other dosages studied. Evidence of oncogenic activity was obtained in studies with related compounds, i.e., oxytetracycline (adrenal and pituitary tumors) and minocycline (thyroid tumors). Doxycycline demonstrated no potential to cause genetic toxicity in an in vitro point mutation study with mammalian cells (CHO/HGPRT forward mutation assay) or in an in vivo micronucleus assay conducted in CD-1 mice. However, data from an in vitro assay with CHO cells for potential to cause chromosomal aberrations suggest that doxycycline is a weak clastogen. Oral administration of doxycycline to male and female Sprague-Dawley rats adversely affected fertility and reproductive performance, as evidenced by increased time for mating to occur, reduced sperm motility, velocity, and concentration, abnormal sperm morphology, and increased pre-and post-implantation losses. Doxycycline induced reproductive toxicity at all dosages that were examined in this study, as even the lowest dosage tested (50 mg/kg/day) induced a statistically signicant reduction in sperm velocity. Note that 50 mg/kg/day is approximately 3.6 times the amount of doxycycline contained in the recommended daily dose of ORACEA for a 60-kg human when compared on the basis of AUC estimates. Although doxycycline impairs the fertility of rats when administered at sufcient dosage, the effect of ORACEA on human fertility is unknown. Pregnancy: Teratogenic Effects: Pregnancy Category D. (see WARNINGS section). Results from animal studies indicate that doxycycline crosses the placenta and is found in fetal tissues. Nonteratogenic effects: (see WARNINGS section). Labor and Delivery: The effect of tetracyclines on labor and delivery is unknown. Nursing Mothers: Tetracyclines are excreted in human milk. Because of the potential for serious adverse reactions in infants from doxycycline, ORACEA should not be used in mothers who breastfeed. (see WARNINGS section). Pediatric Use: ORACEA should not be used in infants and children less than 8 years of age (see WARNINGS section). ORACEA has not been studied in children of any age with regard to safety or efcacy, therefore use in children is not recommended. ADVERSE REACTIONS Adverse Reactions in Clinical Trials of ORACEA: In controlled clinical trials of adult patients with mild to moderate rosacea, 537 patients received ORACEA or placebo over a 16-week period. The most frequent adverse reactions occurring in these studies are listed in the table below.
Incidence (%) of Selected Adverse Reactions in Clinical Trials of ORACEA (n=269) vs. Placebo (n=268)
Nasopharyngitis Pharyngolaryngeal Pain Sinusitis Nasal Congestion Fungal Infection Inuenza Diarrhea Abdominal Pain Upper Abdominal Distention Abdominal Pain Stomach Discomfort
ORACEA 13 (4.8) 3 (1.1) 7 (2.6) 4 (1.5) 5 (1.9) 5 (1.9) 12 (4.5) 5 (1.9) 3 (1.1) 3 (1.1) 3 (1.1)
Placebo 9 (3.4) 2 (0.7) 2 (0.7) 2 (0.7) 1 (0.4) 3 (1.1) 7 (2.6) 1 (0.4) 1 (0.4) 1 (0.4) 2 (0.7)
Note: Percentages based on total number of study participants in each treatment group. Adverse Reactions for Tetracyclines: The following adverse reactions have been observed in patients receiving tetracyclines at higher, antimicrobial doses: Gastrointestinal: anorexia, nausea, vomiting, diarrhea, glossitis, dysphagia, enterocolitis, and inammatory lesions (with vaginal candidiasis) in the anogenital region. Hepatotoxicity has been reported rarely. Rare instances of esophagitis and esophageal ulcerations have been reported in patients receiving the capsule forms of the drugs in the tetracycline class. Most of the patients experiencing esophagitis and/or esophageal ulceration took their medication immediately before lying down. (see DOSAGE AND ADMINISTRATION section). Skin: maculopapular and erythematous rashes. Exfoliative dermatitis has been reported but is uncommon. Photosensitivity is discussed above. (see WARNINGS section). Renal toxicity: Rise in BUN has been reported and is apparently dose-related.(see WARNINGS section). Hypersensitivity reactions: urticaria, angioneurotic edema, anaphylaxis, anaphylactoid purpura, serum sickness, pericarditis, and exacerbation of systemic lupus erythematosus. Blood: Hemolytic anemia, thrombocytopenia, neutropenia, and eosinophilia have been reported. OVERDOSAGE In case of overdosage, discontinue medication, treat symptomatically, and institute supportive measures. Dialysis does not alter serum half-life and thus would not be of benet in treating cases of overdose. DOSAGE AND ADMINISTRATION THE DOSAGE OF ORACEA DIFFERS FROM THAT OF DOXYCYCLINE USED TO TREAT INFECTIONS. EXCEEDING THE RECOMMENDED DOSAGE MAY RESULT IN AN INCREASED INCIDENCE OF SIDE EFFECTS INCLUDING THE DEVELOPMENT OF RESISTANT MICROORGANISMS. One ORACEA Capsule (40 mg) should be taken once daily in the morning on an empty stomach, preferably at least one hour prior to or two hours after meals. Efcacy beyond 16 weeks and safety beyond 9 months have not been established. Administration of adequate amounts of uid along with the capsules is recommended to wash down the capsule to reduce the risk of esophageal irritation and ulceration. (see ADVERSE REACTIONS section). HOW SUPPLIED ORACEA (beige opaque capsule printed with CGPI 40) containing doxycycline, USP in an amount equivalent to 40 mg of anhydrous doxycycline. Bottle of 30 (NDC 64682-009-01). Storage: All products are to be stored at controlled room temperatures of 15C-30C (59F-86F) and dispensed in tight, light-resistant containers (USP). Keep out of reach of children. Patent Information: U.S. Patents 5,789,395; 5,919,775; 7,232,572; 7,211,267 and patents pending. ORACEA is a registered trademark of CollaGenex Pharmaceuticals, Inc. Manufactured by: Marketed by: CardinalHealth Galderma Laboratories, L.P. Winchester, KY 40391 Fort Worth, TX 76177 7961-01 BPI 06/08
Brief Summary of Prescribing Information for STELARA (ustekinumab) STELARA Injection, for subcutaneous use See package insert for Full Prescribing Information INDICATIONS AND USAGE: STELARA is indicated for the treatment of adult patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. CONTRAINDICATIONS: None. WARNINGS AND PRECAUTIONS: Infections STELARA may increase the risk of infections and reactivation of latent infections. Serious bacterial, fungal, and viral infections were observed in subjects receiving STELARA (see Adverse Reactions). STELARA should not be given to patients with any clinically important active infection. STELARA should not be administered until the infection resolves or is adequately treated. Instruct patients to seek medical advice if signs or symptoms suggestive of an infection occur. Exercise caution when considering the use of STELARA in patients with a chronic infection or a history of recurrent infection. Serious infections requiring hospitalization occurred in the psoriasis development program. These serious infections included cellulitis, diverticulitis, osteomyelitis, viral infections, gastroenteritis, pneumonia, and urinary tract infections. Theoretical Risk for Vulnerability to Particular Infections Individuals genetically deficient in IL-12/IL-23 are particularly vulnerable to disseminated infections from mycobacteria (including nontuberculous, environmental mycobacteria), salmonella (including nontyphi strains), and Bacillus Calmette-Guerin (BCG) vaccinations. Serious infections and fatal outcomes have been reported in such patients. It is not known whether patients with pharmacologic blockade of IL-12/IL-23 from treatment with STELARA will be susceptible to these types of infections. Appropriate diagnostic testing should be considered, e.g., tissue culture, stool culture, as dictated by clinical circumstances. Pre-treatment Evaluation for Tuberculosis Evaluate patients for tuberculosis infection prior to initiating treatment with STELARA. Do not administer STELARA to patients with active tuberculosis. Initiate treatment of latent tuberculosis prior to administering STELARA. Consider anti-tuberculosis therapy prior to initiation of STELARA in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed. Patients receiving STELARA should be monitored closely for signs and symptoms of active tuberculosis during and after treatment. Malignancies STELARA is an immunosuppressant and may increase the risk of malignancy. Malignancies were reported among subjects who received STELARA in clinical studies (see Adverse Reactions). In rodent models, inhibition of IL-12/IL-23p40 increased the risk of malignancy (see Nonclinical Toxicology). The safety of STELARA has not been evaluated in patients who have a history of malignancy or who have a known malignancy. Hypersensitivity Reactions Serious allergic reactions, including angioedema and possible anaphylaxis, have been reported post-marketing. If an anaphylactic or other serious allergic reaction occurs, discontinue STELARA and institute appropriate therapy [see Adverse Reactions]. Reversible Posterior Leukoencephalopathy Syndrome One case of reversible posterior leukoencephalopathy syndrome (RPLS) was observed during the clinical development program which included 3523 STELARA-treated subjects. The subject, who had received 12 doses of STELARA over approximately two years, presented with headache, seizures and confusion. No additional STELARA injections were administered and the subject fully recovered with appropriate treatment. RPLS is a neurological disorder, which is not caused by demyelination or a known infectious agent. RPLS can present with headache, seizures, confusion and visual disturbances. Conditions with which it has been associated include preeclampsia, eclampsia, acute hypertension, cytotoxic agents and immunosuppressive therapy. Fatal outcomes have been reported. If RPLS is suspected, STELARA should be discontinued and appropriate treatment administered. Immunizations Prior to initiating therapy with STELARA, patients should receive all immunizations appropriate for age as recommended by current immunization guidelines. Patients being treated with STELARA should not receive live vaccines. BCG vaccines should not be given during treatment with STELARA or for one year prior to initiating treatment or one year following discontinuation of treatment. Caution is advised when administering live vaccines to household contacts of patients receiving STELARA because of the potential risk for shedding from the household contact and transmission to patient. Non-live vaccinations received during a course of STELARA may not elicit an immune response sufficient to prevent disease. Concomitant Therapies The safety of STELARA in combination with other immunosuppressive agents or phototherapy has not been evaluated. Ultraviolet-induced skin cancers developed earlier and more frequently in mice genetically manipulated to be deficient in both IL-12 and IL-23 or IL-12 alone (see Nonclinical Toxicology). Theoretical Risk of Immunotherapy STELARA has not been evaluated in patients who have undergone allergy immunotherapy. STELARA may decrease the protective effect of allergy immunotherapy and may increase the risk of an allergic reaction to a dose of allergen immunotherapy. Therefore, caution should be exercised in patients receiving or who have received allergy immunotherapy, particularly for anaphylaxis. ADVERSE REACTIONS: The following serious adverse reactions are discussed elsewhere in the label: Infections (see Warnings and Precautions); Malignancies (see Warnings and Precautions); and RPLS (see Warnings and Precautions).
STELARA (ustekinumab)
Clinical Studies Experience The safety data reflect exposure to STELARA in 2266 psoriasis subjects, including 1970 exposed for at least 6 months, 1285 exposed for at least one year, and 373 exposed for at least 18 months. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adverse reactions listed below are those that occurred at a rate of at least 1% and at a higher rate in the STELARA groups than the placebo group during the placebo-controlled period of STUDY 1 and STUDY 2. The numbers (percentages) of adverse reactions reported for placebo-treated patients (n=665), patients treated with 45 mg STELARA (n=664), and patients treated with 90 mg STELARA (n=666), respectively, were: Nasopharyngitis: 51 (8%), 56 (8%), 49 (7%); Upper respiratory tract infection: 30 (5%), 36 (5%), 28 (4%); Headache: 23 (3%), 33 (5%), 32 (5%); Fatigue: 14 (2%), 18 (3%), 17 (3%); Diarrhea: 12 (2%), 13 (2%), 13 (2%); Back pain: 8 (1%), 9 (1%), 14 (2%); Dizziness: 8 (1%), 8 (1%), 14 (2%); Pharyngolaryngeal pain: 7 (1%), 9 (1%), 12 (2%); Pruritus: 9 (1%), 10 (2%), 9 (1%); Injection site erythema: 3 (<1%), 6 (1%), 13 (2%); Myalgia: 4 (1%), 7 (1%), 8 (1%); Depression: 3 (<1%), 8 (1%), 4 (1%). Adverse drug reactions that occurred at rates less than 1% included: cellulitis and certain injection site reactions (pain, swelling, pruritus, induration, hemorrhage, bruising, and irritation). One case of RPLS occurred during clinical trials (see Warnings and Precautions). Infections In the placebo-controlled period of clinical studies of psoriasis subjects (average follow-up of 12.6 weeks for placebo-treated subjects and 13.4 weeks for STELARA-treated subjects), 27% of STELARA-treated subjects reported infections (1.39 per subject-year of follow-up) compared with 24% of placebo-treated subjects (1.21 per subjectyear of follow-up). Serious infections occurred in 0.3% of STELARA-treated subjects (0.01 per subject-year of follow-up) and in 0.4% of placebo-treated subjects (0.02 per subject-year of follow-up) (see Warnings and Precautions). In the controlled and non-controlled portions of psoriasis clinical trials, 61% of STELARA-treated subjects reported infections (1.24 per subject-year of follow-up). Serious infections were reported in 0.9% of subjects (0.01 per subject-year of follow-up). Malignancies In the controlled and non-controlled portions of psoriasis clinical trials, 0.4% of STELARA-treated subjects reported malignancies excluding non-melanoma skin cancers (0.36 per 100 subjectyears of follow-up). Non-melanoma skin cancer was reported in 0.8% of STELARA-treated subjects (0.80 per 100 subject-years of follow-up) (see Warnings and Precautions). Serious malignancies included breast, colon, head and neck, kidney, prostate, and thyroid cancers. Immunogenicity The presence of ustekinumab in the serum can interfere with the detection of anti-ustekinumab antibodies resulting in inconclusive results due to assay interference. In STUDIES 1 and 2, antibody testing was done at time points when ustekinumab may have been present in the serum. In STUDY 1 the last ustekinumab injection was between Weeks 28 and 48 and the last test for anti-ustekinumab antibodies was at Week 52. In STUDY 2 the last ustekinumab injection was at Week 16 and the last test for anti-ustekinumab antibodies was at Week 24. In STUDY 1 (N=743), antibody results were found to be positive, negative, and inconclusive in 38 (5%), 351 (47%), and 354 (48%) patients, respectively. In STUDY 2 (N=1198), antibody results were found to be positive, negative, and inconclusive in 33 (3%), 90 (8%), and 1075 (90%) patients, respectively. The data reflect the percentage of subjects whose test results were positive for antibodies to ustekinumab in a bridging immunoassay, and are highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody positivity in an assay may be influenced by several factors, including sample handling, timing of sample collection, concomitant medications and underlying disease. For these reasons, comparison of the incidence of antibodies to ustekinumab with the incidence of antibodies to other products may be misleading. Post-marketing Experience Adverse reactions have been reported during postapproval use with STELARA. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to STELARA exposure. Immune system disorders: Serious allergic reactions (including angioedema, dyspnea and hypotension), hypersensitivity reactions (including rash and urticaria). DRUG INTERACTIONS: Drug interaction studies have not been conducted with STELARA. Live Vaccines Live vaccines should not be given concurrently with STELARA (see Warnings and Precautions). Concomitant Therapies The safety of STELARA in combination with immunosuppressive agents or phototherapy has not been evaluated (see Warnings and Precautions). CYP450 Substrates The formation of CYP450 enzymes can be altered by increased levels of certain cytokines (e.g., IL-1, IL-6, IL-10, TNF, IFN) during chronic inflammation. Thus, ustekinumab could normalize the formation of CYP450 enzymes. A role for IL-12 or IL-23 in the regulation of CYP450 enzymes has not been reported. However, upon initiation of ustekinumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, monitoring for therapeutic effect (e.g., for warfarin) or drug concentration (e.g., for cyclosporine) should be considered and the individual dose of the drug adjusted as needed (see Clinical Pharmacology).
STELARA (ustekinumab)
USE IN SPECIFIC POPULATIONS: Pregnancy Pregnancy Category B There are no studies of STELARA in pregnant women. STELARA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. No teratogenic effects were observed in the developmental and reproductive toxicology studies performed in cynomolgus monkeys at doses up to 45 mg/kg ustekinumab, which is 45 times (based on mg/kg) the highest intended clinical dose in psoriasis patients (approximately 1 mg/kg based on administration of a 90 mg dose to a 90 kg psoriasis patient). Ustekinumab was tested in two embryo-fetal development toxicity studies. Pregnant cynomolgus monkeys were administered ustekinumab at doses up to 45 mg/kg during the period of organogenesis either twice weekly via subcutaneous injections or weekly by intravenous injections. No significant adverse developmental effects were noted in either study. In an embryo-fetal development and pre- and postnatal development toxicity study, three groups of 20 pregnant cynomolgus monkeys were administered subcutaneous doses of 0, 22.5, or 45 mg/kg ustekinumab twice weekly from the beginning of organogenesis in cynomolgus monkeys to Day 33 after delivery. There were no treatment-related effects on mortality, clinical signs, body weight, food consumption, hematology, or serum biochemistry in dams. Fetal losses occurred in six control monkeys, six 22.5 mg/kg-treated monkeys, and five 45 mg/kg-treated monkeys. Neonatal deaths occurred in one 22.5 mg/kg-treated monkey and in one 45 mg/kgtreated monkey. No ustekinumab-related abnormalities were observed in the neonates from birth through six months of age in clinical signs, body weight, hematology, or serum biochemistry. There were no treatment-related effects on functional development until weaning, functional development after weaning, morphological development, immunological development, and gross and histopathological examinations of offsprings by the age of 6 months. Nursing Mothers Caution should be exercised when STELARA is administered to a nursing woman. The unknown risks to the infant from gastrointestinal or systemic exposure to ustekinumab should be weighed against the known benefits of breast-feeding. Ustekinumab is excreted in the milk of lactating monkeys administered ustekinumab. IgG is excreted in human milk, so it is expected that STELARA will be present in human milk. It is not known if ustekinumab is absorbed systemically after ingestion; however, published data suggest that antibodies in breast milk do not enter the neonatal and infant circulation in substantial amounts. Pediatric Use Safety and effectiveness of STELARA in pediatric patients have not been evaluated. Geriatric Use Of the 2266 psoriasis subjects exposed to STELARA, a total of 131 were 65 years or older, and 14 subjects were 75 years or older. Although no differences in safety or efficacy were observed between older and younger subjects, the number of subjects aged 65 and over is not sufficient to determine whether they respond differently from younger subjects. OVERDOSAGE: Single doses up to 4.5 mg/kg intravenously have been administered in clinical studies without dose-limiting toxicity. In case of overdosage, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions or effects and appropriate symptomatic treatment be instituted immediately. PATIENT COUNSELING INFORMATION: Instruct patients to read the Medication Guide before starting STELARA therapy and to reread the Medication Guide each time the prescription is renewed. Infections Inform patients that STELARA may lower the ability of their immune system to fight infections. Instruct patients of the importance of communicating any history of infections to the doctor, and contacting their doctor if they develop any symptoms of infection. Malignancies Patients should be counseled about the risk of malignancies while receiving STELARA. Allergic Reactions Advise patients to seek immediate medical attention if they experience any symptoms of serious allergic reactions. Prefilled Syringe Manufactured by: Centocor Ortho Biotech Inc., Horsham, PA 19044, License No. 1821 at Baxter Pharmaceutical Solutions, Bloomington, IN 47403 Centocor Ortho Biotech Inc. 2010 Vial Manufactured by: Centocor Ortho Biotech Inc., Horsham, PA 19044, License No. 1821 at Cilag AG, Schaffhausen, Switzerland 25ST10221
Poster exhibits
Poster exHiBits
Electronic Poster Exhibits/Poster Presentations: 3rd Level Lobby
Thursday, August 4 ........................................ 7 a.m. 6 p.m. Friday, August 5............................................ 7 a.m. 6 p.m. Poster authors will conduct brief presentations of their electronic posters at the Poster Presentation Center in the 3rd Level Lobby during the meeting. A full schedule of presentations will be available on the Summer Academy meeting website at www.aad.org, and posted on-site at the meeting. electronic Poster exhibits viewing stations will be open during the following hours: Saturday, August 6........................................7 a.m. 5 p.m.
Acne
P100 A double-blind, placebo-controlled, pilot study to determine the efficacy and safety of a clindamycin 1.2% and tretinoin 0.025% combination gel for the treatment of acne rosacea P102 In vitro release of tretinoin from two clindamycin and tretinoin combination gel formulations P103 Bioavailability of clindamycin from a new clindamycin 1% benzoyl peroxide 3% low dose gel P103 An open-label, split-face study evaluating efficacy and safety of photopneumatic therapy for the treatment of acne
P504 Review: Timing of office visits can be a powerful tool to improve adherence in the treatment of dermatologic conditions P505 Unusual presentation of pleurocutaneous fistula P506 Trauma-induced neutrophilic dermatosis of the dorsal hands P507 Cutaneous metastasis to the head from prostate adenocarcinoma: Case report P508 POemS syndrome identified in a patient with multiple atypical hemangiomas P509 Sweet syndrome associated with chlamydia pneumoniae pneumonia P510 A case of plasma cell cheilitis arising from actinic cheilitis P511 mycosis fungoides palmaris et plantaris in childhood
Poster exhibits
Aging/geriAtrics
BAsic science
P400 The contribution of the lysine residue in the dermatological activities of GHK-Cu
dermAtitis, AtoPic
P700 The effect of parenting practices to behavior problems in children with atopic dermatitis P701 Involvement of human histamine N-methyltransferase gene polymorphisms in susceptibility to atopic dermatitis in Korean children P702 A safe, effective, and novel topical herbal preparation for the treatment of atopic dermatitis
P500 Raynauds phenomenon of the nipple in breastfeeding mothers: An underdiagnosed cause of nipple pain P501 Health-related quality of life among Dariers disease patients P502 Plasma histamine concentrations and diamine oxidase activities in chronic idiopathic urticaria P503 Shitake dermatitis and other flagellate dermatoses
P800 Dermatitis in patients undergoing the Nuss procedure for correction of pectus excavatum
For the Latest Program Book InFormatIon PLease reFer to
www.aad.org
83
Poster exhibits
dermAtoPHArmAcology/cosmeceuticAls
P900 Single-center, double-blinded study comparing the long-term UV protective effects of three topical antioxidant products
P901 efficacy and safety of a novel dual resurfacing product that combines the benefits of manual microdermabrasion and chemical peeling
P1500 efficacy of topical imiquimod 5% with cryotherapy for treatment of anthroponotic cutaneous leishmaniasis, compared with intralesional meglumine antimoniate P1501 Case reports of lip leshmaniasis in pediatric patients P1502 Secondary syphilis presenting with clinical features of adulthood atopic dermatitis P1503 mixed cutaneous infection after work accident the importance of making cultures for different agents
digitAl/electronic tecHnology
P1000 A pilot study to evaluate high resolution skin imaging technology (HRSIT) in dermatology clinical practice
infection fungAl
P1600 Naftifine 2% cream has demonstrated safety in the treatment of tinea pedis, tinea cruris and tinea corporis P1601 Naftifine 2% cream demonstrates a low propensity for irritation and no evidence of phototoxicity or photoallergenicity potential P1602 Naftifine 2% cream has demonstrated effectiveness in the treatment of tinea pedis and tinea cruris
P1200 Identifying risk factors via a skin cancer screening program: The moffitt mole Patrol experience P1201 Increased dermatologist density associated with reduction in melanoma mortality P1202 Cosmetic and non-cosmetic skin-related procedures performed in the United States: A 12-year analysis P1203 Time series study of reasons for non-compliance with biologic treatments in psoriasis patients over three years P1204 Psoriasis patient preference study on injectable biologic medications and concerns about self-injection P1205 Adherence to prescription oral or topical treatments in mild, moderate, and severe psoriasis patients P1206 Are urgent referrals actually urgent? Findings from a newlyestablished dermatology urgent care clinic
P1700 Necrolytic acral erythema sine hepatitis C infection: A distinct entity or clue to etiology? P1701 Sweet syndrome with vasculitic pattern in a patient with POemS syndrome P1702 Reactive perforating collagenosis: A case study
P1800 Abnormal B-cell clone in the setting of cutaneous T-cell lymphoma P1801 Paniculitic-like T cell lymphoma of unusual presentation
genodermAtoses
P1900 Neonatal blue light phototherapy and melanocytic nevi: A twin study P1901 mitotic rate as a marker to assess tumor biology in single versus multiple primary melanoma P1902 A case of common blue nevus of the upper lip
P1400 Oral supplementation of silicon and its impact on quality of hair P1401 Investigation of serum vitamin D levels in patients with scarring and nonscarring alopecia P1402 Assessing vitamin D levels in alopecia areata patients
84 |
Poster exhibits
non-melAnomA skin cAncer
P2000 Low frequency of eGFR mutations but high frequency of eGFR copy number anomalies in cutaneous squamous cell carcinoma P2001 Practice trends in the treatment of actinic keratosis in the United States: 0.5% fluorouracil and combination cryotherapy plus fluorouracil are underutilized despite evidence of benefit P2002 A recurred case of malignant eccrine poroma on the ear P2406 efficacy and feasibility of combination excimer laser therapy, clobetasol spray, and calcitriol ointment in the treatment of generalized plaque psoriasis P2407 A qualitative analysis on treatment expectations and experiences among psoriasis patients in the United States P2408 Patient characteristics of ustekinumab utilization in a specialty pharmacy provider (SPP) setting
PediAtric dermAtology
P2500 The role of adenomatous polyposis coli (APC) in epidermal development and hair follicle morphogenesis P2501 Central sensitisation: An under-reported cause of chronic pain in vascular malformations
P2200 Anatomically differentiated dosimetry for optimal phototherapy of generalized psoriasis P2201 An analysis of chronic actinic dermatitis over a period of 25 years
surgery cosmetic
P2600 Academic physicians attitudes towards implementation of multidisciplinary cosmetic centers and the challenges of subspecialties working together P2601 Development and use of a submental fat rating scale
Poster exhibits
P2300 Treatment of melasma with a hydroquinone skin care system plus 0.025% tretinoin cream
surgery lAser
P2700 Treatment of various epidermal-dermal skin lesions with fractional er:yag laser: A Turkish experience P2701 The use of the 1450-nm diode laser in the nonablative treatment of acne scarring in Fitzpatrick skin types IV-VI: A prospective clinical study P2702 Correction of acne scars with fractional CO2 laser in darker skin assessment results and side effects P2703 Treatment of photoaging with CO2 fractional laser evaluation of results and complication in ten dark-skinned patients P2704 Croll technique: Surgical reconstruction with localized laser in acne scars P2705 effectiveness of 595nm pulsed dye laser in the treatment of basal cell carcinoma and squamous cell carcinoma in situ
P2400 Health-related quality of life in patients undergoing etanercept therapy for moderate to severe plaque psoriasis with involvement of the scalp P2401 An assessment of evidence from two phase III randomized placebo-controlled trials in the treatment of moderate-to-severe psoriasis: Benefit-risk analysis of ustekinumab P2402 Response to retreatment with ustekinumab after withdrawal from therapy in moderate-to- severe psoriasis patients: Results from the PHOeNIX 1 and ACCePT phase 3 clinical trials
P2403 Consistency of responses across different ethnic populations with moderate-to-severe psoriasis: Results from the ustekinumab psoriasis clinical development program P2404 efficacy and safety of methotrexate in two fixed doses of 10mg or 25mg orally once weekly in patients with severe plaque type psoriasis: A prospective, randomized, double blind, dose ranging study P2405 Psoriasis and palmoplantar pustulosis attributable to tumor necrosis factor alpha inhibitors: The mayo Clinic experience, 1998-2010
www.aad.org
85
Recommend AmLactin
Everyday hydration 12% lactic acid provides powerful therapy leaving skin noticeably soft and smooth
Targets severely dry skin features ULTRAPLEX, an extra-strength blend of three alpha-hydroxy compounds, clinically proven to improve smoothness and hydration
TM
1-800-654-2299 www.upsher-smith.com 2010 Upsher-Smith Laboratories, Inc., Maple Grove, MN 55369 103985.02
technical exhibits
technicAl exhibit hours
Thursday, August 4 .............................................12 p.m. to 6 p.m. Friday, August 5..................................................12 p.m. to 6 p.m. Unopposed exhibit hours ................................12 p.m. to 2 p.m. Saturday, August 6 .............................................. 10 a.m. to 2 p.m. The American Academy of Dermatology invites you to visit the technical exhibits as part of your educational experience at the Summer Academy Meeting 2011. The products displayed in the technical exhibits area and their uses, suggested by the manufacturers, do not represent an endorsement nor imply that the products have been evaluated or approved by the American Academy of Dermatology. For your convenience, the technical exhibiting companies are listed alphabetically and the products/services they offer are identified as follows: Associations, Foundations and Medical Societies Medical Lighting Equipment Clothing Office Equipment and Supplies Computer Software and Hardware Practice Management Cosmetics and Skin Care Other Medical Equipment and Supplies Disposable Medical Supplies Pharmaceutical EMR/EHR Systems Photographic Equipment and Imaging Services Laboratory Services Phototherapy Supplies and Equipment Laser and Laser Supplies Publishing and Educational Materials Market Research Surgical Instruments A listing by product/services can be found beginning on page 98.
Aerolase . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 223 777 Old Saw Mill River Rd Tarrytown, NY 10591 Phone: (914)345-8300 Fax: (914)345-8303 Email: information@aerolase.com Product Category: Laser and Laser Supplies Allergan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 202 2525 Dupont Drive Irvine, CA 92612 Phone: (714)246-4500 Fax: (714)246-4971 Product Category: Pharmaceutical Alma lasers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 833 485 Half Day Road, Suite 100 Buffalo Grove, IL 60089 Phone: (224)377-2000 Fax: (646)805-1312 Email: contact@almalasers.com Product Category: Laser and Laser Supplies, Other Medical Equipment and Supplies American Academy of Dermatology . . . . . . . . . . . . . . . . . . 906 930 E Woodfield Rd Schaumburg, IL 60173 Phone: (866)503-SKIN (7546) Fax: (847)240-1859 Email: mrc@aad.org Product Category: Associations, Foundations, and Medical Societies American Acne and rosacea society . . . . . . . . . . . . . . . . 433 201 Claremont Ave. Montclair, NJ Phone: (973)783-4575 Fax: (973)783-4576 Email: smoore@physicianresources.org Product Category: Associations, Foundations, and Medical Societies www.aad.org
| 87
technical exhibits
technical exhibits
Amgen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 606 One Amgen Center Drive Thousand Oaks, CA 91320 Phone: (805)447-1000 Email: www.amgen.com Product Category: Pharmaceutical Axia medical solutions . . . . . . . . . . . . . . . . . . . . . . . . . . 316 2015 Camino Vida Roble, Ste L Carlsbad, CA 92011 Phone: (866)494-4466 Email: customerservice@axiamedical.com Product Category: Cosmetics and Skin Care, Pharmaceutical beiersdorf inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 306 187 Danbury Road Wilton, CT 06897 Phone: (203)563-5800 Fax: (203)563-5800 Email: www.eucerinus.com Product Category: Cosmetics and Skin Care bio - oil . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 232 25800 Commercentre Drive Lake Forest, CA 92630 Phone: (949)598-2400 x257 Fax: (949)598-2424 Email: ktinsley@pwcosmetics.com Product Category: Cosmetics and Skin Care biopelle, inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 309 780 W 8 Mile Road Ferndale, MI 48220 Phone: (866)424-6735 Fax: (877)548-7100 Email: contactus@biopelle.com Product Category: Cosmetics and Skin Care bovie medical corporation . . . . . . . . . . . . . . . . . . . . . . . . 329 5115 Ulmerton Road Clearwater, FL 33760 Phone: (800)537-2790 Fax: (800)323-1640 Email: sales@boviemed.com Product Category: Disposable Medical Supplies, Other Medical Equipment and Supplies, Surgical Instruments brymill cryogenic systems . . . . . . . . . . . . . . . . . . . . . . . . 826 105 Windermere Ave Ellington, CT 06029 Phone: (800)779-2796 Fax: (860)872-2371 Email: brymill@brymill.com Product Category: Office Equipment and Supplies, Other Medical Equipment and Supplies, Surgical Instruments canfield imaging systems . . . . . . . . . . . . . . . . . . . . . . . . 805 253 Passaic Ave Fairfield, NJ 07004 Phone: (973)276-0300 Fax: (973)575-9914 Email: info@canfieldsci.com Product Category: Computer Software and Hardware, Photographic Equipment and Imaging Services, Medical Lighting Equipment
88 |
carecredit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 326 2995 Red Hill Ave, Ste 100 Costa Mesa, CA 92626 Phone: (866)247-3049 x2 Fax: (866)874-4093 Email: cosmeticsales@carecredit.com Product Category: Practice Management caris life sciences . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 429 6655 N. MacArthur Blvd Irving, TX 75039 Phone: (800)979-8292 Fax: (214)596-2229 Product Category: Laboratory Services centocor ortho biotech, inc . . . . . . . . . . . . . . . . . . . . . . . 702 800 Ridgeview Drive Horsham, PA 19044 Phone: (610)651-6000 Fax: (215)325-4087 Product Category: Pharmaceutical cobalt medical supply . . . . . . . . . . . . . . . . . . . . . . . . . . . 415 P O Box 367 Pequannock, NJ 07440 Phone: (888)350-3790 Fax: (201)465-3041 Email: sales@cobaltmed.com Product Category: Disposable Medical Supplies, Medical Lighting Equipment, Office Equipment and Supplies, Other Medical Equipment and Supplies, Surgical Instruments, Pharmaceutical compulink business systems, inc . . . . . . . . . . . . . . . . . . . 425 2645 Townsgate Road, Ste 200 Westlake Village, CA 91361 Phone: (800)456-4522 Fax: (208)979-7789 Email: sales@compulinkadvantage.com Product Category: Computer Software and Hardware, EMR/ EHR, Systems, Practice Management conmed . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 821 525 French Rd Utica, NY 13502 Phone: (800)448-6506 Fax: (800)438-3051 Email: info@conmed.com Product Category: Office Equipment and Supplies coria laboratories . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 623 3909 Hulen Street Fort Worth, TX 76107 Phone: (817)501-0372 Product Category: Cosmetics and Skin Care, Pharmaceutical cosmetic surgery times/Dermatology times . . . . . . . . . . . 221 485F US Hwy 1 South, Suite 100 Iselin, NJ 08830 Phone: (732)346-3089 Fax: (732)596-0016 Email: aammon@advanstar.com Product Category: Publishing and Educational Materials cutis and cosmetic Dermatology . . . . . . . . . . . . . . . . . . . 310 7 Century Drive, Suite 302 Parsippany, NJ 07054 Phone: (973)206-8015 Fax: (973)206-9378 Product Category: Publishing and Educational Materials
technical exhibits
technical exhibits
D
Daavlin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 519 205 W Bement St. Bryan, OH 43506 Phone: (800)322-8546 Fax: (419)636-1739 Email: sales@daavlin.com Product Category: Phototherapy Supplies and Equipment Dalos biopharma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 414 421 S Lynnhaven Rd, Ste 101 Virginia Beach, VA 23452 Phone: (888)321-6772 Fax: (757)631-2114 Email: sales@dalosbio.com Product Category: Cosmetics and Skin Care, Pharmaceutical DeKA medical, inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 407 665 Third Street Suite 20 San Francisco, CA 94107 Phone: (877)844-5552 Fax: (415)358-8800 Email: info@dekamedinc.com Product Category: Laser and Laser Supplies Delasco . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 808 608 13th Ave Council Bluffs, IA 51501 Phone: (800)831-6273 Fax: (800)320-9612 Email: questions@delasco.com Product Category: Cosmetics and Skin Care, Disposable Medical Supplies, Laser and Laser Supplies, Medical Lighting Equipment, Other Medical Equipment and Supplies, Pharmaceutical, Publishing and Educational Materials, Surgical Instruments DermAdoctor, inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 834 1901 McGee Street Kansas City, MO 64108 Phone: (816)472-5700 Fax: (816)472-5752 Email: service@dermadoctor.com Product Category: Cosmetics and Skin Care Dermatology foundation . . . . . . . . . . . . . . . . . . . . . . . . . . 818 1560 Sherman Avenue, Suite 870 Evanston, IL 60201-4808 Phone: (847)328-2256 Fax: (847)328-0509 Email: dfgen@dematologyfoundation.org Product Category: Associations, Foundations, and Medical Societies Dermpath Diagnostics . . . . . . . . . . . . . . . . . . . . . . . . . . . 510 7111 Fairway Drive, Suite 400 Palm Beach Gardens, FL 33418 Phone: (866)467-7546 Fax: (214)975-1301 Email: bmccarley@dermpathdiagnostics.com Product Category: Laboratory Services Dusa pharmaceuticals . . . . . . . . . . . . . . . . . . . . . . . . . . . 208 25 Upton Drive Wilmington, MA 01887 Phone: (978)657-7500 Fax: (978)657-9193 Email: cs-dept@dusapharma.com Product Category: Pharmaceutical ellman international . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 806 3333 Royal Ave Oceanside, NY 11572 Phone: (516) 594-3333 Fax: (516)569-0054 Email: ellman@ellman.com Product Category: Other Medical Equipment and Supplies, Surgical Instruments eltamD skincare . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 817 2055 Luna Road # 126 Carrollton, TX 75006 Phone: (800)633-8872 Fax: (972)385-7930 Email: info@eltamd.com Product Category: Cosmetics and Skin Care eZ Derm, llc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 233 90 Cypress Way East Naples, FL 34110 Phone: (800)44-EZDERM Fax: (239)598-0233 Email: info@ezderm.com Product Category: Computer Software and Hardware, EMR/EHR Systems fallene ltd . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 203 2555 Industry Lane Norristown, PA 19403 Phone: (800)332-5536 Product Category: Cosmetics and Skin Care ferndale healthcare, inc . . . . . . . . . . . . . . . . . . . . . . . . . . 526 780 W Eight Mile Rd Ferndale, MI 48220 Phone: (800)621-6003 Fax: (877)548-7100 Email: contactus@ferndalelabs.com Product Category: Pharmaceutical foamix ltd . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 230 PO Box 4038 Weizman Science Park Ness Ziona, Israel 74740 Phone: (972)8-9316233 Fax: (972)8-9474356 Email: info@foamix.co.il Product Category: Cosmetics and Skin Care,Pharmaceutical galderma laboratories, lp . . . . . . . . . . . . . . . . . . . . . . . . 506 14501 North Freeway Fort Worth, TX 76177 Phone: (817)961-5000 Fax: (817)961-5507 Product Category: Pharmaceutical genentech . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 430 1 DNA Way So. San Francisco, CA 94080 Phone: (650)225-2064 Product Category: Pharmaceutical
technical exhibits
www.aad.org
89
technical exhibits
graceway pharmaceuticals . . . . . . . . . . . . . . . . . . . . . . . 432 222 Valley Creek Blvd, Suite 300 Exton, PA 19341 Phone: (267)948-0400 Email: info@gracewaypharma.com Product Category: Pharmaceutical iredale mineral cosmetics . . . . . . . . . . . . . . . . . . . . . . . . 224 51 Church St Great Barrington, MA 01230 Phone: (800)762-1132 Email: info@janeiredale.com Product Category: Cosmetics and Skin Care iriDex . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 513 1212 Terra Bella Avenue Mountain View, CA 94043 Phone: (800)388-4747 Fax: (650)962-0486 Product Category: Laser and Laser Supplies
henry schein . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 915 135 Duryea Road Melville, NY 11747 Phone: (800)P-Schein Fax: (800)329-9109 Email: medsls@henryschein.com Product Category: Clothing, Computer Software and Hardware, Cosmetics and Skin Care, Disposable Medical Supplies, EMR/ EHR Systems, Laboratory Services, Medical Lighting Equipment, Office Equipment and Supplies, Pharmaceutical, Practice Management Surgical Instruments hill Dermaceuticals, inc . . . . . . . . . . . . . . . . . . . . . . . . . . 827 2650 S. Mellonville Ave Sanford, FL 32773 Phone: (800)344-5707 Fax: (407)649-9213 Email: maria@hillderm.com Product Category: Pharmaceutical
Jan marini skin research, inc . . . . . . . . . . . . . . . . . . . . . 802 6951 Via Del Oro San Jose, CA 95119 Phone: (800)347-2223 Fax: (408)362-0140 Email: info@janmarini.com Product Category: Cosmetics and Skin Care Johnson and Johnson consumer products company . . . . . . 505 199 Grandview Rd Skillman, NJ 08558 Phone: (800)325-9821 Product Category: Cosmetics and Skin Care Journal of clinical and Aesthetic Dermatology . . . . . . . . . . 325 1595 Paoli Pike #103 Westchester, PA 19380 Phone: (866)325-9907 Fax: (484)266-0726 Product Category: Publishing and Educational Materials Journal of Drugs in Dermatology/etAs . . . . . . . . . . . . . . . . 421 377 Park Ave South, 6th Floor New York, NY 10016 Phone: (646)736-4333 Fax: (212)213-5435 Email: mary.altamirano@sanovaworks.com Product Category: Publishing and Educational Materials
technical exhibits
histopath lab pA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 333 2671 W Norvell Bryant Hwy Lecanto, FL 34461 Phone: (352)527-1344 Product Category: Laboratory Services hrA research . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 307 400 Lanidex Plaza Parsippany, NJ 07054 Phone: (973)240-1204 Fax: (973)463-1888 Email: kdibiase@hraresearch.com Product Category: Market Research
inga ellzey practice group, inc . . . . . . . . . . . . . . . . . . . . . 426 1211 State Road 436, Suite 297 Casselberry, FL 32707 Phone: (407)571-5536 Fax: (407)678-5751 Email: mdelarosa@iegp.com Product Category: Practice Management innocutis - A JsJ pharmaceuticals co . . . . . . . . . . . . . . . . 212 171 Church St. Suite 140 Charleston, SC 29401 Phone: (800)499-4468 Fax: (843)965-8333 Email: inquiry@jsjpharm.com Product Category: Pharmaceutical, Associations, Foundations, and Medical Societies, Surgical Instruments intendis, inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 801 PO Box 1941 Morristown, NJ 07962-1941 Phone: (866)463-3634 Fax: (973)966-3378 Product Category: Pharmaceutical
90 |
Kaiser permanente . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 308 1800 Harrison St, 7th Floor Oakland, CA 94612 Phone: (800)777-4912 Fax: (510)625-5487 Email: mdrecruitment.tpmg@kp.org Product Category: Practice Management
la roche-posay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 605 575 Fifth Avenue New York, NY 10017 Phone: (888)577-5226 Email: customerservice@laroche-posay.com Product Category: Cosmetics and Skin Care leo pharma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 236 Industriparken 55 Ballerup, 2750 Phone: (45)44945888 Product Category: Pharmaceutical
EA
UTY
CHO
IC
PRODUCT
NE WBEAUT Y
WINNER
AW
ARD
1 2 3 5
CLEANSE
R E J U V E N AT E
R E S U R FA C E
H Y D R AT E
PROTECT
The 5-step system utilizes layered technology to measurably improve the appearance of common skin conditions such as fine lines and wrinkles, acne, rosacea and skin discoloration.
JANMARINI.COM
2011 Jan Marini Skin Research, Inc - NBSS211
technical exhibits
lippincott, Williams and Wilkins . . . . . . . . . . . . . . . . . . . 303 172 W. 109th St. Apt 5E New York, NY 10025 Phone: (914)400-9964 Product Category: Publishing and Educational Materials lucid, inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 220 2320 Brighton Henrietta TL Rd Rochester, NY 14623 Phone: (585)239-9800 Fax: (585)239-9800 Email: colleen@lucid-tech.com Product Category: Laboratory Services, Other Medical Equipment and Supplies, Photographic Equipment and Imaging Services mD moms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 424 9051 Goldenwest St, #106-136 Huntington Beach, CA 92648 Phone: (888)636-6672 Fax: (619)374-7121 Email: customerservice@mdmoms.com Product Category: Cosmetics and Skin Care medelita scrubs and lab coats . . . . . . . . . . . . . . . . . . . . 413 1046 Calle Recodo, Suite D San Clemente, CA 92673 Phone: (877)987-7979 Fax: (949)542-4101 Email: contact.us@medelita.com Product Category: Clothing, Other Medical Equipment and Supplies medesthetics magazine . . . . . . . . . . . . . . . . . . . . . . . . . . 324 7628 Densmore Ave Van Nuys, CA 91406 Phone: (800)442-5667 Product Category: Publishing and Educational Materials medicis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 520 7720 N Dobson Rd Scottsdale, AZ 85256 Phone: (602)808-8800 Fax: (602)808-0822 Email: customer_service@medicis.com Product Category: Pharmaceutical medimetriks pharmaceuticals . . . . . . . . . . . . . . . . . . . . . 322 363 Route 46 West Fairfield, NJ 07004 Phone: (973)882-7512 Fax: (973)882-7502 Email: info@medimetriks.com Product Category: Pharmaceutical, Cosmetics and Skin Care mednet technologies, inc . . . . . . . . . . . . . . . . . . . . . . . . . 321 1975 Linden Blvd, Ste 407 Elmont, NY 11003 Phone: (516)285-2200 Fax: (516)285-1685 Email: info@mednet-tech.com Product Category: Computer Software and Hardware, Practice Management, Publishing and Educational Materials melA sciences . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 409 50 S Buckhout St, Suite 1 Irvington, NY 10533 Phone: (914)591-3783 Fax: (914)591-3701 Email: jglauda@melasciences.com Product Category: Other Medical Equipment and Supplies, Photographic Equipment and Imaging Services merz pharmaceuticals . . . . . . . . . . . . . . . . . . . . . . . . . . . 619 4215 Tudor Lane Greensboro, NC 27410 Phone: (888)merzusa Fax: (336)856-0107 Email: info@merzusa.com Product Category: Pharmaceutical, Cosmetics and Skin Care micro4, inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 314 7118 I-40 West, Bldg. D Amarillo, TX 79106 Phone: (800)235-1856 Fax: (806)463-7021 Email: sales@micro4.com Product Category: Computer Software and Hardware, EMR/EHR Systems, Practice Management microsurgery instruments, inc . . . . . . . . . . . . . . . . . . . . . . 422 PO Box 1378 Bellaire, TX 77402-1378 Phone: (713)664-4707 Fax: (713)664-8873 Email: microusa@microsurgeryusa.com Product Category: Medical Lighting Equipment, Other Medical Equipment and Supplies, Surgical Instruments mJD patient communications . . . . . . . . . . . . . . . . . . . . . . 419 4915 St Elmo Ave, Suite 306 Bethesda, MD 20814 Phone: (301)657-8010 Fax: (301)657-8023 Email: kristy@mjdpc.com Product Category: Computer Software and Hardware, Office Equipment and Supplies, Practice Management molesafe usA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 330 328 W St Georges Ave Linden, NJ 07036 Phone: (908)925-7519 Fax: (908)925-2841 Email: andreak@carestationmedical.com Product Category: Photographic Equipment and Imaging Services molluscum rx . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 420 5349 Lake Jessamine Dr Orlando, FL 32839 Phone: (407)538-5654 Fax: (407)557-3493 Email: sales@virabiotics.com Product Category: Pharmaceutical mti . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 206 3655 West Ninigret Dr Salt Lake City, UT 84104 Phone: (800)924-4655 Fax: (801)952-0548 Email: pat.mccluskey@mti.net Product Category: Medical Lighting Equipment, Office Equipment and Supplies, Other Medical Equipment and Supplies
technical exhibits
92
On average, over 20 million people will board airplanes each month around the world.1 Some will walk barefooted through airport security which may expose them to tinea pedis.
Many eligible patients will receive the Naftin 90gm size at No Out-of-Pocket Cost!**
UP TO $100 OFF * INSTANTLY FOR ANY NAFTIN (naftifine HCl 1%)
90g Pump 90g Cream 90g Gel Rx product
* Subject to eligibility. Restrictions apply. ** Average co-pay shown verified as of August 2010 based on reports from 380 health plans (eg. HMO, PPO, IPA, etc.) inclusive of all benefit designs/co-pay tiers.
RITA. Research and Innovative Technology Administration, Bureau of Transportation Statistics.http://www.transtats.bts.gov/Oneway.asp? Display_Flag=0&Percent_Flag=0. Accessed Aug 24, 2010.
GEL CREAM
Rx ONLY
DESCRIPTION: Naftin Cream, 1% and Naftin Gel, 1% contain the PRECAUTIONS:
synthetic, broad-spectrum, antifungal agent naftifine hydrochloride. Naftin Cream and Gel, 1% are for topical use only.
CHEMICAL NAME:
(E)-N-Cinnamyl-N-methyl-1-naphthalenemethylamine hydrochloride. Naftifine hydrochloride has an empirical formula of C21H21NHCl and a molecular weight of 323.86. Structural Formula:
CH 3 CH 2 NCH 2 H C= C H HCI
General: Naftin Cream and Gel, 1%, are for external use only. If irritation or sensitivity develops with the use of Naftin Cream or Gel, 1%, treatment should be discontinued and appropriate therapy instituted. Diagnosis of the disease should be confirmed either by direct microscopic examination of a mounting of infected tissue in a solution of potassium hydroxide or by culture on an appropriate medium. Information for patients: The patient should be told to: 1. Avoid the use of occlusive dressings or wrappings unless otherwise directed by the physician. 2. Keep Naftin Cream and Gel, 1% away from the eyes, nose, mouth and other mucous membranes. Carcinogenesis, mutagenesis, impairment of fertility: Long-term studies to evaluate the carcinogenic potential of Naftin Cream and Gel, 1% have not been performed. In vitro and animal studies have not demonstrated any mutagenic effect or effect on fertility. Pregnancy: Teratogenic Effects: Pregnancy Category B: Reproduction studies have been performed in rats and rabbits (via oral administration) at doses 150 times or more than the topical human dose and have revealed no evidence of impaired fertility or harm to the fetus due to naftifine. There are, however, no adequate and wellcontrolled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Nursing mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Naftin Cream or Gel,1% are administered to a nursing woman. Pediatric use: Safety and effectiveness in pediatric patients have not been established.
ADVERSE REACTIONS: During clinical trials with Naftin Cream, 1%,
Contains: naftifine hydrochloride Active Ingredient: Naftifine hydrochloride 1%. Inactive Ingredients: Naftin Cream, 1% contains benzyl alcohol, cetyl alcohol, cetyl esters wax, isopropyl myristate, polysorbate 60, purified water, sodium hydroxide, sorbitan monostearate, and stearyl alcohol. Hydrochloric acid may be added to adjust pH. Naftin Gel, 1% contains polysorbate 80, carbomer 934P, diisopropanolamine, edetate disodium, alcohol (52%v/v), and purified water.
CLINICAL PHARMACOLOGY: Naftifine Hydrochloride is a synthetic allylamine derivative. The following in vitro data are available but their clinical significance is unknown. Naftifine hydrochloride has been shown to exhibit fungicidal activity in vitro against a broad spectrum of organisms, including Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans, Epidermophyton floccosum, Microsporum canis, Microsporum audouini, and microsporum gypseum, and fungistatic activity against Candida species, including Candida albicans. Naftin Cream and Gel, 1% have only been shown to be clinically effective against the disease entities listed in the INDICATIONS AND USAGE section.
Although the exact mechanism of action against fungi is not known, naftifine hydrochloride appears to interfere with sterol biosynthesis by inhibiting the enzyme squalene 2, 3-epoxidase. This inhibition of enzyme activity results in decreased amounts of sterols, especially ergosterol, and a corresponding accumulation of squalene in the cells. Pharmacokinetics: In vitro and in vivo bioavailability studies have demonstrated that naftifine penetrates the stratum corneum in sufficient concentration to inhibit the growth of dermatophytes. Following a single topical application of 1% of naftifine cream to the skin of healthy subjects, systemic absorption of naftifine was approximately 6% of the applied dose. Following single topical applications of 3H- labeled naftifine gel 1% to the skin of healthy subjects, up to 4.2% of the applied dose was absorbed. Naftifine and/ or its metabolites are excreted via the urine and feces with a half-life of approximately two to three days.
INDICATIONS AND USAGE: Cream, 1% is indicated for the topical treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum. Naftin Gel, 1% is indicated for the topical treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans*, Epidermophyton floccosum*.
the incidence of adverse reactions was as follows: burning/stinging (6%), dryness (3%), erythema (2%), itching (2%), local irritation (2%). During clinical trials with Naftin Gel, 1%, the incidence of adverse reactions was as follows: burning /stinging (5.0%), itching (1.0%), erythema (0.5%), rash (0.5%), skin tenderness (0.5%).
DOSAGE AND ADMINISTRATION: A sufficient quantity of Naftin
Cream, 1% should be gently massaged into the affected and surrounding skin areas once a day. A sufficient quantity of Naftin Gel, 1% should be gently massaged into the affected and surrounding skin areas twice a day, in the morning and evening. The hands should be washed after application. If no clinical improvement is seen after four weeks of treatment with Naftin Cream or Gel, 1%, the patient should be re-evaluated.
HOW SUPPLIED:
Naftin
Naftin (naftifine hydrochloride) Cream, 1% is supplied in collapsible tubes in the following sizes: 30g NDC 0259-4126-30 60g NDC 0259-4126-60 90g NDC 0259-4126-90 30g NDC 0259-4126-03 (pump) 90g NDC 0259-4126-09 (pump) Naftin (naftifine hydrochloride) Gel, 1% is supplied in collapsible tubes in the following sizes: 40g NDC 0259-4770-40 60g NDC 0259-4770-60 90g NDC 0259-4770-90 Note: Store Naftin Cream, 1% below 30C (86F). Store Naftin Gel, 1% at room temperature.
*Efficacy for this organism in this organ system was studied in fewer than 10 infections.
CONTRAINDICATIONS: Naftin Cream and Gel, 1% are contraindicated
Manufactured for Merz Pharmaceuticals, Greensboro, NC 27410 2009 Merz Pharmaceuticals Rev 2/09
technical exhibits
muhlbauer Dermatopahology lab . . . . . . . . . . . . . . . . . . . 416 61 B Monroe Ave Pittsford, NY 14534 Phone: (585)586-5166 Fax: (585)586-1370 Email: seloverl@muhlbauerlab.com Product Category: Laboratory Services obagi medical products . . . . . . . . . . . . . . . . . . . . . . . . . . 523 3760 Kilroy Airport Way Long Beach, CA 90806 Phone: (562)628-1007 Fax: (562)628-1008 Email: lisae@obagi.com Product Category: Cosmetics and Skin Care, Pharmaceutical onset therapeutics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 234 400 Highland Corporate Drive Cumberland, RI 02864 Phone: (310)503-4621 Email: mcurtin@onsettx.com Product Category: Pharmaceutical organization of teratology information specialists . . . . . . 411 9500 Gilman Dr, MC0828 La Jolla, CA 92093 Phone: (877)311-8972 Fax: (619)294-6191 Email: raandpregnancy@ucsd.edu Product Category: Associations, Foundations, and Medical Societies, Publishing and Educational Materials ortho Dermatologics . . . . . . . . . . . . . . . . . . . . . . . . . . . . 602 5760 West 96th Street Los Angeles, CA 90045 Phone: (310)410-5813 Fax: (310)410-5945 Product Category: Pharmaceutical pharmaceutical specialties, inc . (psi) . . . . . . . . . . . . . . . 823 1620 Industrial Dr. NW Rochester, MN 55901 Phone: (800)325-8232 Fax: (507)288-7603 Email: order@psico.com Product Category: Cosmetics and Skin Care,Pharmaceutical pharmaDerm . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 705 210 Park Avenue Florham Park, NJ 07932 Phone: (866)337-6001 Email: tracey.miller@nycomed.us.com Product Category: Pharmaceutical photocure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 331 100 Overlook Center, 2nd Flr Princeton, NJ 08540 Phone: (609) 375-2263 Email: mike.zucala@photocure.com Product Category: Cosmetics and Skin Care photomedex . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 524 147 Keystone Drive Montgomeryville, PA 18936 Phone: (800)366-4758 Fax: (215)619-3208 Email: cust@photomedex.com Product Category: Cosmetics and Skin Care, Laser and Laser Supplies, Phototherapy Supplies and Equipment
national biological corporation . . . . . . . . . . . . . . . . . . . . 613 23700 Mercantile Road Beachwood, OH 44122 Phone: (800)338-5045 x1 Fax: (216)765-0271 Email: info@PhototherapyExperts.com Product Category: Laser and Laser Supplies, Photographic Equipment and Imaging Services, Phototherapy Supplies and Equipment neocutis, inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 410 512 E. Eleven Mile Rd. #100 Royal Oak, MI 48067 Phone: (866)636-2884 Fax: (313)664-0668 Email: contactus@neocutis.com Product Category: Cosmetics and Skin Care, Pharmaceutical neogenomics laboratories . . . . . . . . . . . . . . . . . . . . . . . . 231 12701 Commonwealth Dr Ft Myers, FL 33913 Phone: (866)776-5907 Product Category: Laboratory Services neostrata company . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 807 307 College Road East Princeton, NJ 08540 Phone: (800)628-9904 Fax: (800)636-7872 Email: custsvc@neostrata.com Product Category: Cosmetics and Skin Care neutrogena . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 502 5760 W 96th St Los Angeles, CA 90045 Phone: (310)642-1150 Fax: (310)410-1631 Email: scropper@its.jnj.com Product Category: Cosmetics and Skin Care nextech . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 820 5550 W. Executive Dr, Ste 350 Tampa, FL 33609 Phone: (813)425-9200 Fax: (813)425-9292 Email: websales@nextech.com Product Category: Computer Software and Hardware, EMR/EHR Systems, Practice Management niadyne niA24/strivectin . . . . . . . . . . . . . . . . . . . . . . . . 1013 4208 Six Forks Road 9th Floor Raleigh, NC 27609 Phone: (919)838-7800 Fax: (919)838-7812 Email: brandolph@strivectin.com Product Category: Cosmetics and Skin Care
technical exhibits
www.aad.org
95
technical exhibits
practical Dermatology . . . . . . . . . . . . . . . . . . . . . . . . . . . 311 c/o Bryn Mawr Communications, LLC Wayne, PA 19087 Phone: (484)581-1800 Product Category: Computer Software and Hardware, Practice Management, Publishing and Educational Materials procter and gamble . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 515 1 PandG Plaza Cincinnati, OH 45202 Phone: (513) 983-1100 Email: miller.c.3@pg.com Product Category: Cosmetics and Skin Care promius pharma, llc . . . . . . . . . . . . . . . . . . . . . . . . . . . . 323 200 Somerset Corporate Blvd Bridgewater, NJ 08807 Phone: (908)429-4500 Product Category: Pharmaceutical propath . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 427 1355 River Bend Drive Dallas, TX 75247 Phone: (800)258-1253 Fax: (214)237-1844 Email: marketing@propath.com Product Category: Laboratory Services saunders/mosby-elsevier . . . . . . . . . . . . . . . . . . . . . . . . . 830 1600 JFK Blvd. #1800 Philadelphia, PA 19103 Phone: (800)325-4177 Product Category: Publishing and Educational Materials skin and Aging . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 210 83 General Warren Blvd, Ste 100 Malvern, PA 19355 Phone: (800)237-7285 Fax: (610)560-0501 Email: rehrlich@hmpcommunications.com Product Category: Publishing and Educational Materials skin and cancer Associates/Advanced Dermatology mgmt . . . 318 1111 Park Centre Blvd, Suite 300 Miami Gardens, FL 33169 Phone: (305)623-5595 Fax: (305)623-1937 Email: d.tomlinson@admcorp.com Product Category: Practice Management skin cancer foundation, the . . . . . . . . . . . . . . . . . . . . . . 734 149 Madison, Suite 901 New York, NY 10016 Phone: (212)725-5176 Fax: (212)725-5751 Email: info@skincancer.org Product Category: Associations, Foundations, and Medical Societies, Publishing and Educational Materials skin Disease education foundation . . . . . . . . . . . . . . . . . 222 5635 Fishers Lane, Suite 6000 Rockville, MD 20852 Phone: (240)221-4405 Fax: (240)221-4400 Email: terrie@sdefderm.com Product Category: Publishing and Educational Materials skinceuticals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 730 3402 West Miller Road Garland, TX 75041 Phone: (800)811-1660 Fax: (972)926-2950 Email: service@skinceuticals.com Product Category: Cosmetics and Skin Care skinmedica, inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 335 5909 Sea Lion Place, Ste H Carlsbad, CA 92010 Phone: (866)867-0110 Fax: (760)448-3604 Product Category: Cosmetics and Skin Care smile reminder . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 312 3098 Executive Parkway Suite 300 Lehi, UT 84043 Phone: (866)605-6867 Fax: (801)772-2034 Email: support@smilereminder.com Product Category: Computer Software and Hardware, Market Research, Practice Management, Office Equipment and Supplies stiefel, a gsK company . . . . . . . . . . . . . . . . . . . . . . 607, 608 c/o GSK 20 T.W. Alexander Dr. Research Triangle Park, NC 27709 Phone: (919)990-6000 Product Category: Cosmetics and Skin Care, Pharmaceutical
technical exhibits
ra medical systems, inc . . . . . . . . . . . . . . . . . . . . . . . . . . 216 2270-L Camino Vida Roble Carlsbad, CA 92011 Phone: (760)804-1648 Fax: (760)804-1657 Email: mburstein@ramed.com Product Category: Laser and Laser Supplies, Phototherapy Supplies and Equipment revision skincare . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 317 9019 Premier Row Dallas, TX 75247 Phone: (800)385-6652 Fax: (214)630-1806 Email: info@revisionskincare.com Product Category: Cosmetics and Skin Care revitalash 6295 McLead Las Vegas, NV 89120 salvona technologies . . . . . . . . . . . . . . . . . . . . . . . . . . . 332 65 Stults Rd Dayton, NJ 08810 Phone: (609)655-0173 Fax: (609)655-9291 Email: sam@salvona.com Product Category: Cosmetics and Skin Care, Pharmaceutical sandstone medical technologies . . . . . . . . . . . . . . . . . . . 313 105 Citation Court Homewood, AL 35209 Phone: (205)290-8251 Fax: (205)290-4269 Email: sandstonemike@bellsouth.net Product Category: Laser and Laser Supplies
96 |
technical exhibits
summers laboratories . . . . . . . . . . . . . . . . . . . . . . . . . . . 320 103 G.P. Clement Drive Collegeville, PA 19426 Phone: (610)454-1471 Fax: (610)454-1475 Email: info@sumlab.com Product Category: Cosmetics and Skin Care syneron and candela . . . . . . . . . . . . . . . . . . . . . . . . . . . . 514 3 Goodyear, Unit A Irvine, CA 92618 Phone: (949)716-6670 Fax: (949)716-6555 Email: info@syneron.com Product Category: Laser and Laser Supplies taro pharmaceuticals . . . . . . . . . . . . . . . . . . . . . . . . . . . 226 3 Skyline Drive Hawthorne, NY 10532 Phone: (914)345-9001 Fax: (914)345-0391 Product Category: Pharmaceutical theraplex company,the . . . . . . . . . . . . . . . . . . . . . . . . . . 235 6410 Poplar Ave Suite 110 Memphis, TN 38119 Phone: (888)437-2753 Fax: (888)437-1050 Email: customerservice@theraplex.com Product Category: Cosmetics and Skin Care tiber laboratories . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 418 5400 Laurel Springs Parkway Suwanee, GA 30024 Phone: (678)208-0388 ext 241 Fax: (608)208-0988 Email: sdrody@tiberlabs.com Product Category: Pharmaceutical tiemann-bernsco . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 406 25 Plant Ave Hauppauge, NY 11788 Phone: (800)843-6266 Fax: (800)577-6050 Email: sales@georgetiemann.com Product Category: Disposable Medical Supplies, Laser and Laser Supplies, Medical Lighting Equipment, Office Equipment and Supplies, Other Medical Equipment and Supplies, Surgical Instruments triax pharmaceuticals . . . . . . . . . . . . . . . . . . . . . . . . . . . 824 11 Commerce Dr Cranford, NJ 07016 Email: info@triaxpharma.com Product Category: Pharmaceutical upsher-smith laboratories, inc . . . . . . . . . . . . . . . . . . . . . 829 6701 Evenstad Dr Maple Grove, MN 55369 Phone: (763)315-2000 Fax: (763)315-2244 Email: uslinfo@upsher-smith.com Product Category: Pharmaceutical uVbioteK, llc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 227 3 Depot Street Hudson Falls, NY 12839 Phone: (518)747-3310 x101 Fax: (518)747-2294 Email: gary@uvbiotek.com Product Category: Medical Lighting Equipment
Verisante technology, inc . . . . . . . . . . . . . . . . . . . . . . . . 431 306-2309 West 41st Ave. Vancouver, BC V6M2A3 Phone: (604)605-0507 Fax: (604)605-0508 Email: ctrinh@verisante.com Product Category: Other Medical Equipment and Supplies Viscot medical . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 334 32 West Street East Hanover, NJ 07936 Phone: (973)887-9273 Fax: (973)887-3961 Email: romola@viscot.com Product Category: Disposable Medical Supplies Visicom . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 328 4520 South 36th St Omaha, NE 68107 Phone: (800)228-3400 Fax: (402)734-6815 Email: customerservice@visicom.net Product Category: Office Equipment and Supplies, Practice Management
technical exhibits
Warner chilcott . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 305 100 Enterprise Drive Rockaway, NJ 07866 Phone: (800)521-8813 Email: WCRX.com Product Category: Pharmaceutical West coast Dermatology billers, llc . . . . . . . . . . . . . . . . 428 319 East Stuart Ave. Redlands, CA 92374 Phone: (909)798-0601 Fax: (909)335-8644 Email: rkanavas@lepg.com Product Category: Practice Management
yodle . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 327 50 W 23rd Street, Ste 401 New York, NY 10010 Phone: (877)276-5104 Fax: (646)753-6312 Email: info@yodle.com Product Category: Practice Management young pharmaceuticals, inc . . . . . . . . . . . . . . . . . . . . . . . 609 1840 Berlin Turnpike Wethersfield, CT 06109 Phone: (860)529-7919 Fax: (860)529-6801 Product Category: Cosmetics and Skin Care, Computer Software and Hardware, Pharmaceutical www.aad.org
| 97
technical exhibits
proDuct cAtegory Directory of exhibiting compAnies
Companies confirmed as of January 7, 2011. Pharmaceutical Specialties, Inc. (PSI).......................................823 Photocure.................................................................................331 PhotoMedex.............................................................................524 Procter and Gamble .................................................................515 Revision Skincare .....................................................................317 Salvona Technologies ...............................................................332 SkinCeuticals ...........................................................................730 Skin Medica .............................................................................335 Summers Laboratories ..............................................................320 Theraplex Company,The ..........................................................235 Young Pharmaceuticals, Inc. ....................................................609
American Academy of Dermatology.........................................906 American Acne and Rosacea Society ........................................433 Dermatology Foundation .........................................................818 Innocutis - A JSJ Pharmaceuticals Co. .....................................212 Organization of Teratology Information Specialists .................411 Skin Cancer Foundation, The ..................................................734
clothing
3Gen, LLC/DermLite ..............................................................405 Canfield Imaging Systems ........................................................805 Compulink Business Systems, Inc ............................................425 EZ Derm, LLC ........................................................................233 Henry Schein ...........................................................................915 Mednet Technologies, Inc........................................................321 Micro4, Inc. .............................................................................314 NexTech ..................................................................................820 Smile Reminder .......................................................................312 Young Pharmaceuticals, Inc. ....................................................609
3M Drug Delivery Systems ......................................................302 Acuderm, Inc. ..........................................................................509 Bovie Medical ..........................................................................329 Cobalt Medical Supply ............................................................415 Delasco ....................................................................................808 Henry Schein ...........................................................................915 Tiemann-Bernsco .....................................................................406 Viscot Medical, LLC ................................................................334
emr/ehr systems
Compulink Business Systems, Inc ............................................425 EZ Derm, LLC ........................................................................233 Henry Schein ...........................................................................915 MELA Sciences ...................................................................... 409 Micro4, Inc. .............................................................................314 NexTech ..................................................................................820
lAborAtory serVices
Axia Medical Solutions ............................................................316 Beiersdorf Inc. .........................................................................306 Bio - Oil ..................................................................................232 Biopelle, Inc. ............................................................................309 Coria Laboratories....................................................................623 Dalos BioPharma .....................................................................414 Delasco ....................................................................................808 DERMAdoctor, Inc. ................................................................834 EltaMD Skincare .....................................................................817 Fallene Ltd ...............................................................................203 Foamix Ltd. .............................................................................230 Henry Schein ...........................................................................915 Iredale Mineral Cosmetics ........................................................224 Jan Marini Skin Research, Inc. ...............................................802 Johnson and Johnson Consumer Products Company .............505 La Roche-Posay ........................................................................605 LEO Pharma .......................................................................... 236 MD Moms...............................................................................424 Medimetriks Pharmaceuticals, Inc............................................322 Merz Pharmaceuticals ..............................................................619 MolluscumRx ........................................................................ 420 Neocutis, Inc............................................................................410 NeoStrata Company ................................................................807 Neutrogena ..............................................................................502 Niadyne NIA24/Strivectin .....................................................1013 Obagi Medical .........................................................................523
98 |
Caris Life Sciences....................................................................429 Dermpath Diagnostics .............................................................510 Henry Schein ...........................................................................915 Histopath Lab PA ....................................................................333 Muhlbauer Dermatopahology Lab ...........................................416 NeoGenomics Laboratories ......................................................231 ProPath ....................................................................................427
Aerolase .....................................................................................223 Alma Lasers ...............................................................................833 DEKA Medical , Inc .................................................................407 Delasco .....................................................................................808 IRIDEX ...................................................................................513 National Biological Corporation ..............................................613 PhotoMedex.............................................................................524 Ra Medical Systems, Inc. .........................................................216 Sandstone Medical Technologies .............................................313 Syneron and Candela ...............................................................514 Tiemann-Bernsco .....................................................................406
mArKet reseArch
technical exhibits
meDicAl lighting equipment
Canfield Imaging Systems ........................................................805 Cobalt Medical Supply ............................................................415 Delasco ....................................................................................808 Henry Schein ...........................................................................915 Microsurgery Instruments, Inc. ................................................422 MTI .........................................................................................206 Tiemann-Bernsco .....................................................................406 UVBIOTEK, LLC ...................................................................227 Henry Schein ...........................................................................915 Hill Dermaceuticals, Inc. .........................................................827 Innocutis - A JSJ Pharmaceuticals Co. .....................................212 Intendis, Inc. ............................................................................801 Medicis ....................................................................................520 Medimetriks Pharmaceuticals, Inc............................................322 Merz Pharmaceuticals ..............................................................619 Neocutis, Inc............................................................................410 Obagi Medical .........................................................................523 Onset Therapeutics ..................................................................234 Ortho Dermatologics ...............................................................602 Pharmaceutical Specialties, Inc. (PSI).......................................823 PharmaDerm ...........................................................................705 Promius Pharma, LLC ............................................................323 Salvona Technologies ...............................................................332 Stiefel, a GSK Company ..................................................607, 608 Taro Pharmaceuticals ...............................................................226 Tiber Laboratories ....................................................................418 Triax Pharmaceuticals, LLC .....................................................824 Upsher-Smith Laboratories, Inc. ..............................................829 Warner Chilcott .......................................................................305 Young Pharmaceuticals, Inc. ....................................................609
3Gen, LLC/DermLite ..............................................................405 Brymill Cryogenic Systems.......................................................826 Cobalt Medical Supply ............................................................415 Conmed ...................................................................................821 Henry Schein ...........................................................................915 Medelita Scrubs and LabCoats ................................................143 MTI .........................................................................................206 Smile Reminder .......................................................................312 Tiemann-Bernsco .....................................................................406 VisiCom...................................................................................328
3Gen, LLC/DermLite ..............................................................405 Acuderm, Inc. ..........................................................................509 Bovie Medical ..........................................................................329 Brymill Cryogenic Systems.......................................................826 Cobalt Medical Supply ............................................................415 Delasco ....................................................................................808 Ellman International ................................................................806 Henry Schein ...........................................................................915 Lucid, Inc. ..............................................................................220 Medelita Scrubs and Lab Coats ................................................413 Microsurgery Instruments, Inc. ................................................422 MTI .........................................................................................206 PhotoMedex ...........................................................................524 Tiemann-Bernsco .....................................................................406 Verisante Technology, Inc. ......................................................431
3Gen, LLC/DermLite ..............................................................405 Canfield Imaging Systems ........................................................805 Lucid, Inc. ...............................................................................220 MELA Sciences ........................................................................409 MoleSafe USA..........................................................................330 National Biological Corporation ..............................................613
Daavlin ....................................................................................519 Delasco ....................................................................................808 National Biological Corporation ..............................................613 Ra Medical Systems, Inc. .........................................................216
phArmAceuticAl
prActice mAnAgement
Abbott......................................................................................706 Allergan ....................................................................................202 Amgen .....................................................................................606 Axia Medical Solutions ............................................................316 Centocor Ortho Biotech, Inc. ..................................................702 Cobalt Medical Supply ............................................................415 Coria Laboratories....................................................................623 Dalos BioPharma .....................................................................414 Delasco ....................................................................................808 Dusa Pharmaceuticals ..............................................................208 Ferndale Healthcare, Inc. .........................................................526 Foamix Ltd. .............................................................................230 Galderma Laboratories, LP.......................................................506 Genentech ................................................................................430 Graceway Pharmaceuticals .......................................................432
CareCredit ...............................................................................326 Compulink Business Systems Inc. ...........................................425 Henry Schein ...........................................................................915 Inga Ellzey Practice Group, Inc. .............................................426 Kaiser Permanente ...................................................................308 Medelita Scrubs and Lab Coats ...............................................143 Mednet Technologies, Inc........................................................321 Micro4, Inc. .............................................................................314 NexTech ..................................................................................820 Skin and Cancer Associates/Advanced Dermatology Mgmt .....318 Smile Reminder .......................................................................312 VisiCom...................................................................................328 Yodle ........................................................................................327 West Coast Dermatology Billers, LLC. ...................................428 www.aad.org
| 99
technical exhibits
publishing AnD eDucAtionAl mAteriAls surgicAl instruments
Bovie Medical ..........................................................................329 Brymill Cryogenic Systems.......................................................826 Cobalt Medical Supply ............................................................415 Conmed ..................................................................................821 Delasco ....................................................................................808 Ellman International ................................................................806 Henry Schein ...........................................................................915 Innocutis - A JSJ Pharmaceuticals Co. .....................................212 Microsurgery Instruments, Inc. ................................................422 Tiemann-Bernsco .....................................................................406
ADVANCE for Healthy Aging ................................................323 Cosmetic Surgery Times/Dermatology Times ..........................221 Cutis and Cosmetic Dermatology ............................................310 Delasco ....................................................................................808 Journal of Clinical and Aesthetic Dermatology ........................325 Journal of Drugs in Dermatology/ETAS ..................................421 Lippincott, Williams and Wilkins ............................................303 Medesthetics Magazine ............................................................324 Mednet Technologies, Inc........................................................321 Organization of Teratology Information Specialists .................411 Practical Dermatology ..............................................................311 Saunders/Mosby-Elsevier .........................................................830 Skin and Aging ........................................................................210 Skin Cancer Foundation, The ..................................................734 Skin Disease Education Foundation.........................................222
100
Important Safety Information CLOBEX (clobetasol propionate) Spray, 0.05%, is a super-high potent topical corticosteroid formulation indicated for the treatment of moderate to severe plaque psoriasis affecting up to 20% body surface area (BSA) in patients 18 years of age or older. Clobetasol propionate has been shown to suppress the HPA axis at the lowest doses tested. Clobetasol propionate spray should not be used in the treatment of rosacea or perioral dermatitis and should not be used on the face, groin or axillae. In controlled clinical trials, the following adverse reactions have been reported: burning, pruritus, hyperpigmentation, infections and infestations, nasopharyngitis, upper respiratory tract infection, and skin and subcutaneous tissue disorders. Treatment should be limited to 4 weeks. Treatment beyond 2 weeks should be limited to localized lesions of moderate to severe plaque psoriasis that have not sufciently improved after the initial 2 weeks of treatment with CLOBEX Spray, 0.05%. CLOBEX Spray, 0.05%, should not exceed 50 g (59 mL or 2 oz) per week. CLOBEX Spray, 0.05%, is not recommended for use on anyone younger than 18 years of age. Pregnancy Category C. Please see adjacent page for brief summary of Prescribing Information.
Committee meetings
All events are held at the Hilton New York unless indicated otherwise. List current as of February 22, 2011.
Thursday, August 4
Corporate Relations Task Force Meeting Midtown Suite . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .7:30 a .m . Development Committee Meeting Morgan Suite . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3:00 p .m .
Friday, August 5
Corporate Partners Circle Meeting Petit Trianon . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .7:00 a .m . Cevnal on Education Midtown Suite . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12:00 p .m . Major Gifts Work Group Lincoln Suite . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12:00 p .m . Council of Government Affairs, Health Policy & Practice New York Suite . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12:15 p .m . Academic Dermatology Leadership Program Session Morgan Suite . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1:00 p .m . Regulatory Policy Committee East Suite . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1:30 p .m .
SkinPAC Board of Advisors Meeting Madison Suite . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Private Sector Advocacy Task Force Midtown Suite . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Corporate Partners Recognition Reception Petit Trianon . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Leadership and Mentoring Reception New York Suite . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Saturday, August 6
Board of Directors Meeting Mercury Ballroom . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .7:00 a .m . Coding & Reimbursement Task Force Midtown Suite . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2:00 p .m . Health Care Finance Commitee Midtown Suite . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4:00 p .m . Workforce Task Force Madison Suite . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4:00 p .m . Scientific Assembly Committee Meeting Morgan Suite . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5:00 p .m .
ancillary meetings
All events are held at the Hilton New York unless indicated otherwise. List current as of February 22, 2011. WDS Board of Directors Meeting Concourse A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Friday, August 5 6:30 a .m . to 9:00 a .m . Breakfast 6:30 a .m . Meeting 7:00 a .m . to 9:00 a .m . WDS Center Concourse B . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Friday, August 5 9:00 a .m . to 5:00 p .m . Saturday, August 6 9:00 a .m . to 3:00 p .m .
www.aad.org
103
Subject Index
How to Use tHe sUBject inDex
The subject index has been updated to help the attendees better plan their educational activities. The index is divided into nine different primary topics with subtopics listed alphabetically under these primary topics.
Basic science
Subject Index
Basic Methodologies in skin Research U011 rom the Dermatology-Rheumatology F Clinic: Practical Tips and Advances in Management, 49 F U016 rom Bench to Bedside: Important Clinical Advances, 58 U025 mpact of Nanotechnology and I Dermatology, 71 U031 e Interface of Skin and Psyche, 76 Th cutaneous Physiology U016 rom Bench to Bedside: F Important Clinical Advances, 58 Pharmacology U016 rom Bench to Bedside: Important F Clinical Advances, 58 Photophysics and Photobiology, including Lasers U017 Photodynamic Therapy, 58 structure and Function of skin U010 Skin of Color, 49
cell Biology U016 rom Bench to Bedside: Important Clinical F Advances, 58 genetics U011 rom the Dermatology-Rheumatology F Clinic: Practical Tips and Advances in Management, 49 immunology U011 rom the Dermatology-Rheumatology F Clinic: Practical Tips and Advances in Management, 49 F U016 rom Bench to Bedside: Important Clinical Advances, 58 Molecular Biology/genetics U016 rom Bench to Bedside: Important Clinical F Advances, 58 Pathophysiology U016 rom Bench to Bedside: Important Clinical F Advances, 58 Photobiology U017 Photodynamic Therapy, 58 Physiology U016 rom Bench to Bedside: Important Clinical F Advances, 58
cLinicaL DeRMatoLogy
acne & Related Disorders F004 ace to Face: Management of Facial F Dermatoses, 40 S005 edication Monitoring and M Complications, 48 S012 hats Breaking Out: Acne and W Rosacea, 78 U025 mpact of Nanotechnology and I Dermatology, 71 U031 The Interface of Skin and Psyche, 76 W003 OC Self-Assessment: Acne, Psoriasis, M Eczema and Inflammatory Dermatosis, 51
104 |
aging/geriatrics U004 edical Management of Actinic M Keratoses, 38 U019 Cellulitis: A Common (Mis)Diagnosis?, 59 U020 Exploring Evidence Based Cosmeceuticals, 64 U031 e Interface of Skin and Psyche, 76 Th Bacterial U025 mpact of Nanotechnology and I Dermatology, 71 U033 nfectious Disease Update What I I Wouldnt Have Known Without Evidence- Based Medicine, 77 Bullous Dermatoses F019 Oral Disease, 69 S001 EADV/AAD Joint Symposium, 41 U019 Cellulitis: A Common (Mis)Diagnosis?, 59 W006 ractical Approaches to Patient P Problems, 70 clinical Dermatology C003 Derm Exam Prep Course: Refresher, 68 F006 hats Boiling Over: Atopic Dermatitis W and Other Eczematous Conditions, 43 F008 Cased Based Controversies: Medical, 44 F012 Case Based Challenges for PA/NPs, 60 F019 Oral Disease, 69 S001 EADV/AAD Joint Symposium, 41 U002 Asian American Skin, 38 U004 edical Management of Actinic M Keratoses, 38 U008 uality and Customer Service for a Better Q Practice, 48 U018 Dermoscopy for the Non-Dermoscopist, 59 U019 Cellulitis: A Common (Mis)Diagnosis?, 59 U022 atch Test Allergens 101: A Detectives P Toolkit, 65 I U025 mpact of Nanotechnology and Dermatology, 71 U030 ptimizing Management of Melanoma: O Recognizing and Responding to Common Dilemmas in Patient Care, 76 clinical Research U016 rom Bench to Bedside: Important Clinical F Advances, 58 U025 mpact of Nanotechnology and I Dermatology, 71 collagen Vascular Disorders F008 Cased Based Controversies: Medical, 44 W006 ractical Approaches to Patient P Problems, 70 cosmetics S008 Whats Hot in Womens Dermatology, 67 U020 Exploring Evidence Based Cosmeceuticals, 64 I U025 mpact of Nanotechnology and Dermatology, 71 Diseases of connective tissue F008 Cased Based Controversies: Medical, 44 eczemas F004 ace to Face: Management of Facial F Dermatoses, 40 F006 hats Boiling Over: Atopic Dermatitis W and Other Eczematous Conditions, 43
P U022 atch Test Allergens 101: A Detectives Toolkit, 65 U025 mpact of Nanotechnology and I Dermatology, 71 U031 The Interface of Skin and Psyche, 76 W003 OC Self-Assessment: Acne, Psoriasis, M Eczema and Inflammatory Dermatosis, 51 endocrine Diseases U019 Cellulitis: A Common (Mis)Diagnosis?, 59 Fungal S009 ermatology Grand Rounds: A Discussion D of Case-Based Dilemmas, 68 U019 Cellulitis: A Common (Mis)Diagnosis?, 59 I U033 nfectious Disease Update What I Wouldnt Have Known Without Evidence Based Medicine, 77 general Dermatology F008 Cased Based Controversies: Medical, 44 U003 Hidradenitis Suppurativa: An Update, 38 U008 uality and Customer Service for a Better Q Practice, 48 U013 hats New in Non-Melanoma Skin W Cancer, 53 U016 rom Bench to Bedside: Important Clinical F Advances, 58 U023 se of Light for Diagnosis and Treatment U in Dermatology, 65 U025 mpact of Nanotechnology and I Dermatology, 71 U030 ptimizing Management of Melanoma: O Recognizing and Responding to Common Dilemmas in Patient Care, 76 genodermatoses U025 mpact of Nanotechnology and I Dermatology, 71 S U032 pitzs Genodermatoses, 76 Hair Disorders F015 lopecia and Hair Loss, 66 A Human Papilloma Virus U019 Cellulitis: A Common (Mis)Diagnosis?, 59 U033 nfectious Disease Update What I I Wouldnt Have Known Without Evidence Based Medicine, 77 infections F005 nfectious Disease and Infestation I Update, 43 S001 EADV/AAD Joint Symposium, 41 U025 mpact of Nanotechnology and I Dermatology, 71 U033 nfectious Disease Update What I I Wouldnt Have Known Without Evidence Based Medicine, 77 infestations/Bites F005 nfectious Disease and Infestation I Update, 43 F008 Cased Based Controversies: Medical, 44 U019 Cellulitis: A Common (Mis)Diagnosis?, 59 inflammatory Disorders F006 hats Boiling Over: Atopic Dermatitis W and Other Eczematous Conditions, 43 U003 Hidradenitis Suppurativa: An Update, 38
Subject Index
U011 rom the Dermatology-Rheumatology F Clinic: Practical Tips and Advances in Management, 49 U019 Cellulitis: A Common (Mis) Diagnosis?, 59 I U025 mpact of Nanotechnology and Dermatology, 71 W003 OC Self-Assessment: Acne, Psoriasis, M Eczema and Inflammatory Dermatosis, 51 internal Medicine F008 Cased Based Controversies: Medical, 44 F012 Case Based Challenges for PA/NPs, 60 F018 Hypercoagulability, Purpura and the Skin, 69 Literature Update/whats new U013 hats New in Non-Melanoma Skin W Cancer, 53 Malignancy/tumors F002 Photoprotection, 39 F012 Case Based Challenges for PA/NPs, 60 F013 Melanoma, 60 F020 Tumor Board, 70 S001 EADV/AAD Joint Symposium, 41 U004 Medical Management of Actinic Keratoses, 38 U013 hats New in Non-Melanoma Skin W Cancer, 53 U014 Mastering Moles in Pediatric Patients, 53 U016 rom Bench to Bedside: Important Clinical F Advances, 58 U018 Dermoscopy for the Non-Dermoscopist, 59 O U030 ptimizing Management of Melanoma: Recognizing and Responding to Common Dilemmas in Patient Care, 76 W004 Dermoscopy, 51 U013 hats New in Non-Melanoma Skin W Cancer, 53 U018 Dermoscopy for the Non-Dermoscopist, 59 U027 ractical Dermoscopy, 72 P nail Disorders S008 Whats Hot in Womens Dermatology, 67 occupational Dermatology U025 mpact of Nanotechnology and I Dermatology, 71 oral/Mucous Membrane Disorders F019 Oral Disease, 69 other U002 Asian American Skin, 38 U008 uality and Customer Service for a Better Q Practice, 48 Papulosquamous Disorders F019 ral Disease, 59 O Pediatric Dermatology F006 hats Boiling Over: Atopic Dermatitis W and Other Eczematous Conditions, 43 F008 Cased Based Controversies: Medical, 44 F012 Case Based Challenges for PA/NPs, 60 U007 Neonatal Dermatology, 46 U014 Mastering Moles in Pediatric Patients, 53 U025 mpact of Nanotechnology and I Dermatology, 71 Photosensitivity Diseases F002 Photoprotection, 39 U025 mpact of Nanotechnology and I Dermatology, 71 Pigmentary abnormalities/Vitiligo U014 astering Moles in Pediatric Patients, 53 M Pregnancy S008 Whats Hot in Womens Dermatology, 67 Pruritus F022 soriasis Guidelines Implementing them in P Your Practice, 73 U025 mpact of Nanotechnology and I Dermatology, 71 Psoriasis S008 Whats Hot in Womens Dermatology, 67 U011 rom the Dermatology-Rheumatology F Clinic: Practical Tips and Advances in Management, 49 U025 mpact of Nanotechnology and I Dermatology, 71 U031 The Interface of Skin and Psyche, 76 M W003 OC Self-Assessment: Acne, Psoriasis, Eczema and Inflammatory Dermatosis, 51 Psychocutaneous Disorders F008 ased Based Controversies: Medical, 44 C sexually transmitted S001 EADV/AAD Joint Symposium, 41 U033 nfectious Disease Update What I I Wouldnt Have Known Without Evidence Based Medicine, 77 sunscreens F002 Photoprotection, 39 U025 mpact of Nanotechnology and I Dermatology, 71 transplant Medicine F012 Case Based Challenges for PA/NPs, 60 U016 rom Bench to Bedside: Important Clinical F Advances, 58 Urticaria U031 The Interface of Skin and Psyche, 76 Viral U033 nfectious Disease Update What I I Wouldnt Have Known Without Evidence Based Medicine, 77
Dermatopathologic Findings in the Perforating Disorders, atrophies, and other Disorders of Dermal connective tissue (includes Degenerative Disorders) U024 hen Clinical and Histological W Findings Converge: Great Cases From a Dermatopathologists Perspective, 71 Dermatopathologic Findings in Various Benign and Malignant cutaneous neoplasms and neoplastic Diseases, including cutaneous Lymphomas F017 ase Based Controversies: C Dermatopathology, 66 U005 Pitfalls in Dermatopathology, 45 U013 hats New in Non-Melanoma Skin W Cancer, 53 U021 Controversies in Dysplastic Nevi, 64 U024 hen Clinical and Histological W Findings Converge: Great Cases From a Dermatopathologists Perspective, 71 Dermatopathologic Findings in Various connective tissue Diseases and other Rheumatologic Disease U024 hen Clinical and Histological W Findings Converge: Great Cases From a Dermatopathologists Perspective, 71 Dermatopathologic Findings in Various Metabolic and systemic Diseases, including the Mucinoses U024 hen Clinical and Histological W Findings Converge: Great Cases From a Dermatopathologists Perspective, 71 Dermatopathologic Findings in Various Papulosquamous Disorders U024 hen Clinical and Histological W Findings Converge: Great Cases From a Dermatopathologists Perspective, 71 Dermatopathologic Findings of Hair and nails, including alopecia F017 ase Based Controversies: C Dermatopathology, 66 Dermatopathology Differential Diagnosis: Dermatologic Diseases with nodular inflammation or infiltrates F017 ase Based Controversies: C Dermatopathology, 66 U010 Skin of Color, 49 Dermatopathology stains, including Histochemistry, immunohistochemistry, and immunofluorescence U024 hen Clinical and Histological W Findings Converge: Great Cases From a Dermatopathologists Perspective, 71 Disorders of Pigmentation U010 Skin of Color, 49 advanced F017 ase Based Controversies: C Dermatopathology, 66 U005 Pitfalls in Dermatopathology, 45 Basic F017 ase Based Controversies: C Dermatopathology, 66 U005 itfalls in Dermatopathology, 45 P clinical Pathologic correlations S006 Whats Hot in Dermatopathology, 57 U005 Pitfalls in Dermatopathology, 45 U024 hen Clinical and Histological W Findings Converge: Great Cases From a Dermatopathologists Perspective, 71 Dermatopathology F017 ase Based Controversies: C Dermatopathology, 66 S006 Whats Hot in Dermatopathology, 57 U005 Pitfalls in Dermatopathology, 45 immunopathology S006 Whats Hot in Dermatopathology, 57 W U024 hen Clinical and Histological Findings Converge: Great Cases From a Dermatopathologists Perspective, 71
DeRMatoPatHoLogy
Subject Index
ePiDeMioLogy
non-Patient communication F010 Legal Dilemmas in Dermatology, 50 S004 Leading High Performance Teams, 47 E S007 ffective Communications: Delivering Key Messages, 58 Y U001 our True Colors: Know Yourself and Understand Others, 38 U006 Bringing Out the Best in Others, 46 U012 atients Satisfaction: Measurement and P Improvement, 53 Patient communication F010 Legal Dilemmas in Dermatology, 50 F011 sing Technology to Improve U Dermatology Access, 59 S003 egotiating Your Way to Great N Leadership, 42 S007 ffective Communications: E Delivering Key Messages, 58 U001 our True Colors: Know Yourself and Y Understand Others, 38 U008 uality and Customer Service for a Better Q Practice, 48 U012 atients Satisfaction: Measurement and P Improvement, 53 U025 mpact of Nanotechnology and I Dermatology, 71
MeDicaL DeRMatoLogy
adult adnexal Diseases U003 idradenitis Suppurativa: An Update, 38 H adult Disorders of cornification and keratinization U019 Cellulitis: A Common (Mis)Diagnosis?, 59 U032 pitzs Genodermatoses, 76 S
www.aad.org
105
Subject Index
adult Patient care: assessment skills, Plan Formulation, and Patient Recommendations F012 Case Based Challenges for PA/NPs, 60 F016 Consultative Dermatology, 66 U018 Dermoscopy for the Non-Dermoscopist, 59 U030 ptimizing Management of Melanoma: O Recognizing and Responding to Common Dilemmas in Patient Care, 76 adult Patient care: History taking and Physical Diagnosis U019 Cellulitis: A Common (Mis)Diagnosis?, 59 U025 mpact of Nanotechnology and I Dermatology, 71 adult Patient care: in-office and ancillary Diagnostics U018 Dermoscopy for the Non-Dermoscopist, 59 U025 mpact of Nanotechnology and I Dermatology, 71 adult Patient care: Patient safety issues U025 mpact of Nanotechnology and I Dermatology, 71 adult Patient care: Population Health and Preventive care U025 mpact of Nanotechnology and I Dermatology, 71 atrophies, Perforating Disorders, and Disorders of Dermal connective tissue W004 Dermoscopy, 51 Benign and Malignant cutaneous neoplasms, including cutaneous Lymphomas U016 rom Bench to Bedside: Important Clinical F Advances, 58 U018 Dermoscopy for the Non-Dermoscopist, 59 Disorders of Hair and nails S008 Whats Hot in Womens Dermatology, 67 eczematous Dermatoses U025 mpact of Nanotechnology and I Dermatology, 71 infections, infestations and Bites F016 Consultative Dermatology, 66 U025 mpact of Nanotechnology and I Dermatology, 71 U033 nfectious Disease Update: What I I Wouldnt Have Known Without Evidence Based Medicine, 77 Medical therapy F003 ase Based Challenges in Consultative C Dermatology, 40 U004 Medical Management of Actinic Keratoses, 38 U008 uality and Customer Service for a Better Q Practice, 48 U016 rom Bench to Bedside: Important Clinical F Advances, 58 U025 mpact of Nanotechnology and I Dermatology, 71 Metabolic and systemic Diseases F018 Hypercoagulability, Purpura and the Skin, 69 Pruritus U025 mpact of Nanotechnology and I Dermatology, 71 Ultraviolet Light therapy and other Physical treatment Modalities U016 rom Bench to Bedside: Important Clinical F Advances, 58 Vasculitis, Vasculopathy and Purpura F018 Hypercoagulability, Purpura and the Skin, 69 Miscellaneous U008 uality and Customer Service for a Better Q Practice, 48 Benign neoplasms, Pediatric cutaneous Malignancy, and tumor syndromes of childhood U014 Mastering Moles in Pediatric Patients, 53 W005 OC Self-Assessment Pediatric M Dermatology, 62 cutaneous Disorders of the newborn S011 Whats Hot in Pediatric Dermatology, 78 U007 Neonatal Dermatology, 46 ectodermal Dysplasia U032 pitzs Genodermatoses, 76 S eczematous eruptions S011 Whats Hot in Pediatric Dermatology, 78 Hereditary Disorders of cornification and keratinization U007 Neonatal Dermatology, 46 U032 pitzs Genodermatoses, 76 S Hereditary Disorders of the Dermis, including atrophies S011 Whats Hot in Pediatric Dermatology, 78 U007 Neonatal Dermatology, 46 U032 pitzs Genodermatoses, 76 S Medical therapy issues in the Pediatric Patient S011 Whats Hot in Pediatric Dermatology, 78 normal skin Variants and Developmental anomalies S011 Whats Hot in Pediatric Dermatology, 78 U007 Neonatal Dermatology, 46 Pediatric collagen Vascular Disorders and other Rheumatologic Disease U028 Morphea: Not Just for Adults Anymore, 72 Pediatric Disorders of Pigmentation U014 Mastering Moles in Pediatric Patients, 53 Pediatric infections, infestations, and Bites W005 OC Self-Assessment Pediatric M Dermatology, 62 Pediatric Metabolic and systemic Diseases (includes endocrine Disorders and the skin) S011 Whats Hot in Pediatric Dermatology, 78 Pediatric Patient care: assessment skills, Plan Formulation, and Patient/Family Recommendations U014 Mastering Moles in Pediatric Patients, 53 Pediatric Patient care: History taking and Physical Diagnosis F012 Case Based Challenges for PA/NPs, 60 U026 Pediatric Dermatology Jeopardy, 71 Pediatric Patient care: in-office and ancillary Diagnostics S011 Whats Hot in Pediatric Dermatology, 78 Pediatric Patient care: non-surgical officebased Procedures S011 Whats Hot in Pediatric Dermatology, 78 U014 Mastering Moles in Pediatric Patients, 53 U025 mpact of Nanotechnology and I Dermatology, 71 Pediatric Patient care: Patient safety issues U025 Impact of Nanotechnology and Dermatology, 71 Vascular Disorders of infancy and childhood, including Hemangiomas and Malformations S011 Whats Hot in Pediatric Dermatology, 78 W005 OC Self-Assessment Pediatric M Dermatology, 62 Vesicobullous Disorders of childhood S011 Whats Hot in Pediatric Dermatology, 78 W005 OC Self-Assessment Pediatric M Dermatology, 62
PeDiatRic DeRMatoLogy
PRoceDURaL DeRMatoLogy
Subject Index
MisceLLaneoUs toPics
controversies F010 Legal Dilemmas in Dermatology, 50 environment issues U009 Smoking and the Skin, 48
106
Subject Index
Mohs Micrographic surgery F009 eview and Update of Regional R Reconstruction, 50 U030 ptimizing Management of Melanoma: O Recognizing and Responding to Common Dilemmas in Patient Care, 76 nail surgery F001 Nails, 39 I U025 mpact of Nanotechnology and Dermatology, 71 Photodynamic therapy S011 Whats Hot in Pediatric Dermatology, 78 I U025 mpact of Nanotechnology and Dermatology, 71 skin cancer in the organ transplant Recipient U025 mpact of Nanotechnology and I Dermatology, 71 skin structure and surgical anatomy F009 eview and Update of Regional R Reconstruction, 48 P F023 athology and Procedures of the Aging Hand, 77 tissue augmentation (Fillers and Fat transplant) C002 ive Patient Demonstration: Neurotoxins L and Soft Tissue Augmentation, 57 F021 ew Technologies in Minimally Invasive N Skin Rejuvenation, 73 wound Healing and wound care F009 eview and Update of Regional R Reconstruction, 50 U025 mpact of Nanotechnology and I Dermatology, 71 Miscellaneous U008 uality and Customer Service for a Better Q Practice, 48 U012 atients Satisfaction: Measurement and P Improvement, 53 office Management/Marketing F010 Legal Dilemmas in Dermatology, 50 N S003 egotiating Your Way to Great Leadership, 42 Q U008 uality and Customer Service for a Better Practice, 48 U011 rom the Dermatology-Rheumatology F Clinic: Practical Tips and Advances in Management, 49 U012 atients Satisfaction: Measurement and P Improvement, 53 Quality assurance F010 Legal Dilemmas in Dermatology, 50 Q U008 uality and Customer Service for a Better Practice, 48 Risk Management/Malpractice F010 egal Dilemmas in Dermatology, 50 L advanced C002 ive Patient Demonstration: Neurotoxins L and Soft Tissue Augmentation, 57 F007 Case Based Controversies: Procedural, 44 S010 utting Edge Surgery and Oncology, 72 C anesthesia F014 Finessing Surgical Technique, 61 Basic/intermediate C002 ive Patient Demonstration: Neurotoxins L and Soft Tissue Augmentation, 57 F014 Finessing Surgical Technique, 61 S010 Cutting Edge Surgery and Oncology, 72 complications Prevention of C002 ive Patient Demonstration: Neurotoxins L and Soft Tissue Augmentation, 57 F014 Finessing Surgical Technique, 61 C002 ive Patient Demonstration: Neurotoxins L and Soft Tissue Augmentation, 57 F021 ew Technologies in Minimally Invasive N Skin Rejuvenation, 73 Lasers F021 ew Technologies in Minimally Invasive N Skin Rejuvenation, 73 S010 Cutting Edge Surgery and Oncology, 72 U015 Laser Update, 53 U023 se of Light for Diagnosis and Treatment U in Dermatology, 65 Micrographic surgery F007 Case Based Controversies: Procedural, 44 F009 eview and Update of Regional R Reconstruction, 50 surgery F009 eview and Update of Regional R Reconstruction, 50 F014 Finessing Surgical Technique, 61 S010 Cutting Edge Surgery and Oncology, 72 U030 ptimizing Management of Melanoma: O Recognizing and Responding to Common Dilemmas in Patient Care, 76 surgical Repair Methods F007 Case-Based Controversies: Procedural, 44 F009 eview and Update of Regional R Reconstruction, 58 F014 Finessing Surgical Technique, 61 S010 Cutting Edge Surgery and Oncology, 72 U025 mpact of Nanotechnology and I Dermatology, 71 wound Healing F009 eview and Update of Regional R Reconstruction, 58 U025 mpact of Nanotechnology and I Dermatology, 71
systeMs-BaseD PRactice
Practice Management and the Business of Dermatology, including office Regulation and accreditation F010 Legal Dilemmas in Dermatology, 50 U008 uality and Customer Service for a Better Q Practice, 49 teaming with other Providers of care to Benefit your Patients U008 uality and Customer Service for a Better Q Practice, 48 P U012 atients Satisfaction: Measurement and Improvement, 53 Utilize Practice services to improve your Practice, including advocacy U008 uality and Customer Service for a Better Q Practice, 48 antifungals U025 mpact of Nanotechnology and I Dermatology, 71 U033 nfectious Disease Update: What I I Wouldnt Have Known Without Evidence Based Medicine, 77 corticosteroids U025 mpact of Nanotechnology and I Dermatology, 71 Dermatopharmacology S005 edication Monitoring and M Complications, 48 Drug Reactions S005 edication Monitoring and M Complications, 48 U016 rom Bench to Bedside: Important Clinical F Advances, 58 U025 mpact of Nanotechnology and I Dermatology, 71 gene therapy & Dna Vaccination U025 mpact of Nanotechnology and I Dermatology, 71 immunosuppression/cytotoxic therapy U016 rom Bench to Bedside: Important Clinical F Advances, 58 U025 mpact of Nanotechnology and I Dermatology, 71 Miscellaneous U008 uality and Customer Service for a Better Q Practice, 48 U025 mpact of Nanotechnology and I Dermatology, 71 outcomes analysis U030 ptimizing Management of Melanoma: O Recognizing and Responding to Common Dilemmas in Patient Care, 76 Phototherapy U023 se of Light for Diagnosis and Treatment U in Dermatology, 65 U025 mpact of Nanotechnology and I Dermatology, 71 U023 se of Light for Diagnosis and Treatment U in Dermatology, 65 Retinoids S005 edication Monitoring and M Complications, 48 therapeutics non-surgical F013 Melanoma, 60 F021 ew Technologies in Minimally Invasive N Skin Rejuvenation, 73 U004 Medical Management of Actinic Keratoses, 38 U016 rom Bench to Bedside: Important Clinical F Advances, 58 I U033 nfectious Disease Update: What I Wouldnt Have Known Without Evidence Based Medicine, 77 topical nonsteroidal therapy U025 mpact of Nanotechnology and I Dermatology, 71
tHeRaPeUtics
sURgeRy
Subject Index
Leadership S004 Leading High Performance Teams, 47 Y U001 our True Colors: Know Yourself and Understand Others, 38 U006 Bringing out the Best in Others, 46 U008 uality and Customer Service for a Better Q Practice, 48 U025 mpact of Nanotechnology and I Dermatology, 71 Professional Development S004 Leading High Performance Teams, 47 U001 our True Colors: Know Yourself and Y Understand Others, 38 U006 Bringing out the Best in Others, 46 U008 uality and Customer Service for a Better Q Practice, 48 sensitivity to a Diverse Patient Population F011 sing Technology to Improve U Dermatology Access, 59 U008 uality and Customer Service for a Better Q Practice, 48 teamwork S004 Leading High Performance Teams, 47 U001 our True Colors: Know Yourself and Y Understand Others, 38 U006 Bringing out the Best in Others, 46 U008 uality and Customer Service for a Better Q Practice, 48 Volunteerism and social consciousness U025 mpact of Nanotechnology and I Dermatology, 71
computers S002 E.H.R. Physician Demonstration, 42 ethics F010 Legal D lemmas in Dermatology, 50 government S002 E.H.R. Physician Demonstration, 42
www.aad.org
107
abrishami, Payam, M.D., 64 alam, Murad, M.D., Chf, Sect Cut & Aesth Surg, Dept Derm, NW U, Chicago, IL, 50, 72 andea, aleodor a., M.D., 45 anderson, Bryan erik, M.D., Asst Prof, Dept Derm, Penn St U, Hershey, PA, 68 antaya, Richard j., M.D., Assoc Prof, Dept Derm Yale U Sch Med, New Haven, CT, 78
Baldwin, Hilary e., M.D., Assoc Prof Clin Derm, SUNY, Brooklyn, NY, 78 Barrio, Victoria R., M.D., M.D. Asst Prof Ped and Med (Derm), U.C.S.D. San Diego, CA, 71 Barton, simon, M.D., 41 Baum, christian L., M.D., 41 Berson, Diane s., M.D., Asst Prof Derm, Weill Med Col of Cornell U, NY, NY, 47 Bhatia, neal D., M.D., Assoc Clin Prof, Dept Derm, U WI Med Sch, Madison, WI, 38 Bichakjian, christopher k., M.D., MD, Asst Prof, U of Michigan, Ann Arbor, MI, 72 Bikowski, joseph B., M.D., Clin Asst Prof Derm, OH State U, Columbus, OH and Director, Bikowski Skin Care Center, Sewickley, PA, 40 Bolognia, jean L., M.D., Prof, Dept Derm, Yale U, New Haven, CT, 41 Bordeaux, jeremy s., M.D., M.P.H., Asst Prof, Dept of Derm, Case Western Reserve University, Univ Hosp Case Med Ctr, Cleveland, OH, 72 Borradori, Luca, M.D., 42 Brewer, jerry D., M.D., 41, 70, 72 Burdick, anne e., M.D., M.P.H., Professor, Department of Dermatology, Associate Dean for TeleHealth, University of Miami, Miami, FL, 43 Burgess, cheryl M., M.D., Asst Clin Prof,Dept Derm, Georgetown U Hosp, Washington, DC, 73 Busam, klaus j., MD, Professor, Cornell University; Attending, Dermpath, Memorial Sloan-Kettering Canc Ctr, New York, NY, 66
carlson, john andrew, M.D., Prof, Div Dermpath, Albany Med Col, Albany, NY, 66 carucci, john a., M.D., Ph.D., Chf, Mohs Surg, Cornell U, New York, NY, 50, 72 carvajal, Richard, Oncology, 60 casparian, jacques Michael, M.D., 45 chang, Mary wu, M.D., Assoc Clin Prof, Dept Derm/Ped, U CT, Dir Pediatric Dermatology of New England, West Hartford, CT, 43 chiu, Melvin w., M.D., 38 ciurea, ana M., M.D., 51 clarke, jennie t., M.D., 68 cohen, Bernard, M.D., Vol Prof, Dept Derm, U Miami, Coral Gables, FL, 62 cohen, David eric, M.D., Vice Chair Dept of Derm, NYU School of Medicine, New York, NY, 42, 55 coldiron, Brett M., M.D., Clin Asst Prof Derm, U Cincinnati, Cincinnati, OH, 61 colegio, oscar, M.D., Ph.D., 41, 58 collishaw, karen, 47 cornelius, Lynn anne, M.D., Chf Div Derm, WA U Sch of Med, St Louis, MO, 60 cotliar, jonathan, M.D., Asst Clin Prof,Division of Dermatology, David Geffen School of Medicine at UCLA, Los Angeles, CA, 40, 66 Daniel, c. Ralph, M.D., Clin Prof Derm, U MS, Jackson, Ms, Clin Assoc Prof Derm, U AL, Birminham, AL, 39 Davey, william Patrick, M.D., Clin Prof, U KY, Lexington KY, 42 Davis, Dawn M. R., M.D., 44, 72 Davis, Mark D. P., M.D., Prof, Dept Derm, Mayo Clin, Rochester, MN, 44 Del Rosso, james Q., D.o., Derm Res Director, Valley Hosp Med Center, Las Vegas, NV, 48, 78 DeLeo, Vincent anthony, M.D., Chmn, Derm, St. Lukes-Roosevelt & Beth Israel Med Ctrs, New York, NY, 43 Donofrio, Lisa M., M.D., Asoc Clin Prof, Dept Derm, Yale U Sch Med, New Haven, CT, Asst Clin Prof, Dept Derm, Tulane U, New Orleans, LA, 47 Draelos, Zoe Diana, M.D., Invest, Dermatology Consulting Services, High Point, NC, 39, 64
callen, jeffrey Phillip, M.D., Prof Med (Derm), Div Derm, Scho Med, U Louisville, Louisville, KY, 68, 70 camilleri, Michael j., M.D., 41 campen, Rebecca B., M.D., j.D., Mass Gen Hosp, Dept Derm, Boston, MA, 50 cappel, Mark a., M.D., 41
108 |
eastern, joseph s., M.D., Clin Asst Prof, UMDNJ and Seton Hall U, Newark, NJ, 42 eichenfield, Lawrence F., M.D., Chf Ped and Adol Derm, Prof Ped Med Derm, U CA, Rady Child Hosp, San Diego, CA, 43 elewski, Boni e., M.D., Prof Derm, U AL, Birmingham, AL, 67
kalaaji, amer nizar, M.D., Mayo Clin, Rochester, MN, 44 kaufman, joely anne, M.D., Asst Prof, Clin Derm, University of Miami Miller School of Medicine; Miami, FL, 78 kaufmann, Mark D., M.D., Assoc Clin Prof, Dept Derm, Mt Sinai School of Med, New York, New York, 42 keri, jonette elizabeth, M.D., Ph.D., 78 kirby, joslyn s., M.D., 51 kroshinsky, Daniela, M.D., 59, 66
garden, jerome M., M.D., Assoc Prof Clin Derm and Ped, NW U, Chicago, IL, 53 garg, amit, M.D., Asst Prof, Dept Derm, Boston U Sch of Med, Boston, MA, 68 gasbarre, christopher c., D.o., 43 geronemus, Roy g., M.D., Clin Prof Derm, NYU Med Ctr, New York, NY, 56 gladstone, Hayes B., M.D., Assoc Prof, Derm/Otolaryngol, Dir, Div Derm Surg, Stanford U, Stanford, CA, 50, 61 glaser, Dee anna, M.D., Prof, Dept Derm, St. Louis U, St. Louis, MO, 77 gloster, Hugh M., M.D., Assoc Prof, Dept Derm, U Cincinnati Col Med, Cincinnati, OH, 61, 77 gold, Michael H., M.D., Gold Skin Care Ctr, TN Clin Rsch Ctr, 42 goldberg, David j., M.D., j.D., Clin Prof, Derm, Mount Sinai Sch of Med, New York, NY, 42 goldenberg, gary, M.D., 53, 57 graf, jeannette o., M.D., 57 grando, sergei a., M.D., Ph.D., UC Irvine, CA, 48 grant-kels, jane Margaret, M.D., Prof, Chmn, Dept Derm, Dir Dermpath, Sch Med, U CT, Farmington, CT, 46, 68 groysman, Vlada, M.D., 67
Lebwohl, Mark, M.D., Prof and Chmn, Dept Derm, Mt Sinai Sch Med, New York, NY, 51, 67, 73 Lee, Robert a., M.D., Ph.D., Clin Instructor, University of Pennsylvania, Philadelphia, PA, 38 Levy, Moise L., M.D., Prof Derm & Ped, Baylor Col Med, TX Childrens Hosp, Houston, TX, 62 Lewis, amy B., M.D., Clin Asst Prof, Dir Derm Surg, Derm, SUNY HSC, Brooklyn, NY, 47 Lim, Henry w., M.D., Chmn and C.S. Livingood Chr, Derm, Henry Ford Hosp, MI, 39, 41, 54 Lizzul, Paul, M.D., Ph.D., 74 Lober, clifford warren, M.D., j.D., Clin Assoc Prof, Div Derm, U So FL, Tampa, FL, 50 Lucas, jennifer, M.D., Assoc Staff, Cleveland Clin, Cleveland, OH, 47
Halpern, allan c., M.D., Chf, Derm Svc, MSKCC, New York, NY, 39, 60 Hamzavi, iltefat H., M.D., MD,Sr Staff Phys, Henry Ford Hospital, Detroit, MI, 65 Harper, julie claire, M.D., Clin Assoc Prof, Dept Derm, U AL Med Ctr, Birmingham, AL, 48 Hectorne, kathleen julie, M.D., 72 Hernandez, claudia, M.D., Asst Prof Derm, U of Illinois at Chicago, Chicago, IL, 59 Hughey, Lauren c., M.D., Asst Prof, Dept Derm, U of AL, Birmingham, AL, 40, 66 Hurst, eva a., M.D., 60 Hwang, sam t., M.D., Ph.D., MD/Ph.D., Sr. Invest., Derm Br, NCI, Bethesda, MD, 55
jackson, Brooke a., M.D., Asst Clin Prof, Dept Derm, Sch Med, Northwestern, Chicago, IL, 73 james, william D., M.D., Prof, Dept Derm, U PA, Philadelphia, PA, 59 jellinek, nathaniel j., M.D., Asst Prof, Dept Derm, Brown Med Sch, Providence, RI, 39 jiang, shang i. Brian, M.D., 50, 72 johnson, timothy M., M.D., U MI, Ann Arbor, MI, 54 johnson-jahangir, Hillary, M.D., Ph.D., 45 johr, Robert H., M.D., Clin Prof Derm Ped, Dir Pgt Lsn, U Miami, Miami, FL, 72
Maccormack, Mollie a., M.D., 58 Margolis, David j., M.D., Assoc Prof, Sch Med, U PA, Philadelphia, PA, 55 Marks, Victor j., M.D., 68 Marks, Victor james, M.D., Assoc, Geisinger Med Ctr, Danville, PA, 47, 53 Marks, james g., M.D., 46 Marmur, ellen s., M.D., Asst Clin Prof, Dept Derm, Sch Med, Mt. Sinai, New York, NY, 47 Martin, elizabeth shannon, M.D., Clin Volunteer Faculty, Univ of AL, 38 Martinez, jose Dario, M.D., 43 Martini, Mary c., M.D., 51 Matarasso, seth L., M.D., Clin Prof Derm, UCSF, San Francisco, CA, 47, 57 Meehan, shane a., M.D., 57 Mercurio, Mary gail, M.D., Assoc Prof Derm, U Rochester, Rochester, NY, 67 Miller, christopher james, M.D., Dept Derm, U of Pennsylvania, Philadelphia, PA, 61, 68, 72, 76 Miller, Danielle M., M.D., Ph.D., 76 Miller, jeffrey j., M.D., Assoc Prof, Dept Derm, Penn State Col Med, Hershey, PA, 68 Mirowski, ginat w., M.D., DM.D., Assoc Prof Derm, Northwestern, Chicago, IL, 69 Morel, kimberly Dawn, M.D., 60 Mowad, christen M., M.D., Assoc Prof, Geisinger Medical Center, 51 Moy, Ronald L., M.D., Clin Prof, Div Derm, Sch Med, UCLA, Dir Derm Surg, VA West, Los Angeles, CA, 54 Mugalian, Ruth, 58
nasir, adnan, M.D., Ph.D., Clin Asst Prof, Dept Derm, UNC, Chapel Hill, NC, 71 neel, Victor allen, M.D., Ph.D., Dir, Derm Surg, MA General Hospital, Boston, MA, 44
www.aad.org
109
olbricht, suzanne, M.D., Chf Derm, Lahey Clin, Assoc Prof Derm, Harvard MS, Boston, MA, 61 osterwalder, Uli, 39 ozog, David M., M.D., 61
Pandya, amit g., M.D., Prof, Dept Derm, U TX SW Med Ctr, Dallas, TX, 59 Parsons, Margaret e., M.D., Asst Clin Prof, Dept Derm, UC-Davis, Sacramento, CA, 47 Patel, Manisha j., M.D., 60 Patel, Rishi R., M.D., 57 Piette, warren w., M.D., Chr, Div Derm, Cook Cty Hosp; and Prof, Dept Derm, RUSH Medical Center, Chicago, IL, 69 Powell, Frank c., M.D., Con Derm, Reg Ctr Derm, Mater Hosp, Dublin, Ireland, 41 Puttgen, katherine B., M.D., 62
Qureshi, abrar a., M.D., M.P.H., Co-Dir, Dept Derm, Brigham & Womens Hosp, Harvard Med Sch, Boston, MA, 49 Rapini, Ronald P., M.D., Prof and Chmn, Dept Derm, U TX, Houston, TX, 43 Ratner, Desiree, M.D., Assoc Clin Prof, Dept Derm, Columbia U Med Ctr, New York, NY, 72 Rich, Phoebe, M.D., Clin Prof, Dept of Derm OHSU and Private Practice Portland, OR, 39 Rigel, Darrell s., M.D., Clin Prof Derm, New York Univ Med Ctr, New York, NY, 60, 67 Roberts, wendy e., M.D., Asst Clin Prof Med, Loma Linda U Med Ctr, Loma Linda, CA, 49, 73 Rogers, Howard woodling, M.D., 74 Rohrer, thomas e., M.D., Skincare Phys of Chestnut Hill, Boston U, Boston, MA, 47 Rokhsar, cameron k., M.D., 57 Romanelli, Paolo, M.D., AssocProf, Dept Derm/dermpath, Miller Sch Med, U Miami, Miami, FL, 71 Rosen, theodore, M.D., Prof, Dept Derm, Baylor Col Med, Houston, TX, 43 Rosenbach, Misha, M.D., 51 sadick, neil s., M.D., FAACS, FACP, FACPh, Clin Prof, Dept Derm, Weill Med College Cornell, New York, NY, 57 sanchez, Fitzgeraldo a., M.D., 74 sanchez, Miguel R., M.D., Assoc Prof, Dept Derm, NYU Sch Med, New York, NY, 77 sanders, jonathan scott, M.D., 50 schaffer, julie V., M.D., Asst Prof, Dept Derm and Ped, NYU, New York, NY, 43, 53, 70 schalock, Peter c., M.D., 65 scher, Richard k., M.D., Prof Derm, U NC, Chapel Hill, North Carolina; Prof Emer Derm, Columbia U, New York, NY, 39, 67 schlosser, Bethanee jean, M.D., Ph.D., 68, 69 schmults, chrysalyne Delling, M.D., Dir, Mohs Micrographic Surgery, Brigham and Womens Hosp, Boston, MA, 70 schwarzenberger, kathryn, M.D., Assoc Prof, Univ Vermont, Burlington, VT, 46
taylor, james selwyn, M.D., Hd Occ Derm, Cleveland Clin, Cleveland, OH, 45 thomas, nancy e., M.D., Assoc Prof, Dept Derm, UNC, Chapel Hill, NC, 60 tomecki, kenneth j., M.D., Vice chairman, Dept Derm, Cleveland Clin, Cleveland, OH, 41, 43 torgerson, Rochelle R., M.D., Ph.D., Asst Prof Derm, Mayo Clin Col of Med, Rochester MN, 69
Van Voorhees, abby s., M.D., Asst Prof, Dept Derm, U PA, Philadelphia, PA, 73
waldorf, Heidi a., M.D., Assoc Clin Prof, Dept Derm, Sch Med, Mt Sinai, New York, NY, 57, 73 wang, steven Q., M.D., Memorial Sloan Kettering Cancer Ctr, NY, 39 weinkle, susan H., M.D., Asst Clin Prof, Dept Derm, U S FL, Bradenton, FL, 57 weinstock, Martin a., M.D., Ph.D., Prof Derm and Community Hlth, Brown U, Providence, RI, 60 wetter, David a., M.D., 44 willemze, Rein, M.D., Dept Derm, LUMC, Leiden, Netherlands, 41 wirtzer, allan s., M.D., Priv Pract, Sherman Oaks, CA, 74 wisco, oliver j., D.o., 45 wolverton, stephen e., M.D., Prof Clin Derm, Dept Derm, IN U Med Ctr, Indianapolis, IN, 48 woolery-Lloyd, Heather clare, M.D., 78 wright, teresa s., M.D., 62
Zaenglein, andrea L., M.D., Assoc Prof, Derm and Ped, Penn State, MS Hershey Med Ctr, Hershey, PA, 68, 78 Zeichner, joshua, M.D., 51 Zic, john a., M.D., Asst Prof, Div Derm, Vanderbilt U Sch Med, Nashville, TN, 48 Zirwas, Matthew, M.D., Asst Prof, Derm, Columbus, OH, 40 Zwald, Fiona oReilly, M.D., Metropolitan Dermatologic Surg, P.C., St Josephs Hospital, Atlanta, GA, 68
110
Advertisers Index
Abbott Laboratories .....................................................................16A-F Centocor .........................................................................80A-D, 81-82 Galderma Laboratories ...............15-16, 36, 79-80, 101-102, IBC-BC . Jan Marini Skin Research ..................................................................91 Medicis ..............................................................................................7-9 Merz Pharmaceuticals ...................................................................93-94 Upsher-Smith Laboratories ............................................................ 5, 86 Young Pharmceuricals ..................................................................... 111 .
advertising Representatives
Ascend Integrated Media, LLC 7015 College Blvd. Suite 600 Overland Park, IL 66211
Cathleen Gorby Phone: (913) 780-6923, Fax: (913) 780-4344 E-mail: cgorby@ascendintegratedmedia.com Amy Galey Phone: (913) 344-1359, Fax: (913) 344-1492 E-mail: galey@ascendintegratedmedia.com Maureen Mauer Phone: (913) 780-6633, Fax: (913) 780-0088
AAD.org ...........................................................................................61 . AAD Buyers Guide ...........................................................................64 AAD Sponsorship Recognition ..................................3, 10, 11, 20, 33 Academy Resource Center ...........................................................34, 35 Annual Meeting 2011 Audio Recordings .........................................67 Dermatology in Action ......................................................................42 Derm Exam Prep Course...................................................................68 Dermatology Self-Assessment Program (DSAP) Tools .....................62 Dermoscopy .......................................................................................51 Leadership Institute ...........................................................................46 . Measurement Tools ...........................................................................65 Named Lectureships ..........................................................................56 Practice Management Essentials Webinars ......................................74 . Psoriasis Guidelines: Implementing them in your Practice ...............74 See SPOT CD ..................................................................................49 Sustaining Fund .................................................................................75 Transition into Practice: A Toolkit for Dermatologists Entering into the Workforce .....................59
Advertisers Index
E-mail: mmauer@ascendintegratedmedia.com
112
Rx only (adapalene and benzoyl peroxide) Gel 0.1% / 2.5% For Topical Use Only Not For Ophthalmic, Oral, or Intravaginal Use. BRIEF SUMMARY INDICATIONS AND USAGE EPIDUO Gel is a combination of adapalene, a retinoid, and benzoyl peroxide, and is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. CONTRAINDICATIONS None. WARNINGS AND PRECAUTIONS Ultraviolet Light and Environmental Exposure: Avoid exposure to sunlight and sunlamps. Wear sunscreen when sun exposure cannot be avoided. Erythema, scaling, dryness, and stinging/burning may occur with use of EPIDUO Gel. ADVERSE REACTIONS Observed local adverse reactions in patients treated with EPIDUO Gel were erythema, scaling, dryness, stinging, and burning. Other most commonly reported adverse events (1%) in patients treated with EPIDUO Gel were dry skin, contact dermatitis, application site burning, application site irritation, skin irritation. DRUG INTERACTIONS Exercise caution in using preparations containing sulfur, resorcinol, or salicylic acid, medicated or abrasive soaps and cleansers and products with high concentrations of alcohol or astringents in combination with EPIDUO Gel. Concomitant use of topical products with a strong drying effect can increase irritation. Use with caution. Pregnancy Pregnancy Category C. There are no well-controlled trials in pregnant women treated with EPIDUO Gel. Animal reproduction studies have not been conducted with the combination gel or benzoyl peroxide. Furthermore, such studies are not always predictive of human response; therefore, EPIDUO Gel should be used during pregnancy only if the potential benefit justifies the risk to the fetus. No teratogenic effects were observed in rats treated with oral doses of 0.15 to 5.0 mg adapalene/kg/day, up to 25 times (mg/m2/day) the maximum recommended human dose (MRHD) of 2 grams of EPIDUO Gel. However, teratogenic changes were observed in rats and rabbits when treated with oral doses of 25 mg adapalene/kg/day representing 123 and 246 times MRHD, respectively. Findings included cleft palate, microphthalmia, encephalocele and skeletal abnormalities in rats; and umbilical hernia, exophthalmos and kidney and skeletal abnormalities in rabbits. Dermal teratology studies conducted in rats and rabbits at doses of 0.6-6.0 mg adapalene/kg/day [25-59 times (mg/m2) the MRHD] exhibited no fetotoxicity and only minimal increases in supernumerary ribs in both species and delayed ossification in rabbits. Nursing Mothers It is not known whether adapalene or benzoyl peroxide is excreted in human milk following use of EPIDUO Gel. Because many drugs are excreted in human milk, caution should be exercised when EPIDUO Gel is administered to a nursing woman. Pediatric Use Safety and effectiveness of EPIDUO Gel in pediatric patients under the age of 12 have not been established. Geriatric Use Clinical studies of EPIDUO Gel did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Carcinogenesis, Mutagenesis, Impairment of Fertility No carcinogenicity, photocarcinogenicity, genotoxicity, or fertility studies were conducted with EPIDUO Gel. Carcinogenicity studies with adapalene have been conducted in mice at topical doses of 0.4, 1.3, and 4.0 mg/kg/day (1.2, 3.9, and 12 mg/m2/day), and in rats
EPIDUO
at oral doses of 0.15, 0.5, and 1.5 mg/kg/day (0.9, 3.0, and 9.0 mg/m2/day). In terms of body surface area, the highest dose levels are 9.8 (mice) and 7.4 times (rats) the MRHD of 2 grams of EPIDUO Gel. In the rat study, an increased incidence of benign and malignant pheochromcytomas in the adrenal medulla of male rats was observed. No significant increase in tumor formation was observed in rodents topically treated with 15-25% benzoyl peroxide carbopol gel (6-10 times the concentration of benzoyl peroxide in EPIDUO Gel) for two years. Rats received maximum daily applications of 138 (males) and 205 (females) mg benzoyl peroxide/kg. In terms of body surface area, these levels are 27-40 times the MRHD. Similar results were obtained in mice topically treated with 25% benzoyl peroxide carbopol gel for 56 weeks followed by intermittent treatment with 15% benzoyl peroxide carbopol gel for rest of the 2 years study period, and in mice topically treated with 5% benzoyl peroxide carbopol gel for two years. The role of benzoyl peroxide as a tumor promoter has been well established in several animal species. However, the significance of this finding in humans is unknown. In a photocarcinogenicity study conducted with 5% benzoyl peroxide carbopol gel, no increase in UV-induced tumor formation was observed in hairless mice topically treated for 40 weeks. No photocarcinogenicity studies were conducted with adapalene. However, animal studies have shown an increased tumorigenic risk with the use of pharmacologically similar drugs (e.g., retinoids) when exposed to UV irradiation in the laboratory or sunlight. Although the significance of these findings to humans is not clear, patients should be advised to avoid or minimize exposure to either sunlight or artificial irradiation sources. Adapalene did not exhibit mutagenic or genotoxic effects in vitro (Ames test, Chinese hamster ovary cell assay, mouse lymphoma TK assay) or in vivo (mouse micronucleus test). Bacterial mutagenicity assays (Ames test) with benzoyl peroxide has provided mixed results, mutagenic potential was observed in a few but not in a majority of investigations. Benzoyl peroxide has been shown to produce single-strand DNA breaks in human bronchial epithelial and mouse epidermal cells, it has caused DNA-protein cross-links in the human cells, and has also induced a dose-dependent increase in sister chromatid exchanges in Chinese hamster ovary cells. In rat oral studies, 20 mg adapalene/kg/day (120 mg/m2/day; 98 times the MRHD based on mg/m2/day comparison) did not affect the reproductive performance and fertility of F0 males and females, or growth, development and reproductive function of F1 offspring. No fertility studies were conducted with benzoyl peroxide. PATIENT COUNSELING INFORMATION Advise patients to cleanse the area to be treated with a mild or soapless cleanser; pat dry. Apply EPIDUO Gel as a thin layer, avoiding the eyes, lips and mucous membranes. Advise patients not to use more than the recommended amount and not to apply more than once daily as this will not produce faster results, but may increase irritation. EPIDUO Gel may cause irritation such as erythema, scaling, dryness, stinging or burning. Advise patients to minimize exposure to sunlight, including sunlamps. Recommend the use of sunscreen products and protective apparel, (e.g., hat) when exposure cannot be avoided. EPIDUO Gel may bleach hair and colored fabric.
Marketed by by: LABORATORIES, L.P. GALDERMA LABORATORIES L P Worth, Fort Worth Texas 76177 USA by: Manufactured by Galderma Production Canada Inc Inc. dUrf, QC, Baie d Urf QC H9X 3S4 Canada Canada. Made in Canada trademark. GALDERMA is a registered trademark Revised: Revised December 2008 008 P51356-0 P51356 0
Galderma is a registered trademark. 2010 Galderma Laboratories, L.P. Galderma Laboratories, L.P. 14501 N. Freeway Fort Worth, TX 76177 EPI-613 Printed in USA 12/10
hcp.epiduo.com
*Individual results may vary. In clinical trials of over 1000 subjects, approximately 30% were clear or almost clear (IGA) by week 12 with a 70% median inammatory lesion count reduction from baseline. Reference: 1. Gollnick HPM, Draelos Z, Glenn MJ, et al; AdapaleneBPO Study Group. Adapalenebenzoyl peroxide, a unique xed-dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double-blind, controlled study in 1670 patients. Br J Dermatol. 2009;161(5):1180-1189. Important Safety Information Epiduo Gel is a retinoid and antimicrobial combination product indicated for the topical treatment of acne vulgaris in patients 12 years and older. The most common adverse events associated with use of Epiduo Gel are erythema, scaling, dryness, stinging and burning. In addition, in clinical trials, adverse events reported in greater than 1% of patients treated with the Gel included contact dermatitis and skin irritation. Excessive exposure to sunlight and sunlamps should be avoided during treatment, and use of sunscreen products and protective clothing is recommended. Concomitant use of irritating topical products (like products containing resorcinol, salicylic acid or sulfur) should be avoided. Epiduo Gel has not been tested in pregnant or nursing women, or with the elderly. Pregnancy Category C. Please see brief summary of Prescribing Information on next page.